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ABSTRACT 
Background: Human papillomavirus (HPV) is one of the most common sexually transmitted 
infections (STIs) globally and a necessary factor for cervical cancer development. While HPV 
infection has been associated with increased Human immunodeficiency virus (HIV) risk, the 
underlying mechanisms remain unclear. Since STIs upregulate cytokine production and 
immune cell recruitment, and reduce epithelial barrier integrity, this study investigated whether 
the immune responses associated with HPV infection contribute to a genital immune 
environment conducive to an increased risk of HIV infection. 
Methods: This study included a baseline assessment of 167 HIV negative women participating 
in the CAPRISA 008 trial. The Roche Linear Array was used to detect the presence of 37 HPV 
genotypes in cervicovaginal lavage (CVL) pellets. The concentrations of 48 cytokines and 9 
matrix metalloproteinases (MMPs) were assessed in matching CVL supernatants by multiplex 
ELISA. The frequencies of activated or proliferating T cells, NK cells, and of HIV target cells 
were assessed on cervical cytobrush-derived specimens by flow cytometry. Multiplex PCR was 
conducted to determine infection with common discharge-associated STIs. 
Results: The study demonstrated a 50.8% HPV prevalence. HPV infection was associated with 
younger age, older male partners, not living with a regular partner, and higher parity. HPV 
infection was also associated with greater levels of IL-5, IL-6 and G-CSF, an association 
otherwise masked by the inflammatory nature of other STI. Concomitant HPV/STI infection 
resulted in reduced concentrations of IL-6 and IL-1RA relative to HPV-STI+ women. In 
multivariate analyses controlling for other STI and nugent score, HPV-infected women had 
increased concentrations of SDF-1α (β = 0.148 pg/ml). Women with HR-HPV had higher 
concentrations of MCP-1 (β = 0.127 pg/ml) and IL-13 (β = 0.117 pg/ml), and greater 
frequencies of lymphocytes (β = 1.987 pg/ml) relative to those infected with LR-HPV. Having 
multiple HPV infections was associated with reduced concentrations of IL-5 (β = -0.170 
pg/ml).  
Conclusion: While discharge-related STIs are inflammatory, a more subtle immune profile 
was associated with HPV infection that did not overtly relate to an increased potential for HIV 
risk. However, this study demonstrated an association between HR-HPV and biomarkers of 
inflammation, suggesting the need for longitudinal investigation to confirm a biological 
mechanism for the relationship between persistent HR-HPV infection and HIV acquisition. 
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1. CHAPTER 1: INTRODUCTION 
The association between STIs and increased HIV risk has been well established (Houlihan et 
al., 2012). HPV is one of the most common STIs globally, and is related to an increased risk 
of HIV acquisition (Smith-McCune et al., 2010a; Averbach et al., 2010; Auvert et al., 2011; 
Low et al., 2011; Konopnicki et al., 2013a). Both HIV and HPV are sexually transmitted, with 
HPV being more prevalent than HIV, even in areas where HIV is endemic (Lissouba et al., 
2013). While the epidemiological link between HPV and HIV risk is well established, the 
biological mechanisms involved remain to be elucidated. 
Since HPV-associated dysplastic cervical lesions are associated with a larger number of CD4+ 
T cells compared to normal cervical epithelium (Kobayashi et al., 2004), HPV infection could 
predispose a woman to HIV by exposing susceptible target CD4+ T cells to HIV. Furthermore, 
dendritic cells (DCs) (van Seters et al., 2008), natural killer (NK) cells (Lee et al., 2001) and 
T cells  are also associated with genital wart regression; and  genital warts are successfully 
treated with Imiquimod, a Toll-like receptor (TLR) 7 agonist that prompts an inflammatory 
response (van Seters et al., 2008). HPV, an epithelial virus, may also increase the risk of HIV 
infection and facilitate HIV dissemination through disruption of the epithelial barrier and 
upregulation of pro-inflammatory cytokines (Herfs et al., 2011; Nicol et al., 2005). Further, 
studies have reported that the risk of acquiring HIV is greatly increased if there are two or more 
types of HPV isolated from the same individual (Konopnicki et al., 2013a; Averbach et al., 
2010). It is therefore possible that multiple concurrent HPV infections could lead to an 
elevated immune response and a greater number of cervical lesions that disrupt the mucosal 
epithelia integrity, facilitating HIV entry at the genital tract (Laga et al., 1993; Freeman et 
al., 2006).  
Low risk (LR), non-oncogenic HPV is generally cleared by the immune system without any 
permanent damage. Conversely, high risk (HR), oncogenic HPV has the ability to evade the 
host immune responses and cause persistent infection, leading to the development of pre-cancer 
lesions and invasive cervical cancer (ICC). Conflicting reports exist for the impact of HPV 
oncogenicity on HIV infection risk (Averbach et al., 2010; Smith-McCune et al., 2010a; Auvert 
et al., 2011). Auvert et al. showed that HIV seroconversion among female sex workers was 
associated with genital HR-HPV infection. Whereas, another study reported that the risk of 
acquiring HIV between women infected with high versus low risk HPV types was similar 
(Averbach et al., 2010). Thus further investigation is required to determine the relationship 
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between HPV oncogenicity and HIV risk in KwaZulu-Natal, the heart of South Africa’s HIV 
pandemic. 
Several studies have shown that discharge-associated and ulcer-linked STIs contribute to 
genital inflammation through the recruitment of immune cells, reduced epithelial barrier 
integrity and upregulation of pro-inflammatory cytokines (Laga et al., 1993; van de Wijgert et 
al., 2009; Van Der Pol et al., 2008; Petrova et al., 2013; Wira et al., 2015; Rasmussen et al., 
1997). HPV coinfection with Chlamydia, Herpes simplex virus type 2 (HSV-2), or even a state 
of vaginal dysbiosis such as Bacterial Vaginosis (BV), has been associated with the persistence 
of HPV infection, and increased risk of cervical cancer (Silins et al., 2005; Simonetti et al., 
2009; Castle et al., 2003). However, it is unclear whether coinfections with HPV and STIs 
have a compounding effect on genital inflammation, cellular activation and HIV risk. 
Nevertheless, increased concentrations of similar pro-inflammatory cytokines have been 
observed in genital specimens of patients with persistent HPV infection (Scott et al., 2013, 
Liebenberg et al., unpublished), as well as in patients with other STIs, and this implies the 
possibility of an additional contribution to the genital inflammation (Masson et al., 2015) that 
promotes HIV acquisition. 
Here it was hypothesized that the immune responses associated with multiple concurrent HPV 
infections, oncogenicity and STI coinfection each contribute to a genital immune environment 
conducive to an increased risk of HIV infection. The CAPRISA 008 trial provided a unique 
opportunity to collectively address these unknowns related to HPV infection, genital 
inflammation and HIV risk among KwaZulu-Natal (KZN) women, since both HPV prevalence 
and the risk of acquiring HIV is particularly high in KZN. This study attempts to expand on 
the research questions posed in a current CAPRISA study underway to determine the immune 
mediators associated with HPV clearance as predictors of HIV acquisition (5R01 AI115983-
02; PI: Liebenberg/Celentano). In this study, multiple HPV genotypes and HPV oncogenicity 
was associated with the frequency of concurrently-infecting discharge-related STIs; and the 
cytokine, cellular and epithelial integrity biomarkers of genital inflammation. 
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2. CHAPTER 1: LITERATURE REVIEW 
2.1. HPV Epidemiology 
HPV is one of the most common STIs globally and a necessary factor for the development of 
cervical cancer. In 2008, approximately 12.7 million new cancer infections occurred globally 
and 4.8% of these were attributable to HPV (Bosch et al., 2013). The estimated global HPV 
prevalence among women with normal and abnormal cervical cytology was 32.1% (Vinodhini 
et al., 2012). Furthermore, the prevalence of HPV was shown to be higher in less developed 
countries (42.2%) compared to more developed countries (22.6%) (Vinodhini et al., 2012). A 
study by Bruni et al. showed that globally, young women (<25 years) remain disproportionately 
affected by HPV, with a prevalence of 43.9% in African countries (Bruni et al., 2010). In Sub-
Saharan Africa (SSA) the HPV prevalence, similar to the prevalence of HIV, is among the 
highest in the world (Bruni et al., 2010; Denny et al., 2014), particularly among women from 
urban and rural KZN with an alarming prevalence of 76.3% (Ebrahim et al., 2016). 
 HPV is generally acquired soon after sexual debut, with the greatest prevalence observed 
among young women (Mbulawa et al., 2015). Although approximately 80% of women will 
acquire HPV at some point in their life, most women are able to clear the infection (Vinodhini 
et al., 2012). However, if infection persists it may result in the development of high grade 
cervical intraepithelial neoplasia (CIN) and eventually, ICC (Vinodhini et al., 2012). There are 
currently more than 200 HPV types that have been identified and approximately 40 types infect 
the anogenital region (Fernandes et al., 2013; Bzhalava et al., 2015). HPV is classified as LR 
or HR based on their relation to the development of benign or malignant lesions (Fernandes et 
al., 2013). LR, non-oncogenic HPV is associated with the development of anogenital warts, 
which are benign, hyperproliferative lesions, the most common types being HPV6 and HPV11 
(Fernandes et al., 2013). HR, oncogenic HPV is associated with the development of 
premalignant and malignant cervical lesion and the most common types are HPV16 and HPV18 
(Fernandes et al., 2013). Persistent infection with an oncogenic HPV type has been established 
as the cause of almost all cervical cancers (Denny et al., 2014; McDonald et al., 2014). The 
International Agency for Research on Cancer (IARC) classifies HPV16, HPV18, HPV31, 
HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58 and HPV59 as 
“carcinogenic” and HPV68 as “probably carcinogenic” to humans (Denny et al., 2014; IARC, 
2015). The prevalence of HPV in women fluctuates by country, region and population group 
and is particularly high among women exhibiting high risk sexual behaviour (Smith, 2008).  
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2.2. HPV Virology 
HPV belongs to the Papillomaviridae family and is further categorised into five genera, 
represented by letters of the Greek alphabet (alpha, beta, gamma, mu and nu) according to their 
nucleotide sequences and their phylogenetic and pathology features (Bernard et al., 2010; de 
Villiers et al., 2004). Alphapapillomaviruses are linked to infections of the anogenital tract and 
the oral mucosa, and consists of a group of oncogenic HPV types that are responsible for the 
majority of cervical cancers and other cancers of the genital tract (Stanley, 2010). 
Alphapapillomaviruses consist of three primary clades in which all potentially carcinogenic 
HPV genotypes are grouped to form one high risk clade, consisting of five species (Alpha 5, 
Alpha 6, Alpha 7 and Alpha 9) (Fernandes et al., 2013). Alpha 9 is the most important HPV 
species group as it is composed solely of carcinogenic types, with the main being HPV16 
(Schiffman et al., 2010). In 1977, Harald zur Hausen postulated that HPV played a significant 
role in the development of cervical cancer (zur Hausen, 1977). In 1983 and 1984 zur Hausen 
and colleagues went on to identify HPV16 and HPV18 in cervical cancer, which has since been 
identified as a major cause of cancer (zur Hausen, 1977). 
Papillomaviruses are non-enveloped viruses consisting of a double-stranded, closed circular 
DNA genome of approximately 8000 base pairs (Fernandes et al., 2013; de Sanjose et al., 2017; 
Schiffman et al., 2016; Doorbar et al., 2012) (Figure 1). HPV encodes proteins that are able to 
initiate cellular DNA synthesis, prevent apoptosis and delay differentiation of infected 
keratinocytes, thereby establishing an environment conducive to viral DNA replication 
(Stanley, 2012). The viral genome is divided into three main regions: the early region (E) which 
encodes genes that play role in the viral life cycle and cell transformation (E1, E2, E4, E5, E6 
and E7), the late region (L) which encodes the major and minor capsid proteins (L1 and L2, 
respectively), and the upstream regulatory region (URR) which consists of the origin of 
replication (ORI) and transcription factor-binding sites that function in the control of early gene 
transcription and replication (de Sanjose et al., 2017; Stanley, 2012).  
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Figure 1. Typical genomic structure of HPV 16 (figure taken from de Sanjosé, 2017). The 
viral genome consists of early and late regions. The early region consists of genes (E2, E1, E6, 
and E7) that are necessary for the viral cycle and they play essential roles in cell 
transformation. The E2 gene encodes a protein involved in viral replication and transcriptional 
regulation of the viral early genes while the E6 and E7 genes encode proteins that play 
essential roles in the viral life cycle of HR-HPV. The major and minor capsid proteins (L1 and 
L2 respectively) are involved in the formation of the capsid during viral assembly. The URR 
controls early gene transcription and replication and is comprised of promoter and enhancer 
elements and the ORI. 
These proteins can be further divided into core (E1, E2, L1 and L2) and accessory proteins (E4, 
E5, E6 and E7) (Schiffman et al., 2016). The core proteins are highly conserved and play 
important roles in viral genome replication (E1 and E2) and viral assembly (L1 and L2) 
(Schiffman et al., 2016). In contrast, the expression and functional characteristics of accessory 
proteins tend to vary (Schiffman et al., 2016). The genes that encode accessory proteins are 
able to modify the host cell, thereby facilitating viral replication (Wise-Draper et al., 2008). 
One of the most important roles of the E6 and E7 proteins is to increase viral fitness and virion 
production by facilitating cell cycle re-entry and genome amplification (Doorbar, 2006; 
Doorbar, 2005). The E6 and E7 oncogenes of HR-HPV also mediate carcinogenesis through 
the inhibition of p53 and the retinoblastoma protein (pRb) which are important tumour 
suppressors (de Sanjose et al., 2017; Stanley, 2012). The E6 protein binds to p53 and degrades 
it, leading to alteration of cell cycle regulation (Stanley, 2012).  
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The E7 protein binds to the pRb and deactivates it, resulting in its degradation which leads to 
the infected cell’s loss of control over its cell cycle (Hoffmann et al., 2004; Jefferies et al., 
2001; Stanley, 2012). Expression levels of the E6 and E7 proteins is related to the type of 
cervical lesions: in low grade cervical lesion, these proteins are present at lower levels in the 
basal cells and greater levels in the upper layers of the epithelium, whilst in high-grade lesions, 
these proteins are present in high levels throughout the epithelium (Scheurer et al., 2005). The 
L1 and L2 capsid proteins are crucial in maintaining replication of the virus and synthesis of 
the genes through differentiation of the epithelium (Morshed et al., 2014). These capsid 
proteins are also required for the virus to complete replication (Remy-Ziller et al., 2014). 
 
 
Figure 2. HPV E6 and E7 oncoproteins mechanisms of action (figure taken from Janicek and 
Averette, 2001). The E6 protein binds to p53 and induces its degradation. The E7 protein binds 
to the Rb gene, causing the transcription factor E2F-1 to become unbound and free to activate 
the cell cycle. 
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2.3. HPV Life Cycle 
The duration of the HPV life cycle is long and even under optimal conditions, it takes 
approximately three weeks from the time of initial infection to the release of HPV virions 
(Stanley, 2012). However, the duration from infection of the host cells to the appearance of 
lesions is variable, ranging from weeks to months, which suggests that in some cases, HPV is 
able to effectively evade host immune responses (Stanley, 2012). HPV is separated into two 
tropism groups: those infecting the keratinized surface of the skin, resulting in the development 
of warts; and those infecting the mucosa of the mouth, throat, respiratory tract and the 
anogenital tract (Burd, 2003; Mistry et al., 2008). HPV is highly infectious and may incubate 
for weeks, to months, or even years. At some point the environmental conditions become 
permissive and viral growth commences, and infectious virions are produced and released from 
the cell (Fernandes et al., 2013). The replication phase can continue for variable lengths of 
time; however, the majority of infected individuals are able to produce an effective immune 
response and are able to clear the infection (Stanley, 2006). HPV is an intraepithelial virus and 
infection and vegetative growth are reliant on the expression of the complete cycle of 
keratinocyte differentiation (Doorbar, 2005). The viral particles enter the basement membrane 
through microabrasions in the squamous epithelium and infect basal epithelial cells (Figure 3) 
(Passmore et al., 2016). High levels of viral gene expression occurs solely in the upper, more 
differentiated layers of the stratum spinosum and granulosum of the squamous epithelium 
(Chow et al., 2010). After the virus has infected the wounded basal cells, viral DNA replication 
occurs and the viral copy number is amplified to 50-100 copies per cell (Stanley, 2012). The 
infected host cell then enters the proliferative compartment of the epithelium, where the viral 
copy number remains unchanged and gene expression is low (Stanley, 2012). At this stage of 
the life cycle of HR-HPV, the expression of the E6 and E7 oncogenes are under stringent 
control and the E6 and E7 transcripts are hardly detectable in the proliferative compartment of 
the epithelium (Stanley, 2012). Once the infected keratinocyte reaches the differentiating 
compartment in the stratum spinosum, viral gene expression is upregulated and the viral copy 
number is amplified to thousands of copies per cell (Chow et al., 2010; Doorbar, 2007). At this 
stage, there is high expression of the E6 and E7 early and late genes from the late promoter 
(Chow et al., 2010; Doorbar, 2007). 
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Figure 3. Human Papillomavirus life cycle (figure taken from Stanley, 2012). HPV is species 
and tissue specific and only infects and replicates in completely differentiated squamous 
epithelium. Microtrauma of the genital epithelium provides a portal of entry for HPV to infect 
keratinocytes of the basal epithelium. In the proliferating compartment of the epithelium, the 
virus replicates along with the host cell and the viral copy number is approximately 50-100 
copies in the daughter cells. In HR-HPV the E6 and E7 genes are under stringent control 
during cell division and are consequently expressed at low levels. Once the host cell stops 
dividing and starts to differentiate into a mature keratinocyte, the virus activates all of its genes 
and the viral genomes is highly expressed. In the upper layers of the epithelium, all viral genes 
are expressed, viral genomes are encapsidated and the resulting virions exit the cell. The time 
taken from infection of the basal cell to the production of infectious viral particles is 
approximately 3 weeks. 
 
2.4. HPV Immune Evasion Strategies 
The life cycle of HPV is suited to the differentiation of the keratinocyte and the virus utilises 
this differentiation program to evade the host immune responses (Stanley, 2012).  HPV 
infection does not culminate in cytolysis or cytopathic death and important events of the virus 
life cycle occurs in fully differentiated keratinocytes, which are cells that are destined for death 
and desquamation at distant locations from immune activation (Stanley, 2012; Sasagawa et al., 
2012). Hence, there is no virus-induced cell death, no inflammatory response throughout most 
of its lifecycle and minimal production of pro-inflammatory cytokines, crucial for activation 
and recruitment of antigen-presenting cells (APCs), into the local environment (Stanley, 2006; 
Sasagawa et al., 2012). HPV is exclusively intraepithelial and does not have a viremic phase 
of the life cycle, thus only small amounts of virus are visible to the host immune defences 
(Figure 4). 
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Figure 4. Human Papillomavirus host immune evasion strategies (figure taken from Stanley, 
2012). HPV is capable of downregulating keratinocyte innate immune responses and 
supressing type I interferon responses, which are crucial for controlling viral infections 
(Stanley, 2012). HPV does not cause viremia or virus-induced cell death, thus there is no host 
inflammatory response (Stanley, 2012). 
 
2.4.1.  Evasion of Host Innate Immunity in HPV Infection 
HPV has developed immune evasion strategies in order to escape the host innate and adaptive 
immunity (Senba et al., 2012; Sasagawa et al., 2012; Stanley, 2012). The innate immune 
response towards HPV infection is non-specific and involves the recruitment of macrophages, 
NK cells and NK T cells (Sasagawa et al., 2012). NK cells are a group of lymphocytes that 
destroy virus-infected and tumour cells not expressing major histocompatibility complex 
(MHC) class I molecules (Sasagawa et al., 2012). Cervical cancer and precursor lesions were 
found to have low expression of NK cell receptors and decreased cytotoxic activity of NK cells 
(Garcia-Iglesias et al., 2009), indicative of a reduced ability to destroy infected cells. 
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Virus-infected cells release type 1 interferons (IFNs), such as IFN-α and IFN-β (Grandvaux et 
al., 2002) that have antiviral, antiproliferative and antiangiogenic properties, and activate NK 
cells (Sasagawa et al., 2012; Le Bon et al., 2002). HPV16 E6 and E7 proteins downregulate 
the transcription of type 1 IFNs (Koromilas et al., 2001) and inhibit its translocation to the 
nucleus (Arany et al., 1995). Downregulation of co-stimulatory molecules such as IFNs during 
antigen recognition may induce immune tolerance of HPV-infected cells (Sasagawa et al., 
2012). Macrophages are activated by cytokines and are able to destroy HPV infected cells 
through Tumour necrosis factor-α (TNF-α) (Routes et al., 2005) secretion or antibody-
dependent cytotoxicity (Sasagawa et al., 2012). Monocyte chemotactic protein-1 (MCP-1) and 
macrophage inflammatory protein-3α (MIP-3α) are chemokines that recruit macrophages to 
the site of infection (Sasagawa et al., 2012). These chemokines are downregulated by the 
HPV16 E6 and E7 proteins, thereby inhibiting translocation of macrophages to the site of HPV 
infection (Hacke, 2010; Guess et al., 2005). 
2.4.2. Evasion of Host Adaptive Immunity in HPV Infection 
The adaptive immune response is specific and is largely mediated by cytotoxic T lymphocytes 
(CTLs) (Sasagawa et al., 2012). MHC class I molecules bind viral peptides and present them 
at the cell surface to CD8+ CTLs.  The HPV16 E5 protein reduces the expression of MHC class 
I and results in evasion of CTL attack (Sasagawa et al., 2012). HPV is exclusively 
intraepithelial and HPV antigens are processed and presented by Langerhans Cells (LCs), 
which are APCs that reside within the epidermis (Stanley, 2012; Sasagawa et al., 2012).  Since 
HPV gene expression is restricted to keratinocytes, cross presentation of viral antigens by LCs 
and other DCs is crucial for the production of effective T cell responses towards HPV proteins 
(Stanley, 2012). However, the suboptimal codon usage by HPV (Zhao et al., 2005) results in 
low levels of protein expression in infected cells and may prevent effective cross presentation 
by intraepithelial DCs (Stanley, 2012). Furthermore, LCs are not activated upon exposure to 
the HPV16 L1 protein (Stanley, 2012; Fausch et al., ), but rather immune tolerance is 
induced (Fausch et al., 2005). Most HPV genotypes are also able to decrease the expression of 
E-cadherins on the epidermal cell surface, thereby decreasing the localization of LCs in the 
epidermis (Leong et al., 2010). Although the host immune responses are able to clear the 
majority of HPV infections (Senba et al., 2012), persistent infection may result in the 
development of lesions that may progress to malignancy and eventually ICC (Moody et al., 
2010; Bodily et al., 2011; Richardson et al., 2003). 
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2.5. HPV Persistence and Clearance 
Infection with oncogenic HPV generally lasts for 12-18 months before it is cleared by the host 
immune responses (Franco et al., 1999). HPV clearance has been linked to an increased risk of 
HIV infection (Averbach et al., 2010), however, the biological mechanisms involved in the 
clearance of HPV remains unclear (Fernandes et al., 2013). HPV clearance results in lasting B 
cell antibody and cellular responses able to prevent reinfection by the same HPV genotype 
(Gonzalez et al., 2010). In contrast, the persistence of HPV infection, dramatically increases 
the risk of progression to cancer (Schiffman et al., 2010). HPV is defined as persistent if the 
same genotype is detectable in two consecutive visits (Fernandes et al., 2013). However, HPV 
infections that go unrecognised by the host’s immunity may be due to viral latency, during 
which viral gene expression levels are below the limit of detectability of current HPV DNA 
detection assays (Fernandes et al., 2013). The persistence of HPV, and its integration into the 
genome of the host cell, leads to an increased possibility of developing high-grade and 
malignant lesions due to genomic instability (Fernandes et al., 2013). The expression of the 
E5, E6 and E7 genes can prompt cellular defects, such as fusion of cells, generation of 
aneuploidy and chromosomal instability (Fernandes et al., 2013). Abnormal centrosome 
duplication may also result in abnormal numbers of centrosomes (Fernandes et al., 2013). 
Disruption of the host cell-cycle through the interference of p53 and pRB, allows retention of 
cells with chromosomal anomalies (Münger et al., 2004). These anomalies culminate in 
genomic instability in HPV-infected cells, thereby increasing the risk of occurrence and 
accumulation of genetic mutations that extend over a long period of time (Fernandes et al., 
2013). The combination of genetic mutations and lack of an effective host immune response to 
identify and eradicate infected cells, provide an environment conducive for cancer to develop 
(Fernandes et al., 2013). Cellular proliferation within benign and malignant HPV lesions 
increase the need for nutrients, thereby causing competition for nutrients and oxygen 
(Fernandes et al., 2013). In order to overcome this, both oncogenic and non-oncogenic HPV 
E7 proteins increase the levels of transcription hypoxia-inducible factor-1 (HIF-1) and HIF-1 
target genes under hypoxic conditions (Toussaint-Smith et al., 2004). The heightening of HIF-
1 activity results in the upregulation of gene transcription that favours angiogenesis, and this 
plays a fundamental role in the persistence and progression of HPV-induced lesions, as it 
provides sufficient nutrients and oxygen in both benign and malignant HPV-induced lesions 
(Smith et al., 2007; Mukonoweshuro et al., 2005). 
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2.6. HPV Symptoms and Risk Factors 
HPV is predominantly a sexually transmitted infection and can be spread through penetrative 
vaginal or anal intercourse, oral sex and by direct contact with infected skin or mucosa 
(Moscicki et al., 2006). HPV infection is generally asymptomatic and is not typically related 
to symptoms such as itching, burning and vaginal discharge (Mao et al., 2003). The 
Papanicolaou (Pap) test is utilised to screen for cervical cancer; however, such tests are only 
recommended for women aged 30 years or older (CDC, 2017). Most HPV infected women are 
unaware that they are infected until they develop genital warts or when they receive abnormal 
Pap test results (CDC, 2017). The HPV genotype is the primary factor that determines the 
progression of persistent HPV infection, however, there are several other risk factors that 
contribute to HPV acquisition and persistence in women, including sexual behaviour and age, 
microabrasions in the genital tract, circumcision, smoking, alcohol abuse, long-term use of oral 
contraceptives and immunosuppression (Zitkute et al., 2016; Burchell et al., 2006; Dunne et 
al., 2007; Kahn et al., 2007; Manhart et al., 2006; Rosa et al., 2009; da Silva Barros et al., 
2012; Vaccarella et al., 2008; Minkoff et al., 2004; Koshiol et al., 2006; Schabath et al., 2015; 
Appleby et al., 2007; ACS, 2016; Goedert et al., 1998).  
2.6.1.  Sexual Behaviour and Age 
Sexually active women between 15-25 years have the highest prevalence of HPV infection and 
are at greatest risk of acquiring incident HPV (Zitkute et al., 2016; Burchell et al., 2006; Dunne 
et al., 2007; Kahn et al., 2007; Manhart et al., 2006). Biological factors and immune responses 
in young women may increase their susceptibility to HPV infection. Younger women lack 
sufficient adaptive immune responses (Dempsey, 2008) and have a large area of cervical 
epithelium undergoing squamous metaplasia, and during this time the cervical cells are more 
vulnerable to HPV infection and persistence (Trottier et al., 2006; Moscicki et al., 1999; Louie 
et al., 2009; Moscicki et al., 2006; Castle et al., 2006).  Studies have demonstrated an important 
link between women who had their sexual debut before the age of 16 years and HPV infection 
(Ribeiro et al., 2015; Baudu et al., 2014).  HPV prevalence has been described as bimodal, 
with a second peak among women 55 years and older, this may be due to weakening immunity, 
reactivation of latent HPV infection or birth-cohort effects (Herrero et al., 2000; Castle et al., 
2005). Sexual intercourse with a new partner or multiple partners has also been linked with 
increased risk of acquiring HPV infection, progression to pre-cancer lesions and invasive 
cervical cancer (Zitkute et al., 2016; Burk et al., 1996).  
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2.6.2. Microabrasions in the Genital Tract 
In order to establish infection, HPV requires a portal of entry to the basal cells through 
microabrasions in the mucosal epithelium (Mammas et al., 2009). Genital warts, HSV and 
chlamydia cause genital inflammation and lesions in the epithelial barrier, providing HPV 
direct access to basal cells (Rosa et al., 2009; da Silva Barros et al., 2012). Friction during 
sexual intercourse may also cause lesions in the epithelium and contribute to HPV acquisition. 
A study conducted by Norvell et al. demonstrated that microabrasions were present in 60% of 
healthy women after consensual sexual intercourse (Norvell et al., 1984).  
2.6.3. Circumcision 
Circumcised men are at a reduced risk of developing penile and prostate cancer (Zitkute et al., 
2016). According to the Centres for the Disease Control, the foreskin of the penis is more 
susceptible to infections than the skin on the shaft of the penis. The foreskin is more susceptible 
to lesions during sexual intercourse, thereby providing a point of entry for HPV infection and 
the ideal environment for viruses and bacteria to flourish (Zitkute et al., 2016). HPV is highly 
infectious and is easily transmitted from one sexual partner to another (Lacey, 2005). Studies 
have shown that HPV is often transmitted from men with penile warts to their female partners 
(Campion et al., 1985). Circumcision of adolescent men was shown to significantly reduce the 
prevalence and incidence of HPV infection among their female partners (Wawer et al., 2011). 
Furthermore, clearance of HR-HPV was more likely among women with circumcised male 
partners as opposed to those with uncircumcised partners (Wawer et al., 2011). Removal of the 
foreskin is likely to be associated with a reduction of penile HPV carriage (Wawer et al., 2011). 
Studies have shown HPV detection differs by the anatomical site and male circumcision is 
related to a reduction in HPV detection at the urethra, coronal sulcus and shaft of the penis 
(Giuliano et al., 2009; Weaver et al., 2004; Nielson et al., 2009). 
2.6.4. Smoking 
Cigarette smoking has been linked to HPV prevalence, persistence and increased risk of 
progression to ICC among women (Vaccarella et al., 2008; Minkoff et al., 2004; Koshiol et 
al., 2006; Bauer et al., 1993; Giuliano et al., 2002; Sellors et al., 2003; Sellors et al., 2000; 
Syrjanen et al., 2007; Winer et al., 2003). Although the biological mechanisms are uncertain, 
studies have demonstrated that smoking upregulates cellular proliferation and metaplasia in 
numerous tissues and cell subsets (Harris et al., 2004; Peters et al., 1993; Sekhon et al., 1994; 
Wright et al., 2001; Wright et al., 1983), which may lead to increased replication of HPV due 
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to cell proliferation that is induced by smoking (Schabath et al., 2012). Acrolein, an aldehyde 
in cigarette smoke, was shown to alter neutrophil function (Finkelstein et al., 2001), cause 
DNA damage (Feng et al., 2006), and suppress resistance to pulmonary infections (Li et al., 
1998). Cigarette smoking may also increase viral load by reducing the cellular immune 
response since it has deleterious effects on systemic and local immunity (Barton et al., 1988; 
Kalra et al., 2000; Poppe et al., 1995; Sopori, 2002). Smoking leads to the recruitment of cells 
and the upregulation of cytokines, chemokines, oxygen radicals and protease production, which 
changes the function of immune cells (Mehta et al., 2008). Additionally, nicotine has been 
associated with immune suppression in animals (Geng et al., 1996) and humans (Guslandi, 
1999). 
2.6.5. Alcohol Abuse 
Alcohol is a potent modulator of immune function and may result in immune deficiency and 
increased susceptibility to chronic and infectious diseases (Dunne, 1989; Szabo, 1997; Cook, 
1998; Diaz et al., 2002). Chronic alcohol abuse and even moderate alcohol consumption may 
have an undesirable effect on the immune system (Szabo, 1997; Diaz et al., 2002; Molina et 
al., 2010; Nelson et al., 2002). Alcohol consumption can hamper both the inflammatory 
response and development of immunity towards the pathogen (Szabo, 1997). Men and women 
who have a greater consumption of alcohol are at increased risk of having multiple HPV 
genotypes, resulting in higher cervical/anal lesions and genital warts (Zitkute et al., 2016). Four 
alcoholic drinks per week has been shown to double the risk of developing genital warts and 
five or more drinks is associated with a 2-4 times greater risk of HPV infection (Schabath et 
al., 2015).  
2.6.6. Long Term use of Oral Contraceptives 
Studies have reported that long-term use of oral contraceptives (OCs) is associated with 
progression to cervical cancer in HPV infected women (ACS, 2016). Contraceptive use may 
affect the clearance or persistence of HPV infection and the progression of pre-cancer lesions 
(Appleby et al., 2007). The risk of acquiring cervical cancer is significantly increased if OCs 
are used for more than 5 years (Appleby et al., 2007; Moreno et al., 2002). Marks et al. showed 
that women who reported current combined oral contraceptive (COC) use were less likely to 
clear HPV infection (Marks et al., 2011a). 
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2.6.7. Immunosuppression  
HIV attacks the immune system leading to an increased risk of incident HPV infection and 
progression to cervical cancer (Mbulawa et al., 2012; Wang et al., 2011; Massad et al., 2004; 
Aubin et al., 2011). Individuals with autoimmune or oncological diseases, undergoing 
immunosuppressive treatments (chemotherapy, monoclonal/polyclonal antibodies and 
glucocorticoids) are also at greater risk of acquiring HPV (Zitkute et al., 2016). 
Immunosuppression may facilitate the reactivation of latent HPV infections (Jamieson et al., 
2002; Moscicki et al., 2000; Ozsaran et al., 1999; Palefsky et al., 1999; Paternoster et al., 2008; 
Savani et al., 2009; Savani et al., 2008; Veroux et al., 2009). The dampening of the T cell 
immune responses through the administration of cyclosporine to renal transplant recipients or 
due to HIV infection, has been suggested as a cause of HPV reactivation (Jamieson et al., 2002; 
Moscicki et al., 2000; Ozsaran et al., 1999; Palefsky et al., 1999; Paternoster et al., 2008; 
Savani et al., 2009; Savani et al., 2008; Veroux et al., 2009). Additionally, among older women 
lacking signs of cervical disease by cytology, waning T cell immunity may be responsible for 
the increased prevalence of HPV infection (Maglennon et al., 2014). 
2.7. HPV Prevention 
Since there is no cure currently available for HPV infection, prevention of HPV infection is of 
utmost importance (Hathaway, 2012). Current HPV prevention strategies include vaccination, 
limiting sexual partners, postponing age of sexual debut, avoiding smoking, use of latex or 
vinyl condoms, and male circumcision (Hathaway, 2012; Diaz, 2008). Vaccines developed to 
prevent HPV infection were initially developed as the first vaccines to prevent cervical cancer 
(Fernandes et al., 2013). These vaccines consist of non-infectious virus-like particles (VLPs) 
that are immunologically similar to HPV and can induce neutralizing antibodies to the specific 
virus genotype (Frazer et al., 2011). Cervarix™ (GlaxoSmithKline), Gardasil™ (Merck and 
Co, Inc.) and Gardasil 9™ (Merck and Co, Inc.) are licensed prophylactic HPV vaccines that 
are accessible to adolescent girls as part of routine immunization schedules in some countries 
(Figure 5) (Frazer et al., 2011). Cervarix, the bivalent vaccine consists of VLPs assembled 
from the major coat proteins (L1) of HPV16 and HPV18 which have been implicated as the 
leading cause of cervical cancer (Stanley, 2012). Gardasil, the quadrivalent vaccine 
incorporates VLPs assembled from the L1 proteins of HPV16, HPV18, HPV6 and HPV11 
(Frazer et al., 2011; Stanley, 2012). Both vaccines are administered intramuscularly with three 
doses and provide rapid access to the local lymph node, thereby escaping the immune evasion 
strategies of the HPV life cycle (Stanley, 2012). These vaccines confer long-term protection 
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for up to 6.4 years for the bivalent vaccine (David et al., 2009) and 8.5 years for the 
quadrivalent vaccine (Villa et al., 2006; Rowhani-Rahbar et al., 2009). Recently, a 9-valent 
vaccine which additionally incorporates HPV31, HPV33, HPV45, HPV52 and HPV58 has 
been approved for routine use and has a high rate of efficacy against cervical lesions (Yang et 
al., 2016). HPV VLPs induce the production of neutralizing antibodies targeting the L1 capsid 
protein (Harro et al., 2001). The protective efficacy of these vaccines has been defined as the 
absence of persistent HPV infection and/or diseases related to the HPV genotypes incorporated 
into vaccines (Frazer et al., 2011). Donovan et al. demonstrated a reduction in the appearance 
of HPV-associated genital warts among women below 28 years old, this provided the first 
evidence of field efficacy of HPV vaccines in the general population (Donovan et al., 2011). 
There are currently thirteen HR-HPV types that may cause cervical cancer and some cross 
protection against other HPV types not included in the current vaccines, has been observed 
(Frazer et al., 2011). 
 
Figure 5. Current HPV vaccines available as routine (figure taken from 
elbiruniblogspotcom.blogspot.com ). The bivalent vaccine incorporates HPV16 and HPV18. 
The quadrivalent vaccine also incorporates HPV6 and HPV11. The 9-valent vaccine confers 
protection against HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV45, HPV52 and 
HPV58. 
  
2.8. HPV Treatment 
Most HPV-infected women will clear infection spontaneously (Hathaway, 2012). However, 
some individuals are unable to do so and may undergo treatment. Treatment of HPV-related 
disease generally involves ablative and/or excisional procedures in order to remove the HPV-
infected cells (Fernandes et al., 2013). Chemical therapy for genital warts include 
trichloroacetic acid, podophyllin compounds, and Imiquimod (Hathaway, 2012; Fernandes et 
al., 2013).   
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Trichloroacetic acid is a caustic substance that is applied topically to the lesion (Hathaway, 
2012). Podophyllin compounds block cell division and Imiquimod compounds induce IFN and 
TNF production (Tyring et al., 1998). Cryotherapy is used to freeze the lesion which leads to 
cell death (Chumworathayi et al., 2010). Common agents used for cryotherapy are liquid 
nitrogen or a cooled metal probe known as a cryoprobe (Hathaway, 2012). The cryoprobe is 
not typically suitable for use in the vagina due to fistula formation, however, liquid nitrogen is 
acceptable (Hathaway, 2012). Extensive HPV lesions may be treated with electrocautery 
(Hathaway, 2012). The spread and damage caused by vaginal lesions can be control with 
precise destruction by a laser (Hathaway, 2012). Large and extensive lesions may require 
surgical removal (Hathaway, 2012). In this case, a scalpel is used to excise the lesion to the 
level of the skin and the base of the lesion is cauterized with electrocautery or a laser 
(Hathaway, 2012). 
2.9. HPV Infection Increases the Risk of HIV Acquisition 
In recent years, the association between genital HPV infection and HIV risk has generated 
much interest. Several studies have reported an association between HIV infection and 
increased HPV prevalence (Banura et al., 2008a; Ng'andwe et al., 2007; Baay et al., 2004; 
Didelot-Rousseau et al., 2006; Safaeian et al., 2008; Marais et al., 2008; Yamada et al., 2008), 
HR-HPV prevalence (Ng'andwe et al., 2007; Didelot-Rousseau et al., 2006), HPV incidence 
(Safaeian et al., 2008) and HPV persistence, which is related to increased risk of HPV-related 
lesions (Safaeian et al., 2008; Banura et al., 2008b) and infection with multiple concurrent 
HPV genotypes (Ng'andwe et al., 2007; Didelot-Rousseau et al., 2006; Marais et al., 2008). In 
women, the risk of acquiring HIV was increased in the presence of any HPV genotype 
compared to those without HPV (Averbach et al., 2010; Low et al., 2011; Smith-McCune et 
al., 2010a). Averbach et al. compared infection with LR-HPV (no HR-HPV) whilst Smith-
McCune et al. compared infection with LR-HPV (irrespective of concurrent HR-HPV 
infection) to no HPV, and a doubling of HIV risk was observed in both studies (Averbach et 
al., 2010; Smith-McCune et al., 2010a). Several studies have shown that infection with HR-
HPV was independently associated with an increased risk of HIV seroconversion (Averbach et 
al., 2010; Auvert et al., 2011; Smith-McCune et al., 2010b). Having 2 concurrent HPV 
genotypes has been related to a doubling in the odds of acquiring HIV, whilst having 4 or more 
concomitant HPV genotypes had a odds ratio of 5.6 (Averbach et al., 2010). Moreover, Auvert 
et al. demonstrated that having multiple concurrent HR-HPV infections significantly increases 
the risk of acquiring HIV (Auvert et al., 2011).  
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2.10. HIV Epidemiology 
In 2015, an estimated 36.7 million people were living with HIV, 2.1 million people became 
newly infected and 1.1 million people died from Acquired Immunodeficiency Syndrome 
(AIDS)-related illnesses globally (UNAIDS, 2016). In Africa, more than 1% of the population 
becomes infected with HIV each year (Wang et al., 2016).  SSA is home to merely 12% of the 
global population, yet accounts for 71% of the global burden of HIV infection (Figure 6) 
(Kharsany et al., 2016; UNAIDS, 2016).  It is interesting to note that it is also in SSA that the 
prevalence of HPV is among the highest in the world (Bruni et al., 2010; Denny et al., 2014). 
 
Figure 6. Global HIV prevalence in 2015 (figure taken from: Kaiser Family Foundation based 
on UNAIDS). Sub-Saharan Africa had the highest global HIV prevalence >10% in 2015.  
 
In 2016, an estimated 7.1 million people were living with HIV in South Africa (UNAIDS, 
2017). HIV incident rates remain unacceptably high in South Africa, with 270,000 new 
infections and 110,000 AIDS-related deaths in 2016 (UNAIDS, 2017). The KZN province 
bares a disproportionate burden of HIV infection, accounting for  the highest percentage 
(16.9%) of prevalent infections in South Africa (Shisana et al., 2014). The introduction of 
antiretroviral therapy (ART) in 1996 has greatly reduced HIV-related mortality (Ford et al., 
2016; Granich et al., 2015). However, maintenance and scale-up of adequately funded AIDS 
efforts will be imperative to accomplish the goal of an “AIDS free generation” by 2030 (Piot 
et al., 2015). New prevention strategies which address the biological risk factors associated 
with HIV acquisition are urgently required. 
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2.11. HIV Transmission in the Female Genital Tract 
In order to develop successful HIV prevention strategies it is important to understand how HIV 
is transmitted in the female genital tract (FGT). Most female HIV-1 infections are the result of 
heterosexual intercourse with an infectious male partner (UNAIDS, 2012). The female 
reproductive tract is comprised of two different mucosal surfaces (Eid et al., 2015). In order 
for HIV to establish infection in the FGT, HIV-1 in the male ejaculate must evade both innate 
and adaptive immune responses, cross the epithelial barrier and establish infection in the 
underlying CD4+ target cells (Carias et al., 2013). The primary receptor for HIV entry into the 
host cells is CD4, and the major co-receptors are CXCR4 and CCR5 (Sattentau et al., 1986; 
Deng et al., 1996; Feng et al., 1996). There are three main mechanisms that HIV employs to 
traverse the epithelial cells of the FGT: through microabrasions in the epithelial barrier, through 
transcytosis mediated by neonatal Fc receptor (FcRn); or by paracellular movement between 
the epithelial cells (Rodriguez-Garcia, 2013). The endocervix and upper reproductive tract is 
made up of a monolayer of columnar epithelial cells (Figure 7A) and the ectocervix and vagina 
which is covered with a multilayer of squamous epithelial cells and tight junctions (Figure 7B 
to F) that HIV-1 must transverse in order to establish infection (Carias et al., 2013; Eid et al., 
2015; Kumamoto et al., 2012).  
 
Figure 7. Epithelial composition and HIV targets of the female genital tract (figure taken 
from Carias et al., 2013). (A) The upper reproductive tract is primarily composed of a 
monolayer of columnar epithelial cells. (B) The lower reproductive tract consisting of the 
ectocervix and vagina is covered with a multilayer of squamous epithelial cells which is made 
up of the stratum corneum (C), stratum granulosum (D), stratum spinosum (E) and stratum 
basale (F). Intraepithelial target cells include Langerhans cells (red). HIV target cells in the 
lamina propria consists of dendritic cells (green), T cells (blue) and macrophages (purple). 
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The columnar epithelium of the endocervix and upper FGT may be an easier route of entry for 
HIV-1 to access target cells since it is composed of a thin, single layer of cells (Shattock et al., 
2003). Additionally, the transition between the squamous and columnar epithelial cells that 
occurs at the transformation zone provides a portal of entry for HIV-1 (Eid et al., 2015). 
2.12. Biological Defences of the Female Genital Tract 
Globally, females are at greater risk of acquiring HIV than their male counterparts (UNAIDS, 
2013; Ramjee et al., 2013; Boily et al., 2009). Although unprotected vaginal sex increases the 
risk of acquiring HIV infection, the majority of exposures to the virus does not lead to infection 
(Boily et al., 2009). This is largely due to the mucosal immune responses at the FGT that help 
to prevent HIV from establishing infection. Mucosal immunity in the FGT consists of innate 
and adaptive immune responses. Innate immunity includes defences such as the epithelial 
barrier, mucus, low or acidic pH, the complement system and cells of the immune system (Reis 
Machado et al., 2014). The layer of mucus produced by the vagina and cervix can trap HIV 
and prevent it from crossing the epithelial barrier and minimises damage caused by friction 
during sexual intercourse (Petrova et al., 2013; Wira et al., 2015). The mucus consists of 
mucins that form a thick gel mesh which acts as a physical barrier to HIV (Gipson, 1997; Vigil, 
2009). The aqueous component of the mucus is rich in immunoglobulins and antimicrobial 
peptides which also provide protection against invading pathogens (Ming, 2007). The 
squamous epithelium of the vagina and ectocervix are many layers thick and acts as a physical 
barrier against HIV entry (Shattock et al., 2003). The multi-layered and single cell layer 
epitheliums are both held together by proteins that form desmosomes, tight junctions and 
adherens junctions, which reduces its permeability (Carias, 2013). Among women in developed 
countries, the lower portion of the FGT (vagina and ectocervix) is colonised by commensal 
bacteria that consists predominantly of Lactobacillus species (Ravel et al., 2011; Martin et al., 
2008). Lactobacillus maintains an acidic pH in the vagina through the production of lactic acid 
and hydrogen peroxide (H2O2), which has antimicrobicidal activity (Ravel et al., 2011; Martin 
et al., 2008; Lai et al., 2009). The adaptive immune response in the FGT consists of antibodies 
and immune cells in the vaginal mucus and epithelial lining that attacks and inactivates HIV 
(Reis Machado et al., 2014)rkell. Although the immune system offers protection against HIV 
infection, the immune cells located in the FGT may also increase vulnerability to HIV 
infection, because HIV can attack these immune cells in the vaginal mucous and epithelial 
lining (Griesbeck et al., 2016; Adimora et al., 2013). The adaptive immune response is 
pathogen-specific that occurs after T cell presentation and stimulation by APCs or by B cell 
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antibody secretions (Reis Machado, 2014). APCs in the FGT include macrophages, DCs, 
Langerhans cells and epithelial cells of the cervix and endometrium (Reis Machado, 2014). 
The effector cells are CD4+ T cells including the cytokines they produce, CD8+ T cells and 
immunoglobulins (Reis Machado, 2014). 
2.13. Genital Inflammation Increases Susceptibility to HIV Infection 
Inflammation is a natural response of the immune system to fight off infection and invading 
pathogens, however, inflammation can increase susceptibility to HIV infection. Genital 
inflammation may render an individual more vulnerable to HIV infection through the 
recruitment and activation of HIV target cells (CD4+CCR5+) (McKinnon et al., 2011; Arnold 
et al., 2016). Infection, irritation and/or epithelial disruption may lead to immune activation in 
the FGT, resulting in increased expression of soluble immune proteins (Haase, 2010) and 
recruitment of cells expressing HIV co-receptors, thereby increasing the risk of HIV acquisition 
(Fichorova et al., 2001b). Although there are several HIV target cells in the FGT, the virus 
either directly infects CD4+CCR5+ T cells in the mucosa or binds to DCs with subsequent 
presentation and infection of CD4+ T cells (Belyakov et al., 2004; Li et al., 2009).  
The innate immune response in the FGT is regulated by cytokines and chemokines. Cytokines 
are small glycoproteins that are synthesised by numerous cell types, primarily leukocytes, they 
regulate immunity, inflammation and haematopoiesis (Khan, 2008). Cytokines can be 
categorized as pro-inflammatory, anti-inflammatory, chemokines, growth factors and adaptive 
cytokines based on their biological activity. Pro-inflammatory cytokines are synthesised 
predominantly by activated macrophages and helper T cells and are involved in the 
upregulation of inflammatory responses (Zhang et al., 2007).  Chemokines are secreted in order 
to recruit immune cells to the epithelial surface (Fahey et al., 2005). The levels of inflammatory 
cytokines and chemokines which recruit activated HIV target cells to the genital mucosa are 
used as biomarkers of inflammation in the FGT (Fichorova et al., 2004; Schwartz et al., 2006; 
Fichorova et al., 2001b; Fichorova, 2004; Masson et al., 2015). In the CAPRISA004 1% 
tenofovir gel trial, a pro-inflammatory cytokine profile predicted HIV acquisition (Figure 8) 
(Masson et al., 2015). Genital inflammation was defined by having at least 5 of 9 pro-
inflammatory cytokines (IL-1α, IL-1β, IL-6, TNF-α, IL-8, IP-10, MCP-1, MIP-1α and MIP-
1β) concentrations above the 75th percentile (Masson et al., 2015). The risk of acquiring HIV 
was increased among women with evidence of genital inflammation, and also with increasing 
concentrations of MIP-1β, IP-10, and IL-8 (Masson et al., 2015). Furthermore, the presence of 
 23 
 
chemokines MIP-1α, MIP-1β and IL-8 in the genital tracts of rhesus macaques was shown to 
be necessary for establishment of SIV infection after vaginal challenge (Li et al., 2009). High 
levels of chemokines also result in the recruitment of CD4+ T cells to the site of infection 
thereby facilitating HIV replication (Li et al., 2009). Genital cytokine production has been 
associated with the frequency of local HIV target cells (Arnold et al., 2016; McKinnon et al., 
2011); and a reduced ability of the genital mucosa to function as an effective physical barrier 
to HIV infection (Arnold et al., 2016).  
 
Figure 8. Clustering of HIV positive and HIV negative women based on their cytokine 
expression profiles (figure taken from Masson et al., 2015). Women who later became HIV 
seropositive (n = 58; blue blocks) had greater cytokine concentrations in CVL specimens and 
clustered together, whilst women who remained HIV seronegative (n = 58; yellow blocks) had 
lower cytokine concentrations and clustered separately. Cytokine concentrations range from 
low (green) to high (red). The dendrogram above the heat map demonstrates degrees of 
relatedness between the genital cytokine profiles. 
 
The epithelial barrier is one of the most important defences against HIV, since the virus must 
cross this barrier in order to establish infection. Matrix metalloproteinases (MMPs) are zinc 
dependent endopeptidases that function in the degradation and remodelling of the epithelial 
barrier (O'Sullivan et al., 2015). They are grouped according to domain structure and substrate 
preferences into collagenases, gelatinases, stromelysins and membrane type MMPs (Egeblad 
et al., 2002). MMPs contribute to inflammation through the regulation of physical barriers, 
modulating cytokines and chemokines and establishing chemokine gradients in inflamed 
tissues that control the recruitment of leukocytes at the site of infection (O'Sullivan et al., 
2015). MMP concentrations have been used as biomarkers of inflammation and an indicator of 
reduced epithelial barrier integrity (Ngcapu et al., 2015; Arnold et al., 2016). Selhorst et al. 
reported that reduced epithelial barrier integrity and HIV target cell recruitment facilitates 
infection by less-infectious HIV variants (Selhorst et al., 2017). Furthermore, among HIV 
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positive individuals, mucosal ulcerations have been associated with higher genital HIV viral 
load (Kreiss et al., 1989), indicating that an intact epithelial barrier may reduce secondary 
sexual HIV transmission from an infected person (Kaul et al., 2008). 
2.14. Sexually Transmitted Infections and Genital Inflammation 
STIs are able to induce robust mucosal immune responses and genital inflammation in order to 
clear infection (Patel et al., 2014). Since STIs upregulate the production of pro-inflammatory 
cytokines and are associated with reduced epithelial barrier integrity and HIV target cell 
recruitment, they are considered risk factors for HIV acquisition (Laga et al., 1993; van de 
Wijgert et al., 2009; Van Der Pol et al., 2008; Anahtar et al., 2015; Arnold et al., 2016; Kaul 
et al., 2008). Ulcerations caused by STIs may facilitate blood to blood contact and HIV 
transmission, furthermore, HIV infected individuals with concomitant STI infection may have 
increased viral shedding at the genital tract (Fox et al., 2010). STIs such as genital herpes or 
syphilis cause ulcerations in the epithelial cell layers of the vagina or cervix, providing a portal 
of viral entry (Petrova et al., 2013; Wira et al., 2015). Furthermore, independent associations 
have also been reported between HIV risk and Chlamydia trachomatis (C. trachomatis), 
Neisseria gonorrhoeae (N. gonorrhoeae), Trichomonas vaginalis (T. vaginalis) and HPV 
(Ramjee et al., 2005; Losina et al., 2010; Wilkinson et al., 1998; Naidoo et al., 2014). 
Gonorrhoea and Chlamydia have been shown to cause genital inflammation and increase 
activated mucosal CD4+ T cells, thereby increasing the risk of HIV acquisition (Levine et al., 
1998).  
Among HPV positive women, concomitant STI infection has been shown to prolong HPV 
infection and increase the risk of CIN (Finan et al., 2002; Syrjänen et al., 1985; Silins et al., 
2005; Alberico et al., 1988). For instance, T. vaginalis infection has been associated with a 
greater risk of squamous intraepithelial lesions and CIN (Noel et al., 2010). N. gonorrhoea was 
identified as a co-factor for the persistence of HR-HPV infection in cervical carcinogenesis (de 
Abreu et al., 2016). Studies have even demonstrated that Mycoplasma genitalium (M. 
genitalium) was significantly associated with an increased risk of HR-HPV infection (Biernat-
Sudolska et al., 2011). Furthermore, coinfection with C. trachomatis has been associated with 
HPV persistence and cancer (Simonetti et al., 2009). Silins et al. demonstrated that among 
women with HR-HPV, antibodies elicited against C. trachomatis were associated with a two-
fold increased risk of cervical cancer (Silins et al., 2005). Cervical carcinoma cell lines infected 
with C. trachomatis secrete increased levels of pro-inflammatory cytokines compared to 
primary uninfected cervical cells and non-cervical epithelial cell lines (Rasmussen et al., 1997), 
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suggesting that coinfection with HPV and C. trachomatis may exacerbate genital inflammation 
(Castle et al., 2003). 
2.15. Genital inflammation as the underlying link between HPV and HIV risk 
The biological mechanisms HPV employs to increase HIV risk remains to be elucidated. HPV 
infection could escalate HIV infection and dissemination via disruption of the epithelial barrier 
and alteration of the genital mucosa (Clarke et al., 2002), through recruitment and activation 
of HIV target cells (Nicol et al., 2005) and upregulation of pro-inflammatory cytokines (Herfs 
et al., 2011; Nicol et al., 2005). Both HIV and HPV use common portals of entry such as the 
squamo-columnar junctions which are primary sites of metaplastic conversion and viral 
establishment in order to gain access to susceptible cells (Herfs et al., 2011). Adhesion 
molecules are less dense at squamo-columnar junctions which allows for paracellular 
permeation (Herfs et al., 2011). Microabrasions which permit HPV access to the basal 
epithelial layers may also favour HIV acquisition (Herfs et al., 2011). The host immune 
response to HPV is mediated by T-lymphocytes, which are also primary target cells for HIV 
(Houlihan et al., 2012; Stanley, 2001). Recruitment of HIV target cells (CD4+CCR5+) to the 
FGT to clear HPV infection may also provide an immune environment conducive to HIV 
acquisition. An abundance of the pro-inflammatory cytokine IL-1β, which activates a promoter 
region in the HIV genome (Osborn et al., 1989) has been observed in women with HPV-
associated abnormal cervical cytology (Behbakht et al., 2002).  
Combining HIV treatment with adequate prevention strategies is crucial in continuing the path 
to altering the trajectory of the AIDS epidemic (Kharsany et al., 2016). HPV is one of the most 
common STIs globally, and prior infection with HPV is associated with an increased risk of 
HPV persistence and HIV acquisition in both women and men (Mbulawa et al., 2012; Smits et 
al., 2005; Heard et al., 2000; Lissouba et al., 2013; Rositch et al., 2013; Chin-Hong et al., 
2009). The HPV vaccine is highly effective in preventing HPV-associated cervical cancers and 
could have potential use as an additional HIV prevention strategy, particularly in KZN where 
both HPV and HIV prevalence are unacceptably high. Understanding the biological 
mechanisms for the relationship between HPV and increased risk of HIV acquisition is critical 
to the design of effective methods to limit the spread of both HPV and HIV. This study 
investigated whether the immune responses associated with HPV infection contribute to a 
genital immune environment conducive to an increased risk of HIV infection.  
 
 26 
 
3. HYPOTHESIS 
The immune responses associated with HPV infection (including multiple HPV infections, 
oncogenicity, and STI coinfection) each contribute to a genital immune environment conducive 
to an increased risk of HIV acquisition. 
4. OBJECTIVES 
1) To compare genital inflammation (as measured by cytokine biomarkers, HIV target cell 
frequency, and/or epithelial barrier integrity) in HPV positive and HPV negative 
women. 
2) To determine the contribution of multiple concurrent HPV infections on genital 
inflammation. 
3) To compare genital inflammation in women with oncogenic and non-oncogenic HPV 
infection.  
4) To compare genital inflammation in women with HPV/STI coinfection and those 
without. 
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5. METHODOLOGY 
5.1. Study Design 
This cross-sectional study was conducted to compare biomarkers of genital inflammation 
among women with HPV infection and those without, women with multiple concurrent HPV 
infections and those without, women with HR-HPV infection and LR-HPV infection, and 
among women with an HPV/STI coinfection and those without. This study was approved by 
the Biomedical Research Ethics Committee at the University of KwaZulu-Natal under the 
ethics number BE248/16 (Appendix A). All laboratory assays were conducted at the 
CAPRISA Mucosal Immunology Laboratory in Durban, South Africa.  
5.2. Study Population 
The study population included 167 HIV negative women from the CAPRISA 008 trial, an 
open-label randomized controlled trial to assess the effectiveness of delivering tenofovir 1% 
gel in the context of routine family planning. The women enrolled in this study were aged 18-
40 years old, were from urban and rural KwaZulu-Natal, and had previously participated in the 
CAPRISA 004 trial. At the time of sampling, all participants had not used 1% Tenofovir gel 
for a minimum of 3 years since exiting the CAPRISA 004 trial. 
5.3. Specimen Collection and Processing 
5.3.1. Cervical Cytobrush Collection and Processing  
The study participants were positioned with their buttocks at the edge of the exam table. The 
speculum was inserted into the vagina and the blades were locked into position wide enough 
to allow complete visualisation of the cervix. The cytobrush was inserted into the endocervical 
canal, gently rotated 360º twice, and removed. The cytobrush was then immediately placed into 
a conical centrifuge tube containing 3ml of collection medium. The tube was labelled, sealed 
and transported on ice to the CAPRISA laboratory within 2 hours of sample collection. 
Immediately upon receipt of the sample, the cytobrushes were irrigated with a Pasteur pipette 
containing sterile PBS and thereafter, centrifuged at 400 xg. The cytobrush pellet was used for 
ex vivo cellular phenotyping by flow cytometry. 
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5.3.2. Cervicovaginal Lavage Collection and Processing  
The tip of a plastic bulb pipette was cut off and the bulb was affixed to a 10 ml syringe. A 
volume of 5 ml of sterile saline was drawn up, a speculum was lubricated and inserted into the 
vagina and the pipette was inserted into the vagina through the speculum. The saline was 
squeezed out of the pipette and allowed to bathe the cervix. The fluid was then aspirated into 
the same pipette and this procedure was repeated 2 to 3 times and then dispensed into a 
collection container. The cervicovaginal lavage (CVL) sample was kept on ice and transported 
to the laboratory along with the cytobrush. Immediately upon receipt at the CAPRISA 
laboratory, the sample was processed by: spinning at 800 g for 10 minutes and the supernatant 
was stored in 1 ml cryovials without disturbing the pellet. The cryovials containing the cell 
pellet and supernatant were stored at -85ºC degrees in the cryofreezer. 
5.3.3. Swab Collection and Processing 
Moistened cotton wool swabs were used to clean the vulva, wiping from front to back. The 
vulva and perineum were examined for external lesions or warts. The labia were then gently 
parted and a swab was inserted into the vagina. Two vaginal swabs were collected and each 
was placed into a 1.5 ml cryovials containing 0.4 ml PBS. The stem of the swab was cut off, 
allowing the swab to fit into the container. The cryovials were sealed and shipped to the 
CAPRISA laboratory. One swab was sent to the National Institute for Communicable Diseases 
(NICD) where Multiplex PCR assays were conducted as a service, to identify infection with 
discharge-associated agents: T. vaginalis, C. trachomatis, N. gonorrhoeae, and M. genitalium, 
as described by Mhlongo et al., 2010. 
5.4. Detection of HPV Genotypes in Cervicovaginal Lavage Pellet Specimens 
The Roche linear array assay was conducted to detect the presence of 37 relevant HPV types 
(HPV 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 67, 68, 
69, 70, 71, 72, 73, 81, 82, 83, 84, 55, 64, CP6108, and IS39) in CVL pellet specimens that were 
collected at baseline.  
5.4.1. HPV Roche Linear Array Assay 
The Linear Array assay (Roche Diagnostics, Indianapolis, IN, USA) was conducted according 
to the manufacturer’s instructions. These are briefly detailed here. 
5.4.1.1. Specimen Preparation 
HPV DNA extraction was conducted using the MagNA Pure 96 DNA and Viral Nucleic Acid 
Small Volume Kit (Roche Applied Science, Manheim, Germany). A volume of 200 µl of the 
 29 
 
CVL pellet was placed into a MagNA Pure 96 Processing Cartridge, which was inserted into 
the MagNA Pure 96 Extraction Machine. The specimen preparation yielded HPV target DNA 
which was subsequently used for polymerase chain reaction (PCR) amplification.    
5.4.1.2. Amplification Reagent Preparation 
The Master Mix (MMX) was prepared by adding 125 µl of Magnesium Chloride solution to a 
vial of HPV MMX, included in the kit. The vial was inverted to mix its contents, which were 
then transferred to a reservoir. A multichannel pipette was used to add 50 µl of Working MMX 
into a 96 well PCR plate. A volume of 50 µl of the samples and controls were added to the 
microtiter plate. 
5.4.1.3. Amplification Procedure 
The 96 well plate containing samples and working MMX was placed into the GeneAmp® PCR 
System 9700 (Applied Biosystems, Norwalk, CT). The thermal cycler program was set 
according to Table 1. In the cycle programs, the ramp rate was set to 50%. The plate was 
removed within 4 hours of the start of the final “Hold” programme, and samples were 
immediately denatured by the addition of 100 µl of the denaturation solution. 
Table 1. Thermal cycler specification for amplification (Table adapted from 
Roche Linear Array Instruction Manual). 
Program Type Description Number of Cycles 
Hold 50ºC, 2 minutes 1 
Hold 
95ºC, 9 minutes 1 
95ºC, 30 seconds 40 
Cycle 
55ºC, 1 minute 40 
72ºC, 1 minute 40 
Hold 72ºC, 5 minutes 1 
Hold 72ºC, forever 1 
 
5.4.1.4. HPV Genotyping 
The Working Hybridization Buffer, Working Ambient Wash Buffer, Stringent Wash Buffer 
and the Working Citrate Buffer (all supplied with kit) were prepared as shown in Table 2. The 
Linear Array HPV strips were removed from the pouch using sterile forceps and labelled. Each 
labelled HPV strip was placed into the 24 well tray with the probe lines facing upwards. 
Thereafter, 4 ml of pre-warmed Working Hybridization Buffer was added into each well 
containing the labelled strip. A volume of 75 µl of denatured PCR product was added to the 
wells and the tray was covered with the lid. The tray contents were mixed by rocking back and 
forth between each sample addition. The covered tray was placed into a 53ºC shaking water 
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bath with a 0.5 kg lead ring on top to prevent the tray from moving. Hybridization occurred for 
30 minutes while shaking at 60 revolutions per minute (RPM) on a Mini Orbital SSM1 Shaker 
(Stuart, Staffordshire, UK). A Working Conjugate was prepared by adding 15 µl of 
Streptavidin-Horseradish Peroxidase (SA-HRP) to 5 ml of Working Ambient Wash Buffer for 
each strip to be tested. The tray was removed from the water bath and the Working 
Hybridization Buffer was vacuum aspirated.  
Table 2. Preparation of Wash Buffers for HPV genotyping. 
Buffer Contents Volume (ml) 
Working Hybridization Buffer 
Distilled Water (dH2O) 388 
Sodium Chloride-Sodium Phosphate-EDTA (SSPE) 100 
20% Sodium Dodecyl Sulfate (SDS) 12 
Working Ambient Wash Buffer 
dH2O 2520 
20x SSPE 133 
20% SDS 13.3 
Stringent Wash Buffer Wash Buffer per strip was warmed to 53ºC for 15 minutes. 5ml per strip 
Working Citrate Buffer 
20x Citrate Buffer 25 
dH2O 475 
 
A volume of 4 ml of Working Ambient Wash Buffer was added to each well of the tray which 
was gently shaken to rinse the strips and the wash buffer was removed using vacuum aspiration. 
A volume of 4 ml of Stringent Wash Buffer was added to each well and the lid was placed onto 
the tray which was incubated in the 53ºC shaking water bath for 15 minutes. Afterwards, the 
tray was taken out of the water bath and the wash buffer was aspirated. A volume of 4 ml of 
Working Conjugate was pipetted into each well and the lid was placed back onto the tray and 
incubated at 60 RPM for 30 minutes at room temperature on the shaker. The Working 
Conjugate was aspirated and 4 ml of Working Ambient Wash Buffer was added to the tray 
which was then gently shaken to rinse the strips and vacuum aspirated once again. A volume 
of 4 ml of the Working Ambient Wash Buffer was added to each well and the tray was 
incubated for 10 minutes at room temperature on a platform shaker. The wash buffer was 
aspirated and the wash step was repeated with aspiration. A volume of 4 ml of Working Citrate 
Buffer was added to each well and incubated at 60 RPM for 5 minutes at room temperature on 
a platform shaker. The Working Substrate was prepared by adding 4 ml of Substrate A to 1 ml 
of Substrate B per strip and mixed well. The Working Citrate Buffer was aspirated and 4 ml of 
Working Substrate was added to each well and incubated for 5 minutes on a platform shaker at 
room temperature. The Working Substrate was aspirated and 4 ml of dH2O was added to each 
well.  The strips were removed from the tray using forceps and left to air dry for up to 72 hours 
at room temperature. The strips were interpreted manually using the HPV Reference Guide by 
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aligning the reference line on the guide with the ink line of the strip. Detection of the 
endogenous beta-globin sequence was used as an internal positive control to determine whether 
DNA extraction was successful.  
5.5. Investigation of Immune Cell Frequency Cervical Cytobrush Pellet Specimens 
Multiparametric flow cytometry was conducted to investigate the dynamics and the frequency 
of activated (CD38+ or HLA-DR+) or proliferating (Ki67+) T cells (CD3+ CD4+ or CD8+), NK 
cells (CD56+CD16+) and activated CCR5+CD4+ targets for HIV replication in cervical 
cytobrush pellet specimens.  
5.5.1. Surface Staining of Cellular Immune Markers 
After processing, cells were isolated from cytobrushes (~100 µl) and placed into a 96 well plate 
for staining.  The cytobrush samples were washed with 150 µl Phosphate Buffered Saline 
(PBS) and added to the respective wells. The cells were pelleted by centrifugation at 2100rpm 
for 3 minutes (833 xg) at 4ºC. The supernatant was discarded and the pellets were resuspended 
in 200 µl PBS and centrifuged at 2100rpm for 3 minutes (833 xg) at 4ºC. The live/dead stain 
Fixable Violet Dead Cell Stain kit (VIVID, Molecular probes, Life technologies, USA) was 
used to identify viable cells. The Vivid dye was prepared by making a 1:40 dilution with dH2O. 
This solution was further diluted 1:20 with PBS and 50 µl of this working stock solution was 
added to each well containing cell pellets. The plate was incubated at 4ºC for 20 minutes in 
darkness. The pellets were resuspended in 200 µl Wash Buffer (1% FBS in PBS) to each well. 
The plate was centrifuged at 2100rpm (833 xg) for 3 minute at 4ºC in an Eppendorf 5810 
Centrifuge (Eppendorf AG, Hamburg, Germany) and the supernatant was discarded. The 
mononuclear cells were stained extracellularly with a concoction of antibody-conjugated 
fluorochromes: Allophycocyanin Tandem Dye (APC-H7)-labelled anti-CD3 (BD Bioscience), 
Pacific Blue–labelled anti-CD14 (BD Bioscience), Pacific Blue labelled anti-CD19 (BD 
Bioscience), eF605-labelled anti-CD16 (eBioscience), Fluorescein Isothiocyanate (FITC)-
labelled anti-CD8 (BioLegend) , Peridinin-Chlorophyll Protein-Cyanine 5.5 (PerCP-Cy5.5)-
labelled anti-CD4 (BD Bioscience)  and Phycoerythrin Cyanine 7 labelled anti-CD56 (BD 
Bioscience). These antibodies were pre-titrated and 2 µl of each was added to the wells, with 
the exception of anti-CD4, of which only 1 µl was added into each well. The plate was 
incubated at 4oC for 20 minutes in darkness to facilitate antibody binding. 
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5.5.2. Intracellular Staining of Cellular Immune Markers 
Once incubation was completed, the cells were gently resuspended in 200 µl Wash Buffer (1% 
FBS in PBS) and centrifuged at 2100rpm for 3 minutes (833 xg) at 4ºC. The supernatant was 
removed and the pellets were treated with 100 µl Cytofix/Cytoperm (BD Bioscience) and the 
plate was incubated at 4ºC for 20 minutes in darkness. A volume of 150 µl of Perm Wash 
Buffer (BD Biosciences) was added to each well and the plate was centrifuged at 2100rpm for 
3 minutes at 4ºC. The supernatant was removed and 10 µl Allophycocyanin-labelled anti-
CCR5, along with 2 µl of the following antibodies were added into each well: eF655-labelled 
anti-CD38 (eBioscence) and Phycoerythrin (PE)-labelled anti-HLA-DR (eBioscience), and 
Brilliant Violet 700 (BV700)-labelled anti-Ki67 (BioLegend). The plate was then incubated 
for 20 minutes at 4ºC in darkness. After incubation, 200 µl of Perm Wash Buffer was added to 
each well and the plate was centrifuged at 2100rpm for 3 minutes (833 xg) at 4ºC. The 
supernatant was removed and 100 µl of BD Cell Fix was added to each well to resuspend the 
pellet. The cells were then transferred to a sterile, fluorescence-activated cell sorting (FACS) 
tube. The plate wells were washed with an additional 50 µl of BD Cell Fix and were transferred 
to FACS tubes. Acquisition was conducted using an LSRII flow cytometer (BD 
Immunocytometry Systems). 
5.5.3. Preparation of Compensation Beads 
The compensation beads were vortexed thoroughly at high speed and 1 drop each of the 
negative and positive beads were added into each FACS tube. A volume of 2 µl of antibodies 
was added into labelled FACS tubes. 
5.5.4. Data Acquisition 
Data acquisition was conducted on a LSRII flow cytometer (BD Immunocytometry Systems), 
and the data was analysed using FlowJo Software version 9.9 (Tree Star). Fluorescence minus 
one (FMO) controls were prepared using thawed peripheral blood mononuclear cells (PBMC). 
FMOs consist of all the markers excluding the one of interest, and are perfect for showing 
gating boundaries in flow cytometry. Specimens with a CMC CD3 T cell event count below 
100 were excluded from analysis. Below is a representative of the gating strategy used (Figure 
9).  
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Figure 9. Representative flow cytometry gating plot for the assessment of T cell activation. 
Live cells were identified, followed by lymphocytes, and CD3+ T cells. The expression of 
activation markers (CD38+, HLA-DR+), the marker of proliferation (Ki67+), and the HIV co-
receptor for entry (CCR5+) was assessed on CD4+ and CD8+ T cell subsets. NK cells were 
assessed by measuring CD16 and CD56 co-expression. 
 
5.6. Investigation of Epithelial Barrier Integrity and Cytokine Biomarkers of Genital   
Inflammation in CVL Supernatant Specimens 
A multiplexed Enzyme-Linked Immunosorbent Assay (ELISA) was used to detect the presence 
of 48 cytokines (IL-1α, IL-2Rα, IL-3, IL-12 (p40), IL-16, IL-18, CTACK, GRO-α, HGF, IFN-
α2, LIF, MCP-3, M-CSF, MIF, MIG, β-NGF, SCF, SCGF-β, SDF-1α, TNF-β, TRAIL, FGF 
basic, Eotaxin, G-CSF, GM-CSF, IFN-γ, IL-1β, IL1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, 
IL-10, IL12 (p70), IL-13, IL-15, IL-17, IP-10, MCP-1 (MCAF), MIP-1α, MIP-1β, PDGF-BB, 
RANTES, TNF-α and VEGF), and to assess markers of epithelial barrier integrity (MMP-1, 
MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, MMP-12 and MMP-13) in CVL 
supernatant specimens. The Bio-Plex Pro Human Cytokine 21 plex (#MF0005KMII), 27 plex 
(#M500KCAF0Y) kits and MMP (#171-AM001M) kits (Bio-Rad, Hercules, CA) were used to 
investigate cytokine and MMP concentrations respectively. 
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5.6.1.  Multiplex ELISA Assay  
The Bio-Plex multiplex ELISA utilises fluorescently dyed beads, each with distinct colour 
codes to distinguish between individual analytes within a multiplex suspension. In this study, 
this allowed for simultaneous detection of 48 cytokines and 9 MMPs in a single well of a 96 
well microplate. Lasers and associated optics measure the various molecules bound to the 
surface of the beads and a high speed digital signal processor efficiently manages the 
fluorescent data (Figure 10). 
 
Figure 10. Graphical representation of multiplex ELISA assay (figure taken from the Bio-
Plex Pro instruction manual). The magnetic bead is coupled to a capture antibody that will 
bind specifically to the analyte of interest. A biotinylated detection antibody is bound to the 
biomarker of interest, sandwiching the analyte between the capture antibody and the detection 
antibody. Streptavidin Phycoerythrin (SA-PE) is added to bind to the biotin. The laser will 
detect the fluorescent phycoerythrin and the mean fluorescence intensity of the analyte of 
interest is determined.  
 
5.6.1.1. Preparation of the Bio-Plex 200 Suspension Array System and Software for Data 
Acquisition 
The Bio-Plex system was switched on and allowed to warm up for approximately 30 minutes. 
In the accompanying Bio-Plex Manager software, the appropriate analytes to be quantified 
were selected, and the assay standard information was loaded. The plate layout was formatted 
similarly to that depicted in Figure 11. On each plate, 8 biological samples in addition to 10 
standards, were run in duplicate to assess intraplate variability. Once the Bio-Plex system had 
been warmed up, calibration was conducted using the Bio-Plex Pro Calibration Kit. 
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Figure 11. Example of a plate layout on the Bio-Plex 200 (figure taken from the Bio-Plex Pro 
instruction manual). The plate layout corresponded with the plating of Standards, Blanks, 
Samples and Controls on the Bio-Plex Pro Magnetic 96 well microtitre plate. Standards were 
encoded by circles, Blanks were diamond shape, Unknown Samples were the square blocks 
and Controls were indicated with octagons.  
 
5.6.1.2. Preparation of samples, standards, beads, controls, the detection antibody and SA-PE 
for the Bio-Plex Pro Human Cytokine Assays 
The biological controls were prepared by combining excess CVL samples, vortexing 
thoroughly, and dispensing into cryovials for impending use. The standards were reconstituted 
with 500 µl of Standard Diluent, vortexed and incubated on ice for 30 minutes. A fourfold 
standard dilution series was prepared as shown in Figure 12. A 15 ml Falcon tube was labelled 
as 10x coupled beads and 5175 µl of Assay Buffer was added to the tube. The beads were 
stored on ice, in darkness until ready for use. The beads were vortexed for 30 seconds and 575 
µl was added to the tube containing Assay Buffer. The Detection Antibody was prepared by 
adding 300 µl of 10x Detection Antibody to a polypropylene tube containing 2700 µl of 
Detection Antibody Diluent. The SA-PE was prepared by adding 60 µl of 100x SA-PE to a 15 
ml Falcon tube containing 5940 µl of Assay Buffer.  Undiluted samples were assessed. 
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Figure 12. Preparation of a fourfold standard dilution series (figure taken from the Bio-Plex 
Pro instruction manual). Ten polypropylene tubes were labelled as standards 1 to 10. A volume 
of 72 µl of standard diluent was added to standard 1, while standards 2 to 10 contained 150 
µl each of the same diluent. A volume of 128 μl of the reconstituted standard was added to the 
tube labelled Standard 1. Thereafter, 50 µl of the previous standard was added to the 
subsequent tube, with thorough vortexing between each liquid transfer. 
  
5.6.1.3.Preparation of sample, standards, beads, controls and detection antibody and SA-PE 
for the Bio-Plex Pro Human MMP Assays 
The biological controls were prepared by combining excess CVL samples, vortexing 
thoroughly, and dispensing into cryovials for impending use. A 1x Wash Buffer was prepared 
by diluting 60 ml of 10x Wash Buffer in 540 ml of dH2O. The 10% Serum-Based Standard 
Diluent was prepared by adding 4 ml Standard Diluent HB to 6 ml Sample Diluent HB. The 
standards were reconstituted with 781 µl of Standard Diluent, vortexed and incubated on ice 
for 30 minutes. A threefold standard dilution series was prepared as shown in Figure 13. The 
beads were kept on ice, in darkness till until ready for use. The beads were vortexed for 30 
seconds and 288 µl was added to a 15 ml Falcon tube containing 5472 µl Assay Buffer. The 
Detection Antibody was prepared by adding 150 µl of 20x Detection Antibody to a 
polypropylene tube containing 2850 µl of Detection Antibody Diluent. The SA-PE was 
prepared by adding 60 µl of 100x SA-PE to a 15 ml Falcon tube containing 5940 µl of Assay 
Buffer. Samples were diluted 1:4 by adding 50 µl of sample to 150 µl Sample Diluent. 
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Figure 13. Preparation of a threefold standard dilution series (figure taken from the Bio-Plex 
Pro instruction manual). Ten polypropylene tubes were labelled as standards 1 to 10. A volume 
of 150 µl of sample diluent was added to each tube. A volume of 75 µl of the reconstituted 
standard was added to the tube labelled standard 1. Thereafter, 75 µl of the previous standard 
was added to the subsequent tube, with thorough vortexing between each liquid transfer. 
 
5.6.1.4. Conducting the Multiplex ELISA Assays (Cytokines and MMPs) 
A volume of 50 µl of the Coupled Beads was added to each well of the 96 well microtiter plate 
using a multichannel pipette. The plate was washed twice with 100 µl of Bio-Plex Wash Buffer. 
Once the plate was washed, the samples, standards, blanks and controls were vortexed and 50 
µl was added to each well. The plate was covered with sealing tape and aluminium foil and 
incubated on the plate shaker for 30 minutes (cytokine assays) or 1 hour for (MMP assays). 
After incubation the plate was washed 3 times with 100 µl of Wash Buffer. The Detection 
Antibodies were vortexed for 30 seconds and 25 µl was added to each well of the microtiter 
plate using a multichannel pipette. The plate was covered with sealing tape and aluminium foil 
and incubated for 30 minutes on the plate shaker. After incubation, the plate was washed 3 
times with 100 µl of Wash Buffer. The SA-PE was vortexed for 30 seconds and 50 µl was 
added to each well of the 96 well microtiter plate. The plate was covered with sealing tape and 
aluminium foil and incubated on the plate shaker for 10 minutes. The plate was then washed 3 
times with 100 µl wash buffer. A volume of 125 µl of Assay Buffer was added to each well 
with a multichannel pipette. The plate was covered with sealing tape and foil and incubated on 
the plate shaker for 1 minute. Finally, the sealing tape and foil were removed and the plate was 
read on the Bio-Plex 200 system (Bio-Rad Laboratories, Inc., USA). Figure 14 depicts a 
summarised version of the Multiplex ELISA protocol. 
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Figure 14. Multiplex ELISA assay protocol summary. 
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5.6.1.5. Data Quality Control 
The standard curves were automatically optimised by Bio-Plex Manager software. For each 
cytokine or MMP, each standard had an acceptable recovery range of between 70% and 130%, 
and those standards outside this range were excluded to obtain an appropriate 5-point standard 
curve. Additionally, standards with coefficients of variation (%CV) greater than 20% were 
either removed partially or completely, depending on its effect on the standard curve. The 
observed concentrations of all the plates were combined for validation. All extrapolated values 
were accepted, and all values below or above the detectable limit were replaced with either half 
the lowest value in the dataset or double the highest value in the dataset, respectively. Intraplate 
and interplate variability was assessed to determine whether there were significant differences 
between duplicate wells or interplate wells, respectively. This was conducted as quality control 
to assess any possible pipetting errors. Significant (P<0.05) Spearman r values >8, and 
Wilcoxon T test P-values <0.05 were considered acceptable when conducting intraplate and 
interplate variability.  
5.7. Statistical Considerations 
Statistical analyses were performed using GraphPad Prism version 7 (GraphPad Software, San 
Diego, CA), STATA version 11 (StataCorp, College Station, TX), SAS version 9.4 (SAS 
Institute Inc., Cary, NC, USA) and Microsoft Excel (2013). The output variables were cytokine 
concentrations (pg/ml), MMP concentrations (pg/ml), cellular frequency (%) and genital 
inflammation status. Cytokine and MMP concentrations were log10-transformed. The immune 
exposure variables were analysed as either dichotomous or continuous variables as appropriate 
based on their presence or level of detection in the population. Genital inflammation was 
defined as having 5 of the 9 pro-inflammatory cytokines above the 75th percentile in the FGT 
and analysed as binary variables using the Fisher’s exact test. Since the cytokine, MMP and 
cellular data were unpaired and followed a non-gaussian distribution, the Mann-Whitney U test 
was used when comparing biomarkers of inflammation between two groups. The Dunn’s post-
test was used to adjust for multiple comparisons. Linear regression models were used to 
compare the levels of immune markers between HPV+ versus (vs.) HPV- women; women with 
HR-HPV vs. LR-HPV; those with single vs. multiple HPV infections; and those with an 
HPV/STI coinfection and those without. Multivariate regression analyses adjusted for 
discharge-associated STIs and nugent score, which was significantly associated with genital 
inflammation in this cohort of women. 
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6. RESULTS 
6.1. HPV prevalence and genotype distribution 
Among the 167 women who participated in this study, 50.8% had detectable HPV DNA at 
baseline (Table 3). The prevalence of HR-HPV was 26.9% (Table 3), and HR-HPV was 
detected in 53% of HPV-infected participants. HPV52 was the most prevalent HR HPV 
genotype; while the most prevalent LR HPV genotype was HPV62 (Figure 15). 
 
 
 
 
 
 
 
6.2. Baseline demographics, behavioural and clinical characteristics of the study 
population 
As expected, HPV positive women had a significantly lower mean age than their HPV negative 
counterparts at baseline [mean±standard deviation (SD) 28.4±4.9 years vs 30.9±5.9 years, 
respectively, P = 0.004; Table 4]. HPV positive women were more likely to have a partner 
with a higher median age [median 34 (interquartile range (IQR) 30 – 37) years vs 32 (IQR 28 
– 36) years, P = 0.005; Table 4], and were less likely to be living with a regular partner than 
HPV negative women (16.5% and 30.5%, respectively, P = 0.026; Table 4). In addition, the 
reported number of live births was higher among HPV positive women compared to HPV 
negative women [median 1 (IOR 1 – 2); median 2 (IQR 1 – 3) respectively, P = 0.015; Table 
4]. There was no significant difference among HPV positive and HPV negative women in terms 
of the age of sexual debut, number of lifetime partners, number of sex acts in the past 30 days, 
condom use, and the presence of inflammatory STIs (gonorrhoea, chlamydia, trichomonas, 
mycoplasma and HSV-2; Table 4). 
 
 
Table 3. Prevalence of HPV at Baseline (N = 167). 
HPV Infection % (n) 
HPV Negative 49.2 (82) 
HPV Positive 50.8 (85) 
Low Risk HPV strains 35.3 (59) 
High Risk HPV strains 26.9 (45)  
Cervarix strains 7.8 (13) 
Gardasil  strains 10.8 (18) 
Gardasil 9 strains 24.6 (41) 
Cervarix: HPV16, HPV18; Gardasil: HPV16, HPV18, HPV6, HPV11; Gardasil 9: HPV16, HPV18, 
HPV6, HPV11, HPV31, HPV33, HPV45, HPV52, HPV58 
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Figure 15. Type-specific HPV prevalence among participants. The red bars indicate HR HPV 
genotypes, while the blue bars indicate LR HPV genotypes detected in the population of 167 
women at baseline. Vaccine strains are indicated by stripes.  
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Table 4. Baseline characteristics by HPV status. 
DEMOGRAPHICS 
 
OVERALL (N = 167) HPV+ (N = 85) HPV- (N = 82) P-VALUE  
% (n) % (n) % (n) 
 
Age mean (SD) 
 
29.6 (5.5) 28.4 (4.9) 30.9 (5.9) 0.004* 
Age (years) 20-25 18.6% (31) 20.0% (17) 17.1% (14) 0.032 
25-29 41.3% (69) 49.4% (42) 32.9% (27)   
>= 30 40.1% (67) 30.6% (26) 50.0% (41)   
Education  
Less than primary school 39.5% (66) 31.8% (27) 47.6% (39) 0.204 
Primary school complete 2.4% (4) 2.4% (2) 2.4% (2)   
High school complete 53.3% (89) 60.0% (51) 46.3% (38)   
Tertiary complete 4.8% (8) 5.9% (5) 3.7% (3)   
Sexual Behaviour median (IQR) 
     
Age of Sexual Debut  
 
18 (16 - 19)  18 (16 - 19) 18 (16 - 20) 0.323 
Age of regular/stable partner 
 
32 (28 - 37) 34 (30 - 37) 32 (28 - 36) 0.005* 
Age of first partner 
 
21 (19 - 24)  20 (19 - 24)  21 (19 - 24)  0.426 
Number of live births 
 
1 (1 - 2)  1 (1 - 2) 2 (1 - 3) 0.015* 
Age at first pregnancy  
 
19 (17 - 22) 19 (17 - 21) 19.5 (18 - 23) 0.191 
Age when started menstruating 
 
14 (13 - 16) 14 (13 - 15)  14 (13 - 16)  0.701 
Number of lifetime partners 
 
2 (2 - 4)  3 (2 - 4)  2 (1 - 4)  0.264 
Number of pregnancies 
 
2 (1 - 2) 1 (1 - 2)  2 (1 - 3)  0.094 
Number of vaginal sex acts in the last 30 
days 
 
4 (2 – 8) 4 (3 – 8) 4 (2 – 6) 0.110 
Anal sex act in the last 30 days Yes 1.2% (2) 0 2.4% (2) 0.240 
No 98.8% (165) 100.0% (85) 97.6% (80) 
 
Partner HIV Status No answer 12.6% (21) 16.5% (14) 8.5% (7) 0.272 
Positive 2.4% (4) 3.5% (3) 1.2% (1)   
Negative 65.9% (110) 64.7% (55) 67.1% (55)   
Unknown 19.2% (32) 15.3% (13) 23.2% (19)   
Partner Circumcision No answer 14.4% (24) 20.0% (17) 8.5% (7) 0.093 
Yes 29.3% (49) 30.6% (26) 28.1% (23)   
No 54.5% (91) 44.0% (40) 62.2% (51)   
Unknown 1.7% (3) 2.4% (2) 1.2% (1)   
Relationship Status Married 15.6% (26) 9.4% (8) 22.0% (18) 0.074 
Stable partner 80.8% (135) 87.1% (74) 74.4% (61)   
Casual Partner 3.6% (6) 3.5% (3) 3.7% (3)   
Living with regular partner Yes 23.4% (39) 16.5% (14) 30.5% (25) 0.026* 
No 76.6% (128) 83.5% (71) 69.5% (57)   
How often see regular/stable partner About every day 27.4% (45/164) 24.1% (20/83) 30.9% (25/81)  0.310 
About every week 43.9% (72/164) 50.6% (42/83) 37.0% (30/81) 
 
About every month 26.2% (43/164) 24.1% (20/83) 28.4% (23/81) 
 
Less than every month 2.4% (4/164) 1.2% (1/83) 3.7% (3/81) 
 
Contraceptive type Depo-provera 57.8% (93/161) 51.9% (42/81) 63.8% (51/80) 0.158 
Oral contraceptive 21.1% (34/161) 19.8% (16/81) 22.5% (18/80) 
 
Nur-isterate 15.5% (25/161) 1.0% (17/81) 10.0% (8/80) 
 
Other 5.6% (9/161) 7.4% (6/81) 3.8% (3/80) 
 
Use of Male Condoms Always 37.7% (63) 34.1% (29) 41.5% (34) 0.638 
Sometimes 48.5% (81) 45.1% (37) 45.1% (37) 
 
Never 13.8% (23) 13.4% (11) 13.4% (11) 
 
STI Testing 
     
Gonorrhoea Negative 96.2% (150/156) 95.0% (76/80) 97.4% (74/76) 1.000 
Positive 3.8% (6/156) 5.0% (4/80) 2.6% (2/76)   
Chlamydia Negative 92.3% (144/156) 93.7% (75/80) 90.8% (69/76) 0.363 
Positive 7.7% (12/156) 6.3% (5/80) 9.2% (7/76)   
Trichomonas Negative 95.5% (149/156) 95.0% (76/80) 96.1% (76/76) 1.000 
Positive 4.5% (7/156) 5.0% (4/80) 3.9% (3/76)   
Mycoplasma Negative 95.5% (149/156) 95.0% (76/80) 96.1% (73/76) 0.720 
Positive 4.5% (7/156) 5.0% (4/80) 3.9% (3/76)   
HSV-2 serostatus Negative 10.2% (17) 10.6% (9) 9.8% (8) 1.000 
Positive 89.8% (150) 89.4% (76) 90.2% (74)   
Any STI 
a
  No 82.6% (138) 82.4% (70) 82.9% (68) 1.000 
Yes 17.4% (29) 17.6% (15) 17.1% (14)   
Bacterial Vaginosis score [median (IQR)] 
 
1 (0 - 4) 2 (0 - 4.5) 1 (0 - 3) 0.330 
*P<0.05 were considered statistically significant and are listed in bold. 
a
Any STI defined as infection with Gonorrhoea, Chlamydia, 
Trichomonas and/or Mycoplasma. IQR, interquartile range; SD, standard deviation. 
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Numerous studies have demonstrated that STIs and BV are able to induce a robust immune 
response and contribute to genital inflammation (Levine et al., 1998; Fichorova et al., 2001a; 
Reddy et al., 2004; Yudin et al., 2003). STIs increase the production of pro-inflammatory 
cytokines, which in turn, recruit immune cells and impact epithelial barrier integrity (Anahtar 
et al., 2015; Arnold et al., 2016; Kaul et al., 2008).  These immune response are presumably 
elicited in order to facilitate pathogen clearance and even defend against reinfection (Kaul et 
al., 2008), but may render individuals more vulnerable to HIV infection (Laga et al., 1993; van 
de Wijgert et al., 2009; Van Der Pol et al., 2008; Mlisana et al., 2012; Masson et al., 2014; 
Taha et al., 1998). However, whether HPV infection has a similar effect on the genital mucosa 
is yet unclear. Here, the relationship between HPV infection and three biomarkers of 
inflammation associated with increased risk of HIV acquisition: genital cytokines, epithelial 
barrier integrity, and immune cell activation was investigated. 
6.3. Prevalent HPV and biomarkers of inflammation  
6.3.1. Association between prevalent HPV and genital cytokine concentrations 
To determine whether HPV infection was associated with a distinct cytokine profile, the 
concentrations of 48 cytokines involved in chemotaxis, growth, inflammation, adaptive 
responses, and regulation were measured in baseline CVL specimens (Table 5). Cytokine 
concentrations were similar between the groups, with the exception of the adaptive cytokine 
IL-5, which trended towards a higher concentration among HPV positive women (P = 0.078; 
Table 5).   
6.3.2. Association between prevalent HPV and epithelial barrier integrity 
An intact epithelium is an important physical barrier protecting against HIV entry. Elevated 
levels of pro-inflammatory cytokines disrupts tight junctions between epithelial cells, thereby 
reducing epithelial barrier integrity (Nazli et al., 2010), as measured by MMPs, the enzymes 
responsible for the degradation and remodelling of the epithelial barrier (Arnold et al., 2016). 
HPV is an epithelial virus and may facilitate HIV dissemination through disruption of the 
epithelial barrier (Herfs et al., 2011). Soluble protein biomarkers of epithelial barrier integrity 
were compared between HPV positive and HPV negative women (Table 6). However, 
concentrations of MMPs did not differ between the groups (Table 6), suggesting that prevalent 
HPV infection may not impact epithelial barrier integrity. 
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Table 5. Cytokine concentrations among HPV- and HPV+ women. 
 OVERALL (N = 163) HPV- (N = 81) HPV+ (N = 82)  
Cytokine Median (IQR) log10 pg/ml Median (IQR) log10 pg/ml Median (IQR) log10 pg/ml P-value 
IL-1α 2,154 (1,806-2,522) 2,074 (1,653-2,616) 2,233 (1,854-2,503) 0.270 
IL-1β 1,706 (1,106-2,295) 1,668 (1,086-2,348) 1,721 (1,109-2,290) 0.926 
IL-6 0,948 (0,700-1,337) 0,897 (0,633-1,363) 0,984 (0,768-1,309) 0.270 
IL-12P40 2,431 (2,317-2,524) 2,429 (2,313-2,515) 2,432 (2,321-2,551) 0.787 
IL-12P70 1,761 (1,495-2,050) 1,712 (1,475-1,969) 1,827 (1,531-2,072) 0.208 
IL-18 2,351 (1,945-2,720) 2,374 (1,934-2,734) 2,267 (1,977-2,730) 0.901 
MIF 3,559 (3,241-3,873) 3,583 (3,237-3,902) 3,534 (3,240-3,860) 0.765 
TNF-α 1,071 (0,859-1,413) 1,026 (0,775-1,494) 1,102 (0,914-1,363) 0.418 
TNF-β 0,548 (0,405-0,708) 0,544 (0,398-0,652) 0,570 (0,407-0,720) 0.381 
TRAIL 1,486 (1,250-1,875) 1,467 (1,240-1,835) 1,495 (1,289-1,879) 0.427 
CTACK 1,272 (1,060-1,453) 1,274 (1,047-1,412) 1,264 (1,095-1,486) 0.515 
EOTAXIN 0,814 (0,477-1,046) 0,794 (0,434-1,023) 0,833 (0,619-1,062) 0.321 
GRO-α 2,882 (2,320-3,494) 2,758 (2,211-3,475) 2,989 (2,402-3,549) 0.331 
IL-8 2,722 (2,353-3,170) 2,701 (2,253-3,174) 2,742 (2,363-3,132) 0.690 
IL-16 1,603 (1,424-1,869) 1,617 (1,367-1,858) 1,590 (1,448-1,905) 0.664 
IP-10 2,325 (1,692-2,913) 2,351 (1,661-2,792) 2,321 (1,782-3,003) 0.455 
MCP-1 1,469 (1,368-1,569) 1,477 (1,368-1,568) 1,467 (1,356-1,607) 0.927 
MCP-3 1,023 (0,807-1,207) 1,039 (0,786-1,180) 0,990 (0,810-1,233) 0.958 
MIG 2,579 (2,061-3,117) 2,589 (1,974-3,052) 2,559 (2,078-3,222) 0.289 
MIP-1α 0,064 (-0,187-0,344) 0,061 (-0,201-0,347) 0,064 (-0,163-0,339) 0.952 
MIP-1β 1,220 (0,822-1,738) 1,203 (0,792-1,688) 1,245 (0,866-1,773) 0.352 
RANTES 0,797 (0,455-1,078) 0,804 (0,372-1,047) 0,793 (0,589-1,190) 0.221 
IFN-α2 1,256 (1,143-1,399) 1,246 (1,154-1,386) 1,267 (1,119-1,409) 0.656 
β-NGF -0,051 (-0,509-0,332) -0,076 (-0,678-0,261) -0,032 (-0,485-0,405) 0.437 
FGF BASIC 1,423 (1,363-1,504) 1,423 (1,360-1,508) 1,422 (1,367-1,499) 0.981 
G-CSF 2,330 (1,876-2,859) 2,286 (1,703-2,813) 2,388 (1,957-2,925) 0.141 
GM-CSF 1,843 (1,795-1,908) 1,851 (1,788-1,911) 1,839 (1,796-1,902) 0.542 
HGF 2,302 (1,924-2,799) 2,247 (1,851-2,797) 2,399 (1,949-2,820) 0.528 
IL-3 2,029 (1,949-2,156) 2,029 (1,943-2,138) 2,018 (1,953-2,188) 0.581 
IL-7 0,862 (0,681-1,051) 0,795 (0,597-1,060) 0,871 (0,704-1,051) 0.256 
IL-9 0,733 (0,566-0,863) 0,708 (0,553-0,864) 0,738 (0,617-0,867) 0.302 
LIF 1,113 (0,940-1,291) 1,103 (0,931-1,292) 1,145 (0,963-1,293) 0.668 
M-CSF 1,851 (1,601-2,132) 1,793 (1,578-2,132) 1,981 (1,613-2,130) 0.200 
PDGF-BB 1,126 (0,895-1,328) 1,103 (0,867-1,311) 1,151 (0,970-1,367) 0.147 
SCF 1,016 (0,750-1,440) 0,990 (0,710-1,323) 1,062 (0,787-1,482) 0.227 
SCGF-β 2,687 (2,302-3,060) 2,645 (2,137-2,980) 2,746 (2,372-3,076) 0.231 
SDF-1α 2,421 (2,133-2,676) 2,378 (2,089-2,666) 2,443 (2,212-2,690) 0.198 
VEGF 2,399 (2,064-2,723) 2,336 (1,970-2,699) 2,437 (2,123-2,746) 0.255 
IFN-γ 1,369 (1,153-1,561) 1,359 (1,072-1,619) 1,386 (1,228-1,546) 0.476 
IL-2 0,446 (0,188-0,668) 0,458 (0,242-0,659) 0,418 (0,174-0,675) 0.486 
IL-4 0,013 (-0,119-0,179) -0,009 (-0,140-0,200) 0,037 (-0,072-0,164) 0.535 
IL-5 0,236 (-0,921-0,498) 0,041 (-1,222-0,443) 0,299 (-0,189-0,522) 0.078 
IL-13 0,543 (0,373-0,735) 0,537 (0,366-0,730) 0,563 (0,386-0,738) 0.607 
IL-15 0,310 (-1,260-0,633) 0,283 (-1,260-0,633) 0,317 (-1,260-0,687) 0.491 
IL-17 1,086 (0,957-1,302) 1,081 (0,946-1,304) 1,093 (0,977-1,291) 0.542 
IL-2RA 1,318 (1,115-1,498) 1,329 (1,120-1,501) 1,316 (1,094-1,504) 0.620 
IL-10 1,629 (1,494-1,784) 1,620 (1,452-1,770) 1,636 (1,521-1,812) 0.289 
IL-1RA 4,101 (3,939-4,220) 4,107 (3,946-4,219) 4,096 (3,931-4,227) 0.901 
P-values <0.05 were considered significant. Nonparametric comparisons were conducted using the Mann Whitney U test. 
Cytokine/Chemokine functions: Pro-inflammatory, Chemokines, Growth Factors, Adaptive response, Anti-
inflammatory. 
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Table 6. MMP concentrations by HPV status. 
 OVERALL (N = 163) HPV- (N = 81) HPV+ (N = 82)  
 Median (IQR) log10 pg/ml Median (IQR) log10 pg/ml Median (IQR) log10 pg/ml P-value 
MMP-1 3,200 (2,780-3,450) 3,210 (2,795-3,480) 3,190 (2,750-3,420) 0.596 
MMP-2 3,460 (2,900-3,840) 3,400 (2,860-3,900) 3,560 (3,128-3,803) 0.535 
MMP-3 2,950 (2,630-3,230) 2,920 (2,640-3,210) 3,020 (2,618-3,263) 0.660 
MMP-7 2,440 (2,000-3,180) 2,420 (1,870-3,135) 2,455 (2,088-3,223) 0.261 
MMP-8 5,010 (4,210-6,230) 5,010 (4,275-6,520) 5,010 (4,150-6,093) 0.648 
MMP-9 4,720 (3,970-5,540) 4,630 (4,015-5,660) 4,750 (3,895-5,440) 0.670 
MMP-10 2,940 (2,390-3,290) 2,960 (2,390-3,275) 2,925 (2,385-3,295) 0.877 
MMP-12 2,930 (2,520-3,400) 2,930 (2,540-3,310) 2,965 (2,508-3,435) 0.926 
MMP-13 2,270 (1,740-2,650) 2,310 (1,725-2,665) 2,270 (1,785-2,623) 0.857 
P-values <0.05 were considered significant. Unpaired nonparametric comparisons were conducted using the Mann 
Whitney U test. 
 
 
6.3.3. Association between prevalent HPV and immune cell recruitment 
The frequency of activated (CD38+ and/or HLA-DR+) or proliferating (Ki67+) T cells (CD3+ 
CD4+ or CD8+), NK cells (CD56+CD16+) and activated CCR5+CD4+ T cell targets for HIV 
replication was compared between HPV positive and HPV negative women (Table 7). Cellular 
frequencies were similar between the groups, with the exception of the CD4+ T cell population, 
which trended towards a reduced frequency among HPV positive women (P = 0.056; Table 
7). 
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Table 7. Cellular frequencies by HPV status. 
 OVERALL (N = 163) HPV- (N = 80) HPV+ (N = 83)  
 Median % (IQR)  Median % (IQR)  Median % (IQR)  P-value 
LYMPHOCYTES 2,360 (1,020-5,590) 2,325 (1,008-6,053) 2,610 (1,020-5,410) 0.852 
CD3 11,200 (2,330-25,500) 10,350 (1,883-27,980) 12,000 (2,650-23,800) 0.908 
CD3CD38DR+CCR5+ 5,670 (1,490-14,000) 6,060 (1,395-15,100) 5,225 (1,950-13,850) 0.942 
CD3CCR5+CD38+ 17,650 (6,800-30,100) 16,800 (6,170-31,600) 19,400 (6,950-28,400) 0.808 
CD3CCR5+DR+ 11,300 (4,620-28,000) 11,200 (4,515-24,150) 11,700 (4,643-32,700) 0.512 
CD3CCR5+KI67+ 7,725 (0,000-21,950) 6,320 (0,000-18,230) 9,510 (0,000-24,700) 0.380 
CD3CD38+DR+ 11,100 (5,058-24,330) 10,700 (4,935-22,250) 11,200 (5,055-25,300) 0.700 
CD3CCR5+ 43,350 (23,950-64,080) 41,700 (21,200-66,700) 44,900 (24,500-63,300) 0.989 
CD3CD38+ 39,700 (21,300-58,100) 38,650 (25,000-57,400) 43,500 (18,100-61,500) 0.908 
CD3HLA-DR 25,050 (12,480-47,080) 24,900 (11,450-41,950) 25,550 (14,500-51,900) 0.510 
CD3KI67 18,700 (0,099-37,100) 14,100 (0,106-36,080) 22,900 (0,098-38,100) 0.433 
CD3 - 37,250 (23,450-58,950) 40,700 (24,330-60,730) 33,500 (22,250-58,430) 0.450 
NK Cells 2 4,365 (1,380-14,030) 5,465 (1,324-12,830) 4,020 (1,340-17,000) 0.954 
CD3 Activation 1 75,000 (55,500-91,000) 72,850 (54,450-91,480) 75,600 (59,500-90,100) 0.860 
CD4 60,000 (48,100-68,900) 62,250 (49,350-72,000) 57,500 (46,200-66,700) 0.056 
CD4CD38DR+CCR5+ 4,270 (0,484-12,100) 4,300 (0,371-11,600) 4,125 (0,535-12,130) 0.987 
CD4CCR5+CD38+ 18,950 (6,033-32,280) 18,300 (4,940-33,600) 20,400 (6,360-32,200) 0.725 
CD4CCR5+DR+ 8,970 (2,210-25,900) 9,090 (2,500-20,550) 8,940 (2,045-27,750) 0.887 
CD4CCR5+KI67+ 3,610 (0,000-23,250) 3,390 (0,000-19,730) 3,830 (0,000-27,330) 0.713 
CD4CD38+DR+ 8,305 (1,813-17,950) 8,535 (1,788-18,080) 8,035 (1,768-17,480) 0.843 
CD4CCR5 45,450 (24,900-69,000) 45,300 (25,000-69,800) 45,700 (22,200-66,800) 0.798 
CD4CD38 42,600 (21,900-59,300) 40,100 (23,530-59,830) 44,100 (19,100-58,300) 0.861 
CD4HLA-DR 18,550 (6,720-34,650) 17,300 (7,673-32,480) 19,000 (4,898-39,680) 0.826 
CD4KI67 10,500 (0,000-34,900) 10,400 (0,000-33,680) 10,500 (0,000-35,700) 0.895 
CD4 Activation 1 75,000 (54,700-90,200) 75,800 (52,980-91,580) 75,000 (55,000-89,400) 0.706 
CD8 35,700 (25,400-46,400) 35,200 (25,580-48,350) 35,800 (25,000-46,300) 0.978 
CD8CD38DR+CCR5+ 5,310 (0,000-13,300) 4,170 (0,000-12,350) 6,280 (0,419-14,080) 0.316 
CD8CCR5+CD38+ 11,500 (3,233-22,500) 10,300 (3,030-22,300) 13,100 (4,260-24,600) 0.445 
CD8CCR5+DR+ 11,600 (1,800-25,400) 10,900 (0,729-19,050) 13,200 (2,273-27,130) 0.267 
CD8CCR5+KI67+ 3,920 (0,000-19,150) 2,355 (0,000-14,550) 7,275 (0,000-25,300) 0.280 
CD8CD38+DR+ 12,500 (2,638-30,750) 11,800 (2,060-25,830) 13,100 (2,783-33,700) 0.491 
CD8CCR5 31,750 (16,300-53,280) 30,900 (15,400-52,800) 31,900 (18,200-55,200) 0.802 
CD8CD38 37,800 (14,300-56,500) 35,450 (14,080-52,000) 38,700 (15,300-60,400) 0.455 
CD8HLA-DR 35,900 (10,630-58,430) 33,600 (9,418-57,150) 36,850 (11,600-62,530) 0.628 
CD8KI67 13,700 (0,000-40,000) 14,250 (0,000-38,250) 13,600 (0,000-40,400) 0.771 
CD8 Activation 1 72,800 (53,300-90,500) 72,100 (53,780-91,900) 72,900 (51,200-89,300) 0.970 
P-values <0.05 were considered significant. Unpaired nonparametric comparisons were conducted using the Mann 
Whitney U test. 1Activation refers to cells expressing CCR5, HLA-DR and/or CD38. 2NK cells refers to those expressing 
CD56+CD16+ markers. 
 
Taken together, the detection of any HPV genotype in CVL specimens was not associated with 
significant increases in cytokine concentrations, markers of immune cell activation or 
epithelial barrier integrity. To limit the potential for the inflammatory nature of discharge-
associated STIs and BV to mask a contribution of HPV to genital immunity, regression models 
were used to validate the above observations by controlling for the presence of discharge-
associated STIs and nugent score (Figure 16; Appendix B). 
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Controlling for an impact of STIs and BV on genital cytokine concentrations, HPV infection 
was associated with increased concentrations of the chemokine SDF-1a [β = 0.148 pg/ml, P = 
0.036; Figure 16A]. Although not statistically significant, being HPV positive was associated 
with trending decreases of MMP-9 concentrations [β = -0.357 pg/ml, P = 0.092; Figure 16B] 
and reduced frequencies of CD4 cells [β = -6.315 pg/ml, P = 0.054; Figure 16C].  
Based on their respective well-established roles in HIV acquisition, a relationship between 
genital inflammation (Masson et al., 2015) and HPV status was also investigated. Genital 
inflammation, as defined by having 5 or more of 9 pro-inflammatory cytokines and chemokines 
(IL-1α, IL-1β, IL-6, TNF-α, IL-8, IP-10, MCP-1, MIP-1α and MIP-1β) above the 75th 
percentile (Masson et al., 2015), did not distinguish HPV-infected from uninfected women (P 
= 0.700), suggesting that being HPV positive was not associated with this measurement of 
genital inflammation.  
In summary here, HPV infection predicted increased concentrations of the chemokine SDF-
1α, but was not associated with markers of epithelial barrier integrity, immune cell activation, 
or genital inflammation. Further investigations were therefore conducted to determine whether 
other features of HPV infection, also associated with HIV infection, had an impact on genital 
immunity; namely, the number of infecting strains, the oncogenic potential of the HPV, and 
coinfection with other STI. 
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Figure 16. Association between HPV status and biomarkers of genital inflammation. β-coefficients and corresponding P-values were determined using linear regression 
models. Β-coefficients are indicated by shapes and error bars indicate 95% confidence intervals.  Significant P-values (P<0.05) are indicated by (*) and shading, whilst trends 
(P<0.1) are indicated by shading only. 1Activation refers to cells expressing CCR5, HLA-DR and/or CD38. 2NK cells refers to those expressing CD56+CD16+ markers. 
Cytokines are ordered according to functionality: pro-inflammatory, chemokines, growth factors, adaptive response and anti-inflammatory 
cytokines.……………………………………………………………………………….......................................................................................................................... .....................................................................
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6.4. Association between multiple HPV genotypes and genital immunity 
To determine whether having multiple concurrent HPV infections contributes to the genital 
immune response, HPV positive women were stratified into groups based on the number of 
infecting HPV types. Women were classified as having “1” or “2+” based on whether they had 
one or multiple HPV genotypes detected in CVL specimens.  Concentrations of cytokines, 
immune cell activation, and epithelial barrier integrity were compared between these groups 
(Figure 17; Appendix C).  
 
In univariate analysis, having multiple infecting HPV strains was inversely associated with 
concentrations of the growth factor M-CSF [β = -0.162 pg/ml, P = 0.044; Figure 17A]. 
However, after controlling for STI and BV, this significant association with M-CSF was lost, 
and an association between multiple genotypes and reduced concentrations of the adaptive 
cytokine IL-5 was observed [β = -0.170 pg/ml; P = 0.033; Figure 17A]. Having multiple 
concurrent HPV infections was not significantly associated with MMP concentrations (Figure 
17B), with immune cell activation (Figure 17C), nor with genital inflammation as defined by 
elevated levels of 5/9 pro-inflammatory cytokines and chemokines (P = 0.215).  
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Figure 17. Association between multiple HPV genotypes and biomarkers of genital inflammation. β-coefficients and corresponding P-values were determined using linear 
regression models. Β-coefficients are indicated by shapes and error bars indicate 95% confidence intervals.  Significant P-values (P<0.05) are indicated by (*) and shading, 
whilst trends (P<0.1) are indicated by shading only. 1Activation refers to cells expressing CCR5, HLA-DR and/or CD38. 2NK cells refers to those expressing CD56+CD16+ 
markers. Cytokines are ordered according to functionality: pro-inflammatory, chemokines, growth factors, adaptive response and anti-inflammatory cytokines.
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6.5. Association between oncogenic HPV and genital immunity 
Soluble protein biomarkers of inflammation and immune cell activation was compared between 
women with at least 1 HR-HPV type (HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, 
HPV45, HPV51, HPV52, HPV56, HPV58, HPV59, HPV68) and women infected with LR-
HPV types only (Figure 18; Appendix D).  
 
In univariate analysis, infection with HR-HPV was associated with the chemokine MCP-1 (β 
= 0.124 pg/ml, P = 0.052), the adaptive cytokine IL-13 (β = 0.119 pg/ml, P = 0.028) and the 
pro-inflammatory cytokine IL-12p70 [β = 0.154 pg/ml, P = 0.054; Figure 18A]. Controlling 
for STI and BV in multivariate regression models, infection with HR-HPV was significantly 
associated with increased concentrations MCP-1 (β = 0.127 pg/ml, P = 0.046) and IL-13 (β = 
0.117 pg/ml, P = 0.031). In addition, although not statistically significant, women with HR-
HPV were more inclined to have increased concentrations of the pro-inflammatory cytokines: 
IL-1β (β = 0.268 pg/ml, P = 0.078) and IL-12P70 (β = 0.150 pg/ml, P = 0.064), chemokines: 
eotaxin (β = 0.284 pg/ml, P = 0.073), IL-8 (β = 0.222 pg/ml, P = 0.088), IP-10 (β = 0.341 
pg/ml, P = 0.055) and MIG (β = 0.268 pg/ml, P = 0.067), growth factor: VEGF (β = 0.175 
pg/ml, P = 0.088) and the adaptive cytokine IL-2 [β = 0.307 pg/ml, P = 0.066; Figure 18A]. 
Even though HR-HPV was associated with several cytokines, no association was observed 
between oncogenicity and the definition of genital inflammation, suggesting that oncogenic 
HPV infection was not associated with this measurement of genital inflammation. 
 
HR-HPV infection trended towards an association with increased MMP-3 concentrations [β = 
0.239 pg/ml, P = 0.075; Figure 18B]. Further, HR-HPV infection was significantly associated 
with greater frequencies of lymphocytes [β = 1.987 pg/ml, P = 0.042; Figure 18C]. It is 
important to note that the number of infecting HPV types did not differ significantly between 
women with LR-HPV and HR-HPV infections [median 0 (IQR 0 – 2); median 1 (IQR 0 – 3) 
respectively, P = 0.109]. 
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Figure 18. Association between oncogenic HPV and biomarkers of genital inflammation. β-coefficients and corresponding P-values were determined using linear regression 
models. Β-coefficients are indicated by shapes and error bars indicate 95% confidence intervals.  Significant P-values (P<0.05) are indicated by (*) and shading, whilst trends 
(P<0.1) are indicated by shading only. 1Activation refers to cells expressing CCR5, HLA-DR and/or CD38. 2NK cells refers to those expressing CD56+CD16+ markers. Cytokines 
are ordered according to functionality: pro-inflammatory, chemokines, growth factors, adaptive response and anti-inflammatory cytokines.
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6.6. HPV, discharge-associated STIs, and biomarkers of inflammation 
To investigate a potential compounding effect of co-infecting HPV and inflammatory STI on 
biomarkers of inflammation, the biomarkers were compared between participants categorised 
as uninfected (HPV-STI-), having discharge-associated STI only (HPV-STI+), having HPV 
only (HPV+STI-), and co-infected (HPV+STI+; Table 8; Appendix E).  
6.6.1. Association between HPV, STIs, and genital cytokine concentrations 
HPV+STI- women had increased concentrations of the adaptive cytokine IL-5, pro-
inflammatory cytokine IL-6, and the growth factor G-CSF compared to uninfected women, 
indicating that HPV infection is associated with a distinct cytokine signature [Table 8; 
Appendix E: Table 10]. However, these associations did not withstand adjustment for multiple 
comparisons. Infection with STI only was associated with elevated levels of several cytokines 
relative to uninfected women; with concentrations of IL-1β, IL-6, TNF-α, TRAIL, CTACK, 
IL-16, MIG, MIP-1α, RANTES, β-NGF, FGF, HGF, SCF, SCGF-β and IL-5 remaining 
significant even after adjustment. Infection with STIs induced a robust pro-inflammatory 
cytokine response compared to HPV infection [Table 8; Appendix E: Table 10]. Women with 
an HPV/STI coinfection were associated with a similar cytokine profile as women with STI 
only, and coinfection was associated with significant increases in additional cytokines: TNF-
β, MCP-3, IL-9 and M-CSF relative to uninfected women [Table 8; Appendix E: Table 10]. 
Additionally, comparisons between the STI only and coinfection groups demonstrated that for 
some cytokines (IL-6 and IL-1RA) the effect of concomitant HPV infection was a reduction of 
the cytokine when compared to the concentrations observed in women with STI alone. These 
data suggested that the inflammatory response observed in co-infected women was solely 
driven by discharge-associated STIs and HPV infection had limited impact on the cytokine 
milieu in HPV+STI+ women. As expected, STI was significantly associated with genital 
inflammation status relative to uninfected women (P = 0.0054), suggesting that infection with 
non-HPV related pathogens induced an inflammatory response at the genital mucosa. 
 
Taken together, these data suggests that infection with this panel of discharge-associated 
agents was related to an inflammatory response, more so than HPV infection alone; and that 
HPV co-infection with STI has a limited impact on cytokine concentrations. 
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Table 8. Cytokine concentrations among HPV-STI-, HPV+STI-, HPV-STI+ and HPV+STI+ women. 
  HPV-STI- (N = 67) HPV ONLY (N = 66) STI ONLY (N = 14) HPV+STI+ (N = 15) 
Cytokine 
Median (IQR) log10 
pg/ml 
Median (IQR) log10 
pg/ml 
Median (IQR) log10 
pg/ml 
Median (IQR) log10 
pg/ml 
IL-1α 2,032 (1,614-2,473) 2,143 (1,834-2,444) # 2,683 (1,930-3,111)* 2,540 (2,247-2,797)* 
IL-1β 1,563 (1,009-2,098) 1,557 (1,044-2,251) 2,395 (1,650-2,826)*  2,118 (1,719-2,335)* 
IL-6 0,795 (0,522-1,256) 1,004 (0,787-1,351)* 1,207 (0,972-1,735)* # 0,892 (0,711-1,055) 
IL-12P40 2,425 (2,296-2,507) 2,423 (2,320-2,520) 2,551 (2,370-2,731)* 2,512 (2,317-2,594) 
IL-12P70 1,709 (1,457-1,939) 1,774 (1,476-2,072) 1,892 (1,481-2,160) 1,943 (1,617-2,054) 
IL-18 2,351 (1,855-2,677) 2,293 (1,954-2,684) 2,541 (2,037-2,801) 2,219 (2,113-3,025) 
MIF 3,551 (3,244-3,904) 3,549 (3,249-3,834) 3,617 (3,197-3,902) 3,487 (3,085-3,948) 
TNF-α 0,983 (0,769-1,388) 1,074 (0,906-1,348) 1,369 (1,085-1,874)* 1,209 (1,031-1,483) 
TNF-B 0,542 (0,387-0,633) 0,537 (0,405-0,661) # 0,560 (0,403-1,005) 0,734 (0,524-0,848)* 
TRAIL 1,420 (1,092-1,738)  1,472 (1,236-1,842) # 1,861 (1,448-2,354)* 1,866 (1,489-2,004)* 
CTACK 1,222 (1,040-1,402)  1,216 (1,084-1,405) # 1,392 (1,284-1,759)* 1,481 (1,195-1,590)* 
EOTAXIN 0,732 (0,418-0,996) 0,823 (0,475-1,063) 1,003 (0,460-1,299) 0,900 (0,732-1,064) 
GRO-A 2,693 (2,192-3,456) 2,956 (2,352-3,484) 3,075 (2,778-3,754) 3,206 (2,532-3,783) 
IL-8 2,601 (2,143-3,038) 2,692 (2,344-3,050) 3,028 (2,589-3,638)* 2,962 (2,669-3,221) 
IL-16 1,542 (1,349-1,816) 1,578 (1,437-1,890) 1,876 (1,673-2,332)* 1,828 (1,456-2,137)* 
IP-10 2,306 (1,599-2,728) 2,322 (1,704-2,959) 2,636 (2,290-3,472)* 2,280 (1,901-3,523) 
MCP-1 1,458 (1,368-1,544) 1,469 (1,356-1,611) 1,540 (1,377-1,800) 1,458 (1,316-1,485) 
MCP-3 1,036 (0,751-1,156) 0,975 (0,774-1,185) # 1,047 (0,920-1,457) 1,184 (0,958-1,365)* 
MIG 2,422 (1,821-2,889) 2,466 (2,059-3,046) 3,200 (2,447-3,821)* 3,247 (2,299-3,516)* 
MIP-1α 0,009 (-0,252-0,316) 0,008 (-0,204-0,313) 0,314 (0,028-0,698)* 0,193 (-0,004-0,483) 
MIP-1B 1,043 (0,728-1,663) 1,281 (0,846-1,752) 1,487 (1,135-1,877)* 1,224 (1,015-1,940) 
RANTES 0,754 (0,340-0,975) 0,793 (0,525-1,114) 1,161 (0,796-1,527)* 1,035 (0,732-1,251)* 
IFN-α2 1,225 (1,143-1,345) 1,242 (1,119-1,369) # 1,379 (1,233-1,648)* 1,437 (1,160-1,518)* 
β-NGF -0,131 (-2,000-0,246) -0,117 (-0,498-0,302) 0,221 (-0,144-0,754)* 0,366 (-0,377-0,630)* 
FGF BASIC 1,409 (1,358-1,493) 1,422 (1,371-1,482) 1,503 (1,426-1,587)* 1,481 (1,353-1,562) 
G-CSF 2,199 (1,591-2,701) 2,395 (2,066-2,965)* 2,517 (2,202-3,307)* 2,239 (1,800-2,730) 
GM-CSF 1,840 (1,789-1,908) 1,855 (1,802-1,907) # 1,890 (1,775-1,932) 1,799 (1,751-1,861) 
HGF 2,167 (1,747-2,748) 2,323 (1,918-2,780) 2,788 (2,227-3,329)* 2,575 (2,299-2,915)* 
IL-3 2,024 (1,891-2,114) 1,997 (1,951-2,154) 2,118 (1,996-2,479)* 2,258 (1,964-2,326)* 
IL-7 0,781 (0,547-1,049) 0,865 (0,683-1,031) 0,992 (0,741-1,073) 0,903 (0,780-1,086) 
IL-9 0,655 (0,515-0,844) 0,733 (0,590-0,848) 0,785 (0,617-1,021) 0,815 (0,717-0,930)* 
LIF 1,073 (0,899-1,262) 1,075 (0,936-1,239) # 1,164 (1,100-1,620)* 1,305 (1,216-1,375)* 
M-CSF 1,778 (1,565-2,020) 1,926 (1,598-2,121) 1,995 (1,661-2,350) 2,056 (1,729-2,203)* 
PDGF-BB 1,078 (0,817-1,300) 1,127 (0,966-1,361) 1,270 (1,040-1,669)* 1,276 (0,971-1,392)* 
SCF 0,960 (0,694-1,232) 1,010 (0,765-1,337) 1,443 (0,894-1,810)* 1,477 (0,887-1,706)* 
SCGF-β 2,548 (2,090-2,900) 2,734 (2,384-3,037) 3,137 (2,438-3,350)* 2,756 (2,367-3,094) 
SDF-1A 2,303 (2,054-2,646) 2,426 (2,188-2,679) 2,511 (2,375-2,734)* 2,511 (2,216-2,736) 
VEGF 2,333 (1,943-2,571) 2,405 (2,092-2,710) 2,581 (2,108-3,058) 2,681 (2,275-2,833) 
IFN-G 1,312 (1,060-1,536) 1,371 (1,192-1,530) 1,562 (1,222-1,826)* 1,448 (1,335-1,615) 
IL-2 0,446 (0,236-0,659) 0,436 (0,187-0,680) 0,546 (0,389-0,886) 0,322 (-0,495-0,520) 
IL-4 -0,013 (-0,181-0,158) 0,025 (-0,107-0,133) 0,204 (-0,034-0,399)* 0,093 (-0,066-0,290) 
IL-5 -0,051 (-1,222-0,403) 0,243 (-0,253-0,500)* 0,496 (0,266-0,727)* 0,427 (0,255-0,593)* 
IL-13 0,535 (0,332-0,728) 0,563 (0,329-0,733) 0,614 (0,392-0,813) 0,543 (0,403-0,780) 
IL-15 0,093 (-1,260-0,614) 0,350 (-1,260-0,700) 0,532 (-1,260-0,943) 0,188 (-1,260-0,496) 
IL-17 1,069 (0,937-1,266) 1,093 (0,975-1,279) 1,201 (1,034-1,698)* 1,129 (0,977-1,406) 
IL-2rα 1,272 (1,115-1,420) 1,241 (1,081-1,420) #  1,476 (1,319-1,957)* 1,562 (1,246-1,673)* 
IL-10 1,606 (1,434-1,715) 1,626 (1,513-1,815) 1,694 (1,518-1,873)* 1,640 (1,608-1,773) 
IL-1RA 4,107 (3,911-4,211) 4,115 (3,985-4,248) # 4,108 (4,000-4,291) # 3,943 (3,749-4,095) 
Mann-Whitney U tests were used to compare medians between groups. P-values<0.05 were considered significant. * denote 
significant differences between HPV-STI-  and HPV only, or STI only or HPV+STI+; while # represents a statistical difference 
in medians between  HPV+STI+ and HPV only, or STI only. * or # in red print indicate p values significant after multiple 
comparisons adjustment by Dunn’s post-testing. Cytokines are ordered according to functionality: pro-inflammatory, 
chemokines, growth factors, adaptive response and anti-inflammatory cytokines. 
 
 
6.6.2. Association between HPV, STIs, and epithelial barrier integrity 
Women with STI only had significantly higher levels of MMP-1, MMP-2, MMP-3, MMP-8, 
MMP-9, MMP-12 and MMP-13 compared to uninfected women [Table 9; Appendix E: Table 
11]. Coinfection was associated with increases in similar MMPs [MMP-2, MMP-3 and MMP-
12] as the HPV-STI+ group. Additionally, women with HPV only had significantly reduced 
concentrations of MMP-2, MMP-12 and MMP-13 compared to HPV+STI+ women, suggesting 
that STI alone contributed to increases of these enzymes observed in co-infected women. 
 
 
6.6.3. Association between HPV, STIs, and immune cell recruitment 
The inflammatory nature of STIs extended to the investigation of immune cell subsets in the 
context of HPV [Table 10; Appendix E: Table 12]. Women with STI only had increased 
frequencies of activated (CD3+CD38+), highly activated (CD3+CD38+DR+), total activated and 
activated CCR5+CD3+ T cell targets (CD3+CCR5+CD38+, CD3+CD38+DR+CCR5+) compared 
to uninfected women. These T cell associations were attributable to the CD8+ population since 
activated (CD8+CD38+), highly activated (CD8+CD38+DR+)  and activated CCR5+CD8+ T cell 
targets (CD8+CCR5+CD38+, CD8+CD38+DR+CCR5+) were significantly higher among HPV-
STI+ women relative to uninfected women [Table 10; Appendix E: Table 12]. However, these 
associations did not withstand multiple comparisons. These same cell subsets were increased 
among women with a coinfection; in addition, co-infected women had increased frequencies 
of activated (CD3+DR+) CD3 cells, activated CCR5+CD4+ T cell targets (CD4+CCR5+CD38+) 
Table 9. MMP concentrations among HPV-STI-, HPV+STI-, HPV-STI+ and HPV+STI+ women. 
  HPV-STI- (N = 67) HPV ONLY (N = 66) STI ONLY (N = 14) HPV+STI+ (N = 15) 
Protein 
Median (IQR) log10 
pg/ml 
Median (IQR) log10 
pg/ml 
Median (IQR) log10 
pg/ml 
Median (IQR) log10 
pg/ml 
MMP-1 2,690 (3,150-3,440) 2,435 (3,150-3,420) 3,163 (3,550-3,848)* 3,160 (3,350-3,480) 
MMP-2 2,700 (3,340-3,770) 2,838 (3,525-3,780) # 3,415 (4,050-4,355)* 3,400 (3,730-4,160)* 
MMP-3 2,630 (2,810-3,170) 2,510 (2,930-3,273) 2,813 (3,265-3,603)* 2,810 (3,170-3,240)* 
MMP-7 1,810 (2,420-3,110) 2,003 (2,515-3,150) 2,098 (2,760-3,330) 2,210 (2,460-3,610) 
MMP-8 4,190 (5,000-5,920) 4,108 (4,950-6,223) 4,905 (6,560-7,623)* 4,930 (5,240-6,050) 
MMP-9 3,890 (4,500-5,410) 3,680 (4,635-5,443) 4,340 (5,685-6,335)* 4,510 (5,000-5,440) 
MMP-10 2,290 (2,890-3,180) 2,270 (2,960-3,313) 2,793 (3,135-3,538) 2,700 (2,900-3,010) 
MMP-12 2,440 (2,830-3,230) 2,268 (2,855-3,408) # 2,895 (3,330-4,013)* 2,840 (3,240-3,700)* 
MMP-13 1,710 (2,140-2,630) 1,708 (2,185-2,605) # 2,278 (2,595-2,965)* 2,270 (2,490-2,690) 
Mann-Whitney U tests were used to compare medians between groups. P-values<0.05 were considered significant. * denote 
significant differences between HPV-STI-  and HPV only, or STI only or HPV+STI+; while # represents a statistical 
difference in medians between  HPV+STI+ and HPV only, or STI only. * or # in red print indicate p values significant after 
multiple comparisons adjustment by Dunn’s post-testing. 
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and activated CD8+ cells (CD8+DR+) compared to uninfected women. Furthermore, women 
with HPV only had reduced frequencies of multiple cellular subsets [(CD3+DR+, CD3 total 
activation, CD4+CD38+, CD4+CCR5+CD38+, CD4 total activation, CD8+CD38+, CD8+DR+, 
CD8+CD38+DR+ and CD8 total activation), Table 10; Appendix E: Table 12] relative to co-
infected women, suggesting that cellular associations observed in HPV+STI+ women were 
driven by discharge-associated STIs. 
 
Table 10. Cellular frequencies among HPV-STI-, HPV+STI-, HPV-STI+ and HPV+STI+ women. 
  HPV-STI- (N = 66) HPV ONLY (N = 69) STI ONLY (N = 14) HPV+STI+ (N = 13) 
Cell Type Median % (IQR) Median % (IQR) Median % (IQR) Median % (IQR) 
LYMPHOCYTES 1,083 (2,170-5,350) 0,982 (2,290-5,715) 0,631 (3,520-7,860) 1,050 (2,940-4,365) 
CD3 1,178 (10,350-27,730) 2,755 (13,400-23,450) 3,678 (10,190-38,700) 1,290 (11,400-24,350) 
CD3CD38DR+CCR5+ 0,829 (4,770-13,530) 1,550 (5,090-13,730) 6,935 (10,300-26,850)* 3,625 (6,450-30,500) 
CD3CCR5+CD38+ 4,650 (16,400-25,600) 6,170 (17,900-27,800) 13,250 (28,800-42,600)* 15,600 (21,900-40,950) 
CD3CCR5+DR+ 3,403 (8,990-19,980) 3,883 (11,000-28,500) 8,050 (14,600-51,600) 6,885 (25,200-50,200)* 
CD3CCR5+KI67+ 0,000 (3,800-13,850) 0,000 (8,765-24,900) 0,074 (17,700-57,350) 0,000 (16,600-28,050) 
CD3CD38+DR+ 3,135 (10,200-20,450) 4,680 (11,050-24,550) 13,250 (18,900-28,850)* 6,150 (16,900-47,000) 
CD3CCR5+ 21,100 (38,700-59,950) 22,250 (44,600-57,850) 34,200 (57,450-73,050) 30,950 (46,700-84,000) 
CD3CD38+ 21,180 (37,600-52,380) 16,900 (42,400-53,650) 32,700 (54,700-73,550)* 26,350 (61,700-75,600) 
CD3HLA-DR 10,550 (23,900-40,900) 13,230 (24,950-49,530) # 21,150 (27,800-61,050) 24,000 (34,900-66,500)* 
CD3KI67 0,513 (13,500-31,180) 0,049 (21,400-40,750) 0,072 (21,600-63,280) 3,342 (29,000-38,250) 
CD3 - 23,650 (41,500-59,780) 21,850 (35,500-58,850) 24,880 (29,750-67,780) 22,550 (33,200-59,800) 
NK Cells 2 1,580 (5,520-12,350) 1,830 (4,080-17,500) 0,403 (2,730-20,650) 1,283 (3,745-12,530) 
CD3 Activation 1 53,250 (68,200-91,030)  55,150 (74,600-86,850) # 75,250 (86,050-93,630)* 76,500 (90,100-98,850)* 
CD4 49,030 (62,250-72,880) 48,350 (58,000-67,050) 53,780 (64,450-70,300) 29,050 (45,900-63,850) 
CD4CD38DR+CCR5+ 0,084 (3,715-10,980) 0,608 (4,125-12,180) 4,065 (7,610-18,900) 1,260 (5,910-15,200) 
CD4CCR5+CD38+ 3,370 (16,700-30,700)  4,725 (18,600-31,500) # 9,128 (26,950-38,280) 18,300 (27,300-56,000)* 
CD4CCR5+DR+ 2,270 (8,740-19,380) 2,090 (8,940-28,300) 5,310 (12,600-37,850) 1,260 (9,460-28,450) 
CD4CCR5+KI67+ 0,000 (3,770-19,250) 0,000 (3,400-27,780) 0,000 (0,275-37,950) 0,000 (18,200-26,550) 
CD4CD38+DR
+ 1,230 (8,160-17,450) 1,890 (8,770-18,230) 7,685 (12,300-21,750) 2,180 (6,920-21,850) 
CD4CCR5 24,800 (44,700-69,200) 19,750 (43,300-62,800) 24,380 (56,550-75,830) 30,700 (54,500-95,450) 
CD4CD38 21,280 (39,650-58,100)  17,700 (42,900-54,600) # 26,080 (56,150-74,880) 30,800 (63,600-75,400) 
CD4HLA-DR 7,140 (16,800-32,750) 5,500 (19,100-41,550) 9,795 (20,300-43,950) 3,050 (10,800-35,950) 
CD4KI67 0,000 (12,050-33,430) 0,000 (8,860-36,850) 0,000 (0,240-44,880) 0,000 (25,000-36,050) 
CD4 Activation 1 50,850 (72,750-91,580)  53,000 (72,700-84,400) # 62,350 (83,050-91,980) 74,650 (84,300-98,950) 
CD8 24,080 (35,650-49,100) 24,400 (36,600-45,700) 29,600 (32,350-44,430) 20,700 (35,100-54,000) 
CD8CD38DR+CCR5+ 0,000 (3,615-9,955) 0,000 (6,280-13,700) 4,735 (11,600-17,100)* 3,165 (8,320-30,550) 
CD8CCR5+CD38+ 0,597 (9,300-18,550) 3,585 (12,900-22,850) 9,155 (18,250-46,430)* 6,360 (18,100-36,050) 
CD8CCR5+DR+ 0,137 (8,110-19,130) 1,958 (12,150-26,500) 8,830 (14,300-27,950) 4,765 (23,600-51,350) 
CD8CCR5+KI67+ 0,000 (2,380-13,900) 0,000 (5,265-26,180) 0,000 (0,171-47,150) 0,000 (9,520-24,900) 
CD8CD38+DR+ 0,163 (10,400-21,600)  1,830 (12,700-30,980) # 15,050 (18,800-34,800)* 5,865 (34,900-68,700)* 
CD8CCR5 14,250 (28,500-51,250) 17,450 (31,900-50,000) 24,830 (42,500-64,200) 17,150 (32,600-70,750) 
CD8CD38 8,730 (33,200-50,200)  13,150 (38,600-54,100) # 32,050 (50,100-75,680)* 23,700 (67,400-81,800)* 
CD8HLA-DR 6,210 (29,900-54,050) 10,550 (36,650-57,150) # 29,350 (40,000-68,150) 28,750 (54,300-85,850)* 
CD8KI67 0,000 (13,500-35,100) 0,000 (11,700-41,050) 0,000 (20,000-97,680) 0,000 (26,100-39,700) 
CD8 Activation 1 45,230 (67,950-90,580) 50,500 (70,800-88,150) # 73,580 (85,150-94,200)* 71,900 (88,400-99,750)* 
Mann-Whitney U tests were used to compare medians between groups. P-values<0.05 were considered significant. * denote significant 
differences between HPV-STI-  and HPV only, or STI only or HPV+STI+; while # represents a statistical difference in medians between  
HPV+STI+ and HPV only, or STI only. * or # in red print indicate p values significant after multiple comparisons adjustment by Dunn’s 
post-testing. 1Activation refers to cells expressing CCR5, HLA-DR and/or CD38. 2NK cells refers to those expressing CD56+CD16+ markers. 
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7. DISCUSSION 
The association between STIs, BV and their contribution to genital inflammation (Levine et 
al., 1998; Fichorova et al., 2001a; Reddy et al., 2004; Yudin et al., 2003) and increased HIV 
risk has been well established (Laga et al., 1993; van de Wijgert et al., 2009; Van Der Pol et 
al., 2008; Mlisana et al., 2012; Masson et al., 2014; Taha et al., 1998). However, even though 
HPV is one of the most common STIs globally, and is associated epidemiologically with an 
increased risk of HIV acquisition (Smith-McCune et al., 2010b; Averbach et al., 2010; Auvert 
et al., 2011; Konopnicki et al., 2013a; Low et al., 2011), the underlying mechanisms of this 
remain elusive. Therefore, the hypothesis of this study was that the immune responses 
associated with HPV (whether in the context of multiple concurrent HPV infections, high or 
low risk HPV infection, and coinfection with other STI) contribute to a genital immune 
environment conducive to an increased risk of HIV infection. Specifically, associations 
between HPV and biological factors known to increase HIV risk, namely genital cytokines and 
inflammation (Nicol et al., 2005; Masson et al., 2015), genital epithelial microabrasions (Herfs 
et al., 2011; Arnold et al., 2016), and HIV target cells frequencies (Arnold et al., 2016; 
Kobayashi et al., 2004) were investigated. 
 
The study population included 167 HIV negative, sexually active women aged 18-40 years 
attending the CAPRISA eThekwini and Vulindela Clinics or their neighbouring public sector 
family-planning services in KZN. In this study, more than half the population had detectable 
HPV DNA at baseline. As expected, HPV positive women were significantly younger than 
their HPV negative counterparts. Younger, sexually active women generally have the highest 
prevalence of HPV infection and are at greatest risk of acquiring HPV (Burchell et al., 2006; 
Dunne et al., 2007; Kahn et al., 2007; Manhart et al., 2006). HPV prevalence has often been 
described as bimodal, with peaks among younger women and those 55 years or older (Herrero 
et al., 2000; Castle et al., 2005). Younger women are more likely to have a transformation zone 
remaining on the ectocervix and are at increased risk of developing premalignant lesions of the 
cervix due to direct exposure to carcinogenic agents (Autier et al., 1996). With increasing age, 
the transformation zone shifts upward into the endocervix, becoming less susceptible to 
carcinogenic agents (Autier et al., 1996) such as HPV. Additionally, younger women have a 
large area of cervical epithelium undergoing squamous metaplasia; and during this period the 
cervical cells are more vulnerable to HPV infection and persistence (Trottier et al., 2006; 
Moscicki et al., 1999; Louie et al., 2009; Moscicki et al., 2006; Castle et al., 2006).  
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HPV positive women were also more likely to have a partner with a higher mean age, and were 
less likely to be living with a regular partner than HPV negative women. Young women in 
African countries are known to engage in sexual relationships with older men for financial 
gain, sexual gratification and recognition from peers, which generally outweigh the concern of 
acquiring STIs and HIV infection (Longfield et al., 2004). In fact, young women in age-
disparate relationships are reportedly more concerned about the risk of becoming pregnant, 
rather than acquiring STIs and HIV infection (Silberschmidt et al., 2001; Jones, 2006; Nkosana 
et al., 2007). This age disparate dynamic was further demonstrated in a recent study which 
showed that young women in KZN acquire HIV infection through sexual relations with older men, 
who in turn acquired the virus from women of similar age (de Oliveira et al., 2017). Additionally, 
women in casual relationships are more likely to acquire incident HPV infections. Sexual 
intercourse with a new partner or multiple partners has also been associated with increased risk 
of acquiring HPV infection, progression to pre-cancer lesions and invasive cervical cancer 
(Zitkute et al., 2016; Burk et al., 1996). Programmatic strategies that emphasize the importance 
of condom use, decreasing peer pressure to pursue such relationships, and improving women's 
access to alternative sources of income are key in averting age-disparate relationships among 
young African women (Longfield et al., 2004).  
 
In this cohort of women, parity was also higher among HPV positive women compared to HPV 
negative women. High parity is known to increase the risk of squamous-cell carcinoma of the 
cervix among HPV positive women (Boyd et al., 1964; Muñoz et al., 2002; Jensen et al., 2013; 
Almonte et al., 2011). Although the exact mechanism by which parity influences the risk of 
cervical cancer is unclear, factors may include: poor nutrition, poorly managed parturition, 
hormones, the method of delivery and reduced immunity during pregnancy (Muñoz et al., 
2002; Autier et al., 1996), all likely to impact the integrity of the genital epithelium, the portal 
for HPV entry (Stanley, 2012). 
 
Taken together, the baseline epidemiologic findings observed in this study support established 
demographic, behavioural and clinical associations with HPV infection. Since none of these 
factors except STIs and nugent score were associated with genital inflammation status at 
baseline, only these were controlled for in multivariate analyses investigating the impact of 
HPV infection on biomarkers of inflammation.  
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In this study, concordant with reports of the inflammatory nature of STIs (Levine et al., 1998; 
Fichorova et al., 2001a; Reddy et al., 2004; Anahtar et al., 2015; Arnold et al., 2016; Kaul et 
al., 2008), having a discharge-associated STI alone was significantly associated with several 
genital cytokines, and genital inflammation status, compared to women uninfected by HPV or 
discharge-associated STI (HPV-STI- women). These data suggest that infection with these 
non-HPV pathogens may result in increased HIV risk, since the definition of inflammation 
used is associated with HIV seroconversion (Masson et al., 2015). Genital inflammation, 
however, was not associated with prevalent HPV infection, the number of infecting types, or 
the oncogenic potential of the HPV. These findings were corroborated by other studies using a 
similar definition of genital inflammation (Kriek et al., 2016; Shannon et al., 2017). Although 
HPV infection is not associated with this definition of genital inflammation [which was 
originally generated in association with other discharge and ulcer-related STI (Masson et al., 
2014), HPV infection was indeed associated with a more subtle immune response, and further 
investigation to further characterise this response is warranted. 
 
Prevalent HPV infection was significantly associated with increases in the chemokine SDF-1α 
at baseline, even after controlling for inflammatory STI and BV. SDF-1α is involved in cell 
growth and apoptosis, and is associated with HPV infection (Jaafar et al., 2009) and invasion 
and metastasis of various cancer types (Feig et al., 2013; Teng et al., 2016; Chen et al., 2015).  
A recent study by Song et al. suggested that the relationship between SDF-1α and cervical 
cancer may be mediated by SDF-1α-associated activation of the NF-κB pathway via 
interactions with its ligand, CXCR4 (Song et al., 2017). This pathway participates in the 
regulation of cell proliferation, apoptosis and angiogenesis in cervical cancer (Song et al., 
2017). Elevated levels of this chemokine among HPV positive women may indicate increased 
risk of progression to cervical cancer if infection persists. Moreover, CXCR4 is a co-receptor 
for HIV-1, and the binding of SDF-1α to it inhibits viral entry (Maréchal et al., 1999). In 
addition to SDF-1α inhibiting the entry of CXCR4-tropic HIV, it is known to increase the 
infectivity of the CCR5-tropic HIV-1 envelope (Maréchal et al., 1999). An understanding of 
whether the association observed between SDF-1α and HPV infection contributes to protection 
from CXCR4-tropic HIV, or promotion of CCR5-tropic infectivity in HPV-infected women 
would require assessments outside the scope of this study e.g. the additional measurement of 
CXCR4+ T cell populations, a longitudinal analysis of HIV outcome, etc. However, the 
 60 
 
association between SDF-1α and HPV infection suggests a potential impact on HIV risk, as 
well as on progression to cervical cancer.  
 
Prevalent HPV infection was not associated with genital inflammation, immune cell activation, 
or markers of epithelial barrier integrity. However, although not significant, a trend towards a 
relationship between prevalent HPV infection and reduced frequencies of CD4 cells was 
observed, implying that a compromised immune response may be associated with an increased 
risk HPV acquisition. While this investigation took place in an HIV negative population, this 
observation of reduced CD4 cells in HPV-infected women is broadly in keeping with numerous 
studies demonstrating that reduced CD4 count is associated with increased prevalence of HPV 
infection in HIV positive women (Ortiz et al., 2017; Piper et al., 1999; Denny et al., 2012; da 
Silva et al., 2015). Among HIV positive women, higher CD4 counts were shown to reduce the 
risk of persistent infection with HR-HPV types (Konopnicki et al., 2013b; Kang et al., 2012). 
Some studies even report that CD4 counts are a stronger predictor of HPV infections than HIV 
viral load (Denny et al., 2012; da Silva et al., 2015; Konopnicki et al., 2013b). Although 
prevalent HPV infection was not associated with the upregulation of pro-inflammatory 
cytokines nor immune cell recruitment, further investigations were conducted to determine 
whether other features of HPV infection, also associated with HIV infection, had an impact on 
genital immunity. 
 
This study examined the contribution of multiple concurrent HPV infections as the 
epidemiologic link between HPV infection and increased HIV risk. Although several studies 
have demonstrated that having multiple infections is associated with a significantly increased 
risk of HIV infection (Konopnicki et al., 2013a; Averbach et al., 2010), there was no 
association between infection with multiple HPV types and pro-inflammatory cytokines, 
immune cell recruitment or epithelial barrier disruption in this study. However, multiple 
concurrent infections were associated with reduced concentrations of the adaptive cytokine IL-
5. IL-5, a Th2-affiliated cytokine, is generally associated with non-specific innate immunity to 
environmental allergens (Marks et al., 2011b), and is known to regulate the expression of genes 
involved in the proliferation, maturation and effector functions of B cells and eosinophils. It is 
possible that this limited immune response among women with multiple infections may be a 
mechanism whereby HPV evades host immune responses. While we and others (Marks et al., 
2011b) observed a signature of elevated IL-5 concentrations in HPV infected women relative 
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to uninfected women, perhaps indicative of an immune response to current infection, it is 
interesting that having more than one HPV genotype detectable at the genital epithelium 
corresponds to reduced levels of this cytokine. This may allude to potential immune evasion 
strategies that are activated by HPV upon infection with multiple types in an effort to remain 
undetectable by the host immune responses. Having multiple concurrent HPV infection was 
not associated with an upregulated immune response at the genital tract as originally postulated. 
Although other studies corroborate these findings that infection with multiple HPV does not 
affect the concentrations of pro-inflammatory cytokines genital tract (Kriek et al., 2016), it was 
however, associated with a reduction in the concentrations of the adaptive response cytokine 
IL-5. It is important to note that there are more than 120 HPV types in existence and only 37 
types were assessed in this study. Therefore the number of concurrently infecting HPV types 
may be under-represented and other HPV types may also contribute to an immune response at 
the genital mucosa.  
 
Since the number of infecting HPV types was not associated with markers of a traditional 
inflammatory response, it was further investigated whether the type of infecting HPV was 
associated with biomarkers of inflammation instead. Having a HR-HPV infection predicted 
significant increases in the chemokine MCP-1 and the adaptive cytokine IL-13. MCP-1 recruits 
monocytes, memory T cells and DCs to sites of infection (Carr et al., 1994; Xu et al., 1996) 
and is included in the definition of genital inflammation used here (Masson et al., 2015). MCP-
1 has been linked to chronic inflammatory diseases (Baggiolini et al., 1994; Ransohoff et al., 
1996), antitumor immunity (Huang et al., 1994; Rollins et al., 1991), atherosclerosis (Charo et 
al., 2004) and cervical cancer (Kleine-Lowinski et al., 1999; Kleine-Lowinski et al., 2003; 
Rösl et al., 1994). Several studies have shown that MCP-1 expression and infiltrating cells of 
the monocyte/macrophage lineage were only detectable in premalignant precursor cells and 
absent in high-grade lesions of cervical cancer patients (Kleine-Lowinski et al., 1999; 
Riethdorf et al., 1996; Spinillo et al., 1993). Furthermore, HIV-infected women were found to 
have elevated concentrations of this chemokine compared to HIV negative women (Kriek et 
al., 2016), suggesting a potential link between increased concentrations of MCP-1 among 
women with HR-HPV infection and increased risk of HIV acquisition.  
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The role of IL-13 in genital inflammation and HIV acquisition is unclear. Older women with 
HR-HPV have been shown to have greater concentrations of IL-13, also a Th2-associated 
cytokine linked to non-specific innate immunity and response to environmental allergens 
(Marks et al., 2011b). IL-13, which is responsible for the activation and control of eosinophils 
(Pope et al., 2001; Rothenberg et al., 1999; Zimmermann et al., 2003), were elevated among 
women with HR-HPV (Marks et al., 2011a). Eosinophils have been investigated as mediators 
of tumour immunity, and eosinophilia as a potential prognostic marker in oral cancers 
(Martinelli-Klay et al., 2009). These data may indicate that increased concentrations of IL-13 
are associated with a non-specific immune response toward HR-HPV infection, similar to the 
host immune response elicited toward environmental allergens. 
 
Although not statistically significant, there was a trend toward increased concentrations of the 
pro-inflammatory cytokines IL-1β and IL-12p70; chemokines eotaxin, IL-8, IP-10 and MIG; 
the growth factor, VEGF; and the adaptive cytokine IL-2 among women with HR-HPV 
infection. Both IL-1β and IL-12p70 are pro-inflammatory and elevated concentrations of these 
cytokines is associated with active STI infection (Masson et al., 2014). In support of these 
findings, a recent study found that HPV positive participants had upregulated genital 
concentrations of IP-10 and MIG (Shannon et al., 2017), both of which are IFN-γ-induced, 
bind CXCR3 (Hsieh et al., 2006), and may indicate immune activation. Genital levels of both 
chemokines are reduced among women who remained HIV negative despite frequent HIV 
exposure (Lajoie et al., 2012). However, elevated levels of IL-8 and IP-10 are significantly 
associated with HIV seroconversion among South African women (Masson et al., 2015) and 
form part of the definition of inflammation used in this study. Although the exact mechanisms 
by which IP-10 and MIG enhance HIV susceptibility is unknown, Shannon et al. found both 
chemokines to be moderately correlated with increases in CCR5+CD4+ T cells (Shannon et al., 
2017). It has been suggested that the innate immune response may be critical for HPV clearance 
(Daud et al., 2011; Scott et al., 2013). In keeping with this, treatment of HR-HPV infections 
with Imiquimod, a TLR-7 agonist, induces IFN-α, IL-1, IL-6, IL-8, IL-10 and IL-12, promotes 
migration of Langerhans cells and enhances antigen presentation, resulting in the clearance of 
infection (Stanley, 2002; Schon et al., 2004). Although, the cross-sectional design of this study 
prevents conclusions to be made regarding HPV clearance, there was a trend towards infection 
with oncogenic HPV and increased concentrations of IL-1, IL-8 and IL-12, all of which are 
associated with the clearance of HPV infection (Stanley, 2002; Schon et al., 2004). Moreover, 
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women with an oncogenic HPV infection were more inclined to have increased concentrations 
of the adaptive cytokine IL-2. Clearance of HPV infection is mediated by a robust CD8+ 
cytotoxic T lymphocyte response which is characterized by elevated concentrations of IL-2 
and IFN-γ (Stanley, 2006). Thus increased levels of IL-2 may be indicative of an attempt to 
clear HPV infection.  
 
A trend towards increases in eotaxin was also observed among women with HR-HPV. Eotaxin 
is another Th2-induced chemokine that is primarily responsible for the recruitment and 
regulation of eosinophils and basophils (Marks et al., 2011b), again suggesting that a non-
specific innate immune response may be elicited toward infection with HR-HPV. Even though 
this study did not assess CIN nor progression to cervical cancer, the trend toward increased 
concentrations of VEGF among women HR-HPV infection may indicate progression to 
cervical cancer, since VEGF has been implicated as an early marker of cervical carcinogenesis 
(Branca et al., 2006).  
 
Although there were no significant associations between oncogenic HPV and markers of 
epithelial barrier integrity, women with HR-HPV had a trend toward increased concentrations 
of MMP-3. MMPs play a pivotal role in the degradation of the extracellular matrix and 
basement membrane and hence, may play a key role in cancer development (Stott-Miller et al., 
2011). MMP-3 concentrations are known to be upregulated in tumours and 
immunohistochemistry has revealed over-expression of MMP-3 in cancers compared to normal 
cervical epithelium (Rajkumar et al., 2011). Additionally, HPV may facilitate HIV entry and 
dissemination through disruption of the epithelial barrier (Herfs et al., 2011). However, this 
study was not designed to address this, and further investigation is warranted.  
 
Additionally, this study demonstrated a significant association between HR-HPV and increased 
frequencies of lymphocytes. Increased lymphocyte frequencies among women with HR-HPV 
may indicate immune cell recruitment to the site of infection in an attempt to clear infection. 
Histological examination of regressing genital warts have shown a large infiltrate into the wart 
stroma and epithelium of T cells (CD4+ and CD8+) and macrophages (Coleman et al., 1994). 
The host immune response to HPV is mediated by T-lymphocytes, which are also primary 
target cells for HIV (Houlihan et al., 2012; Stanley, 2001). Recruitment of HIV target cells 
(CD4+CCR5+) to the female genital tract to clear HPV infection may also provide an immune 
environment conducive to HIV acquisition. Although some of these associations were not 
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statistically significant, elevated levels of these cytokines, MMPs, and immune cell recruitment 
among women with HR-HPV may provide a possible mechanistic link between HR-HPV and 
a contribution toward genital inflammation which is associated with HIV acquisition.  
 
Lastly, investigations were conducted to determine the contribution of HPV infection to genital 
inflammation in the context of other STI (C. trachomatis, T. vaginalis, M. genitalium and/or 
N. gonorrhoeae). STIs are a well-established contributor to genital inflammation and increased 
HIV risk (Levine et al., 1998; Fichorova et al., 2001a; Reddy et al., 2004; Anahtar et al., 2015; 
Arnold et al., 2016; Kaul et al., 2008). The immune responses that are elicited by the host in 
order to facilitate pathogen clearance and defend against reinfection also may render 
individuals more vulnerable to HIV infection (Laga et al., 1993; van de Wijgert et al., 2009; 
Van Der Pol et al., 2008; Mlisana et al., 2012; Masson et al., 2014; Taha et al., 1998). Infection 
by sexually transmitted pathogens have been shown to influence the persistence and 
progression or clearance on concurrent HPV infection (Castle et al., 2003). Multiple STIs were 
found to be risk factors for cervical cancer, suggesting that non-HPV STIs may act as HPV 
cofactors (Castle et al., 2003). Among women with HR-HPV infection, antibodies to C. 
trachomatis was associated with an increased risk of cervical cancer (Smith et al., 2002). A 
study by Silins et al. demonstrated that history of previous C. trachomatis infection was 
associated with the persistence of HPV infection (Silins et al., 2005). T. vaginalis has been 
associated with increased risk of squamous intraepithelial lesions, CIN based on biopsy results 
and HR-HPV infection (Verteramo et al., 2009; Watts et al., 2005; Noel et al., 2010; Yap et 
al., 1995). T. vaginalis infection produces microabrasions in the cervical epithelium, thereby 
facilitating HPV entry (Thurman et al., 2011). Moreover, Neisseria gonorrhoea and 
Mycoplasma genitalium have been linked to persistence of HR-HPV infection (de Abreu et al., 
2016; Biernat-Sudolska et al., 2011).  
  
In this study women with HPV only (HPV+STI-) had greater levels of IL-5, IL-6 and G-CSF 
compared to uninfected women. However, HPV-STI+ women had elevated levels of these and 
several other cytokines, MMP concentrations and greater immune cell recruitment compared 
to HPV-STI- women, indicative of the inflammatory nature of the discharge-associated STIs 
assessed. A study by Fichorova et al. showed that human endocervical, ectocervical and 
vaginal cell lines that were actively invaded by N. gonorrhoeae had elevated concentrations of 
IL-8 and IL-6 (Fichorova et al., 2001a). Cervical secretions of Chlamydia positive women 
revealed upregulated recruitment of CD8 lymphocytes to the genital tract and increased 
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concentrations of IFN-γ, TNF-α, IL-10 and IL-12 (Reddy et al., 2004), all of which have been 
broadly substantiated in this study. Moreover, persistent infection with M. genitalium has been 
associated with elevated concentrations of IL-8, MCP-1 and MIP-1β (McGowin et al., 2012). 
Additionally, discharge-related STIs were significantly associated with the definition of 
inflammation validating the findings of Masson et al. which additionally demonstrated that 
chlamydia and gonorrhoea were highly inflammatory relative to the other STIs measured 
(Masson et al., 2014). Data from these studies are broadly in keeping with the findings here, 
which demonstrated distinct pro-inflammatory host responses associated with these 
discharged-related STIs. These immune response associated with STIs in this study, may be 
associated with increased risk of HIV infection.  
 
On the contrary, women with HPV only also had reduced levels of multiple cytokines, MMPs 
and several immune cell subsets, (most notably activated CCR5+CD4 HIV target cells), relative 
to HPV+STI+ women. These data indicate that the inflammatory response associated with 
coinfection was driven by infection with the panel of discharge-associated agents assessed. 
Furthermore, women with an HPV/STI coinfection had lower concentrations of the pro-
inflammatory cytokine IL-6 and anti-inflammatory cytokine IL-1RA compared to women with 
STI only, suggesting that the effect of concomitant HPV infection is a reduction of cytokine 
production. Anti-inflammatory cytokines function in the downregulation of pro-inflammatory 
cytokines in order to maintain homeostasis (Gérard et al., 1993; Howard et al., 1993), however, 
an excessive anti-inflammatory response may lead to immune suppression (Davidoff, 1996; 
Fisher et al., 1996). A reduction of these cytokines in HPV+STI+ women may be attributed to 
the ability of HPV to evade host immune responses. Evasion of the host immunity has been 
considered vital for HPV to persist and cause HPV-related cancers (Senba et al., 2012).  
  
This study had several limitations, most notably, the cross-sectional design prevented the 
classification of HPV infections as persistent or transient. It is likely that different immune 
signatures may have been associated with the persistence or clearance of HPV infection, or 
even impending acquisition. Additionally, upon categorization of women according to multiple 
genotypes and oncogenicity, the sample size was considerably reduced and perhaps a larger 
cohort would demonstrate significant associations rather than several trends as seen in women 
with HR-HPV. The use of CVL specimens for the measurement of cytokine concentrations 
may be limiting since CVLs are diluted and may prevent measurement of cytokines present at 
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lower levels. Perhaps the use of Softcup specimens may be a more suitable method of 
measuring cytokine concentrations in genital specimens since these samples are concentrated. 
Several other factors that may have contributed to genital inflammation were not assessed in 
this study, including: age, oral contraceptive use, menstrual cycles, microbiome composition, 
HPV viral load, and the use of vaginal insertive products. It is important to note that tight 
junction proteins and other adhesion molecules may have been better measures of epithelial 
barrier integrity as a reduction in these would provide HPV with direct access to basal epithelial 
cells. Finally, disease outcomes such as progression to cervical cancer or HIV seroconversion 
were not measured in this study, therefore conclusive statements regarding HPV, STIs and 
disease cannot be made. 
 
It was originally hypothesized that the immune responses associated with prevalent HPV, with 
having multiple concurrent HPV infections, with oncogenic HPV and an HPV/STI coinfection 
were associated with a genital immune response conducive to HIV acquisition. When 
investigating the compounding effect of co-infecting HPV and inflammatory STI on 
biomarkers of inflammation, several cytokines, MMPs and immune cell subsets were elevated 
among women with STI only (HPV-STI+) compared to uninfected women (HPV-STI-); 
suggesting, as expected, that the panel of discharge-associated STIs assessed in this study, are 
highly inflammatory and significantly associated with genital inflammation. Interestingly, in 
this analysis, HPV infection in the absence of other STI was associated with reductions in 
selected cytokine and MMP concentrations, and with reduced frequencies of immune cells 
relative to women with coinfection, indicative of a modulatory effect on the STI-associated 
immune response. In multivariate models controlling for STI and BV, HPV infection (not 
taking into account the number or type of infecting HPV) predicted increased concentrations 
of the chemokine SDF-1α, but was not associated with markers of epithelial barrier integrity, 
or immune cell activation. Further investigations were conducted to determine whether 
multiple HPV infections, oncogenicity and coinfection with other STI had an impact on genital 
immunity. Having multiple HPV infections was associated with reduced concentrations of IL-
5, but was not, however, significantly associated with MMP concentrations nor with T cell 
activation. Further, infection with HR-HPV was associated with increased concentrations of 
MCP-1 and IL-13, and was also significantly associated with greater frequencies of 
lymphocytes at the genital tract, but not with markers of epithelial barrier integrity.  This study 
demonstrates a distinct immune response associated with HPV infection, and more specifically 
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oncogenic HPV strains, which may contribute to an environment conducive to HIV infection 
by virtue of its relationship with cytokines and the recruitment of immune cells. HPV infection 
is not associated with the traditional definition of genital inflammation and may be associated 
more with a Th-2 immune response. This study is one of few that investigated immune 
responses associated with the risk of acquiring HIV infection among HPV positive women in 
KZN, and one of the first to investigate the contribution of an HPV/STI coinfection on 
biomarkers of genital inflammation. The HPV prevalence among this population of women 
may have important public health implication related to the role-out of HPV vaccinations. 
Furthermore, these findings among women with HR-HPV infection, if validated, has potential 
to be used in future cancer control strategies.  
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8. CONCLUSION 
In conclusion, this study demonstrated that while discharge-related STIs are highly 
inflammatory, a more subtle immune profile was associated with HPV infection, whether in 
terms of viral oncogenicity, having multiple HPV infections, and even on HPV/STI 
coinfection. In this study, HPV was unlike discharge-associated STIs in terms of the cytokine 
profile, the impact on epithelial barrier integrity, and immune activation, and implied a more 
modest associated immune response that did not overtly relate to an increased potential for 
HIV risk. However, the observed association between HR-HPV and the genital cytokine and 
immune cell profiles suggests the need for longitudinal investigation to conclusively assess 
whether genital inflammation associated with oncogenic persistent HPV infection does indeed 
translate to increased risk of HIV acquisition.  
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APPENDIX A 
 
Figure 1. BREC Approval Letter. 
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Figure 2. BREC Recertification Approval Letter. 
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APPENDIX B 
Association between prevalent HPV and soluble protein biomarkers of inflammation  
 Table 1. Cytokine concentrations among HPV- (n = 81) and HPV+ (n = 82) women. 
  Unadjusted Adjusted 
Cytokine β-Coefficient 95% CI P-Value β-Coefficient 95% CI P-Value 
IL-1α 0,080 (-0,085-0,244) 0,341 0,064 (-0,091-0,219) 0,419 
IL-1β -0,033 (-0,276-0,209) 0,787 -0,060 (-0,287-0,166) 0,599 
IL-6 0,055 (-0,113-0,223) 0,520 0,049 (-0,118-0,216) 0,563 
IL-12P40 0,062 (-0,131-0,254) 0,527 0,063 (-0,128-0,254) 0,518 
IL-12P70 0,075 (-0,041-0,190) 0,204 0,074 (-0,042-0,189) 0,208 
IL-18 0,031 (-0,153-0,214) 0,742 0,026 (-0,156-0,209) 0,775 
MIF 0,037 (-0,162-0,236) 0,714 0,033 (-0,167-0,233) 0,745 
TNF-α 0,013 (-0,121-0,146) 0,852 0,002 (-0,127-0,131) 0,974 
TNF-β 0,022 (-0,084-0,128) 0,679 0,025 (-0,078-0,129) 0,631 
TRAIL 0,076 (-0,110-0,262) 0,420 0,073 (-0,106-0,252) 0,422 
CTACK 0,034 (-0,097-0,166) 0,606 0,032 (-0,096-0,160) 0,623 
EOTAXIN 0,171 (-0,084-0,427) 0,187 0,157 (-0,096-0,410) 0,223 
GRO-α 0,135 (-0,142-0,412) 0,337 0,156 (-0,114-0,425) 0,256 
IL-8 0,021 (-0,178-0,220) 0,837 0,017 (-0,181-0,215) 0,865 
IL-16 0,082 (-0,089-0,252) 0,346 0,077 (-0,093-0,247) 0,371 
IP-10 0,136 (-0,145-0,416) 0,341 0,171 (-0,082-0,424) 0,183 
MCP-1 0,000 (-0,086-0,085) 0,992 0,002 (-0,084-0,087) 0,972 
MCP-3 0,021 (-0,153-0,196) 0,812 0,022 (-0,151-0,195) 0,805 
MIG 0,139 (-0,099-0,377) 0,251 0,153 (-0,069-0,376) 0,176 
MIP-1α 0,081 (-0,104-0,266) 0,391 0,069 (-0,112-0,249) 0,453 
MIP-1β 0,087 (-0,091-0,265) 0,338 0,086 (-0,090-0,262) 0,336 
RANTES 0,187 (-0,030-0,403) 0,090 0,174 (-0,037-0,386) 0,105 
IFN-α2 0,041 (-0,042-0,123) 0,331 0,040 (-0,040-0,120) 0,325 
SDF-1α 0,142 (0,001-0,284) 0,049* 0,148 (0,010-0,287) 0,036* 
β-NGF 0,124 (-0,154-0,402) 0,380 0,125 (-0,147-0,397) 0,366 
FGF BASIC -0,002 (-0,046-0,043) 0,944 -0,005 (-0,048-0,038) 0,813 
G-CSF 0,143 (-0,071-0,357) 0,188 0,145 (-0,068-0,359) 0,180 
GM-CSF -0,007 (-0,034-0,021) 0,632 -0,006 (-0,033-0,021) 0,670 
HGF 0,050 (-0,131-0,231) 0,587 0,037 (-0,137-0,212) 0,672 
IL-3 0,051 (-0,057-0,160) 0,351 0,051 (-0,056-0,158) 0,347 
IL-7 0,099 (-0,020-0,218) 0,103 0,091 (-0,027-0,208) 0,128 
IL-9 0,045 (-0,038-0,128) 0,282 0,040 (-0,041-0,120) 0,332 
LIF 0,037 (-0,070-0,144) 0,500 0,029 (-0,074-0,133) 0,577 
M-CSF 0,067 (-0,047-0,182) 0,245 0,058 (-0,053-0,170) 0,300 
PDGF-BB 0,087 (-0,017-0,190) 0,101 0,077 (-0,023-0,177) 0,130 
SCF 0,148 (-0,039-0,335) 0,120 0,155 (-0,024-0,333) 0,089 
SCGF-β 0,169 (-0,040-0,378) 0,112 0,169 (-0,038-0,375) 0,109 
VEGF 0,081 (-0,068-0,229) 0,284 0,078 (-0,069-0,225) 0,298 
IFN-γ 0,019 (-0,086-0,124) 0,725 0,009 (-0,092-0,111) 0,855 
IL-2 -0,048 (-0,291-0,196) 0,700 -0,055 (-0,298-0,188) 0,656 
IL-4 0,036 (-0,046-0,118) 0,383 0,029 (-0,050-0,108) 0,473 
IL-5 0,193 (-0,032-0,419) 0,092 0,169 (-0,045-0,384) 0,122 
IL-13 0,033 (-0,056-0,121) 0,466 0,027 (-0,060-0,115) 0,536 
IL-15 0,145 (-0,142-0,433) 0,320 0,136 (-0,153-0,425) 0,354 
IL-17 0,045 (-0,056-0,145) 0,381 0,041 (-0,057-0,139) 0,411 
IL-2rα -0,025 (-0,124-0,074) 0,623 -0,029 (-0,124-0,067) 0,553 
IL-1rα 0,028 (-0,061-0,116) 0,537 0,032 (-0,056-0,120) 0,472 
IL-10 0,044 (-0,022-0,110) 0,193 0,044 (-0,022-0,110) 0,192 
P-values were determined using linear regression models. P<0.05 indicated by (*) and trending p-values in bold. 
Cytokine/Chemokine functions: Pro-inflammatory, Chemokines, Growth Factors, Adaptive response, Anti-
inflammatory.  
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Table 2. MMP concentrations among HPV- (n = 81) and HPV+ (n = 82) women. 
  Unadjusted Adjusted 
Protein β-Coefficient 95% CI P-Value β-Coefficient 95% CI P-Value 
MMP-1 -0,099 (-0,377-0,179) 0,483 -0,110 (-0,387-0,167) 0,434 
MMP-2 0,017 (-0,321-0,354) 0,922 -0,002 (-0,331-0,328) 0,434 
MMP-3 0,029 (-0,168-0,226) 0,769 0,018 (-0,175-0,210) 0,857 
MMP-7 0,161 (-0,116-0,438) 0,253 0,172 (-0,104-0,448) 0,221 
MMP-8 0,019 (-0,771-0,808) 0,962 0,023 (-0,767-0,813) 0,955 
MMP-9 -0,341 (-0,764-0,082) 0,114 -0,357 (-0,772-0,059) 0,092 
MMP-10 0,018 (-0,265-0,300) 0,901 0,004 (-0,277-0,285) 0,977 
MMP-12 -0,057 (-0,325-0,210) 0,674 -0,067 (-0,329-0,195) 0,615 
MMP-13 -0,011 (-0,289-0,266) 0,937 -0,028 (-0,299-0,243) 0,838 
P-values were determined using linear regression models. Trending values indicated in bold. 
 
 Table 3. Cellular frequency among HPV- (n = 80) and HPV+ (n = 83) women. 
  Unadjusted Adjusted 
Cell Type β-Coefficient 95% CI P-Value β-Coefficient 95% CI P-Value 
LYMPHOCYTES -0,559 (-2,140-1,021) 0,486 -0,479 (-2,067-1,108) 0,552 
CD3 -0,819 (-5,771-4,132) 0,744 -0,692 (-5,701-4,318) 0,785 
CD3CD38DR+CCR5+ 1,999 (-2,286-6,283) 0,358 2,235 (-2,028-6,498) 0,302 
CD3CCR5+CD38+ 0,979 (-5,206-7,165) 0,755 1,367 (-4,790-7,525) 0,662 
CD3CCR5+DR+ 3,249 (-3,587-10,085) 0,349 3,688 (-3,061-10,437) 0,282 
CD3CCR5+KI67+ 3,393 (-3,604-10,390) 0,340 3,608 (-3,417-10,632) 0,312 
CD3CD38+DR+ 2,066 (-3,277-7,408) 0,446 2,426 (-2,853-7,706) 0,365 
CD3CCR5+ -0,283 (-8,567-8,002) 0,946 0,295 (-7,938-8,528) 0,944 
CD3CD38+ 0,228 (-7,769-8,225) 0,955 0,790 (-7,109-8,689) 0,844 
CD3HLA-DR 2,860 (-4,920-10,639) 0,469 3,516 (-4,144-11,175) 0,366 
CD3KI67 2,939 (-5,332-11,210) 0,484 3,191 (-5,145-11,527) 0,451 
CD3 - -2,286 (-9,404-4,831) 0,527 -2,161 (-9,370-5,048) 0,555 
NK Cells 2 0,067 (-4,472-4,606) 0,977 0,218 (-4,424-4,859) 0,926 
CD3 Activation 1 -0,924 (-8,772-6,924) 0,816 -0,105 (-7,747-7,538) 0,978 
CD4 -5,858 (-12,251-0,535) 0,072 -6,315 (-12,728-0,098) 0,054 
CD4CD38DR+CCR5+ 0,273 (-3,324-3,870) 0,881 0,463 (-3,140-4,065) 0,800 
CD4CCR5+CD38+ 0,955 (-5,552-7,462) 0,772 1,463 (-4,982-7,908) 0,655 
CD4CCR5+DR+ -0,389 (-6,881-6,103) 0,906 -0,206 (-6,760-6,348) 0,951 
CD4CCR5+KI67+ 1,383 (-5,638-8,405) 0,698 1,556 (-5,540-8,652) 0,666 
CD4CD38+DR+ -0,520 (-4,778-3,738) 0,810 -0,246 (-4,515-4,024) 0,910 
CD4CCR5 -1,393 (-10,376-7,590) 0,760 -0,871 (-9,878-8,135) 0,849 
CD4CD38 -1,495 (-9,675-6,684) 0,719 -0,923 (-9,039-7,193) 0,823 
CD4HLA-DR -0,837 (-7,923-6,249) 0,816 -0,547 (-7,711-6,618) 0,880 
CD4KI67 0,514 (-7,978-9,007) 0,905 0,601 (-8,006-9,209) 0,890 
CD4 Activation 1 -3,120 (-11,541-5,301) 0,465 -2,539 (-10,966-5,887) 0,553 
CD8 -1,271 (-6,601-4,059) 0,638 -1,106 (-6,488-4,275) 0,685 
CD8CD38DR+CCR5+ 3,035 (-1,387-7,457) 0,177 3,194 (-1,157-7,546) 0,149 
CD8CCR5+CD38+ 2,805 (-2,900-8,511) 0,333 3,145 (-2,506-8,795) 0,273 
CD8CCR5+DR+ 3,340 (-3,470-10,149) 0,334 3,676 (-3,121-10,473) 0,287 
CD8CCR5+KI67+ 3,661 (-3,457-10,779) 0,311 3,722 (-3,463-10,907) 0,308 
CD8CD38+DR+ 4,023 (-2,478-10,524) 0,223 4,493 (-1,794-10,780) 0,160 
CD8CCR5 0,857 (-7,291-9,006) 0,836 1,267 (-6,915-9,449) 0,760 
CD8CD38 2,951 (-5,593-11,495) 0,496 3,642 (-4,742-12,025) 0,392 
CD8HLA-DR 2,519 (-6,778-11,817) 0,593 3,343 (-5,747-12,433) 0,469 
CD8KI67 1,089 (-8,781-10,960) 0,828 1,219 (-8,746-11,185) 0,809 
CD8 Activation 1 -0,416 (-9,523-8,691) 0,928 0,532 (-8,382-9,446) 0,906 
 P-values were determined using linear regression models. Trending p- values in bold. 1Activation refers to cells expressing 
CCR5, HLA-DR and/or CD38. 2NK cells refers to those expressing CD56+CD16+ markers. 
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APPENDIX C 
Association between multiple concurrent HPV infections and soluble protein biomarkers of 
inflammation  
Table 4. Cytokine concentrations among women 1 (n = 48) vs 2+ (n = 37) HPV genotypes. 
  Unadjusted Adjusted 
Cytokine β-Coefficient 95% CI P-Value β-Coefficient 95% CI P-Value 
IL-1α -0,178 (-0,371-0,014) 0,069 -0,054 (-0,146-0,038) 0,248 
IL-1β -0,078 (-0,405-0,249) 0,635 -0,020 (-0,175-0,135) 0,798 
IL-6 0,019 (-0,195-0,233) 0,858 -0,010 (-0,118-0,098) 0,851 
IL-12P40 0,039 (-0,190-0,268) 0,737 0,034 (-0,082-0,150) 0,560 
IL-12P70 -0,050 (-0,211-0,112) 0,544 -0,006 (-0,089-0,077) 0,881 
IL-18 -0,078 (-0,304-0,148) 0,495 0,020 (-0,095-0,135) 0,733 
MIF -0,108 (-0,355-0,139) 0,386 -0,036 (-0,163-0,091) 0,573 
TNF-α -0,089 (-0,250-0,072) 0,277 -0,023 (-0,104-0,057) 0,564 
TNF-β 0,004 (-0,141-0,149) 0,958 0,018 (-0,054-0,090) 0,622 
TRAIL 0,068 (-0,174-0,309) 0,578 0,044 (-0,077-0,164) 0,473 
CTACK 0,001 (-0,183-0,184) 0,994 0,038 (-0,053-0,130) 0,408 
EOTAXIN 0,142 (-0,178-0,462) 0,380 0,062 (-0,099-0,223) 0,444 
GRO-α -0,222 (-0,610-0,165) 0,257 -0,072 (-0,267-0,122) 0,462 
IL-8 -0,142 (-0,401-0,116) 0,276 -0,050 (-0,182-0,083) 0,458 
IL-16 -0,013 (-0,237-0,211) 0,910 0,009 (-0,104-0,123) 0,871 
IP-10 -0,029 (-0,416-0,358) 0,881 0,009 (-0,173-0,190) 0,926 
MCP-1 -0,035 (-0,163-0,094) 0,593 -0,028 (-0,093-0,037) 0,391 
MCP-3 -0,039 (-0,267-0,189) 0,736 -0,039 (-0,153-0,075) 0,501 
MIG -0,014 (-0,321-0,293) 0,928 0,023 (-0,127-0,172) 0,764 
MIP-1α 0,050 (-0,176-0,275) 0,662 0,007 (-0,106-0,119) 0,906 
MIP-1β 0,035 (-0,225-0,295) 0,788 0,000 (-0,133-0,133) 0,997 
RANTES 0,040 (-0,279-0,359) 0,805 -0,023 (-0,184-0,138) 0,776 
IFN-α2 -0,055 (-0,151-0,040) 0,253 -0,004 (-0,053-0,044) 0,853 
SDF-1α -0,065 (-0,213-0,084) 0,387 0,001 (-0,075-0,077) 0,976 
β-NGF -0,129 (-0,504-0,246) 0,497 -0,039 (-0,230-0,151) 0,684 
FGF BASIC -0,034 (-0,084-0,015) 0,175 -0,006 (-0,031-0,019) 0,617 
G-CSF -0,159 (-0,430-0,111) 0,245 -0,064 (-0,203-0,074) 0,357 
GM-CSF -0,010 (-0,045-0,025) 0,583 0,001 (-0,017-0,018) 0,936 
HGF -0,082 (-0,307-0,144) 0,473 -0,026 (-0,138-0,085) 0,639 
IL-3 -0,035 (-0,145-0,075) 0,531 -0,003 (-0,058-0,053) 0,929 
IL-7 -0,083 (-0,217-0,050) 0,217 -0,041 (-0,108-0,027) 0,234 
IL-9 -0,081 (-0,192-0,030) 0,152 -0,044 (-0,100-0,012) 0,120 
LIF -0,083 (-0,230-0,063) 0,261 -0,018 (-0,092-0,056) 0,628 
M-CSF -0,162 (-0,321--0,004) 0,044 -0,053 (-0,133-0,028) 0,197 
PDGF-BB -0,034 (-0,168-0,100) 0,614 -0,028 (-0,096-0,040) 0,411 
SCF -0,013 (-0,248-0,221) 0,910 0,001 (-0,114-0,115) 0,993 
SCGF-β 0,018 (-0,238-0,274) 0,889 0,008 (-0,122-0,139) 0,898 
VEGF -0,072 (-0,276-0,133) 0,489 -0,011 (-0,115-0,094) 0,839 
IFN-γ -0,071 (-0,199-0,057) 0,272 -0,022 (-0,087-0,043) 0,497 
IL-2 -0,050 (-0,398-0,298) 0,776 -0,044 (-0,214-0,126) 0,609 
IL-4 -0,050 (-0,146-0,046) 0,305 -0,031 (-0,079-0,017) 0,203 
IL-5 -0,169 (-0,487-0,150) 0,295 -0,170 (-0,326--0,014) 0,033* 
IL-13 -0,065 (-0,173-0,043) 0,234 -0,020 (-0,076-0,035) 0,466 
IL-15 0,153 (-0,250-0,556) 0,452 0,069 (-0,131-0,270) 0,494 
IL-17 -0,038 (-0,160-0,084) 0,536 -0,017 (-0,079-0,045) 0,582 
IL-2rα -0,094 (-0,230-0,043) 0,177 -0,027 (-0,094-0,041) 0,438 
IL-1rα 0,008 (-0,107-0,122) 0,895 0,002 (-0,054-0,057) 0,955 
IL-10 -0,048 (-0,135-0,040) 0,279 -0,012 (-0,057-0,032) 0,583 
P-values were determined using linear regression models. P<0.05 indicated by (*) and trending p-values in bold. 
Cytokine/Chemokine functions: Pro-inflammatory, Chemokines, Growth Factors, Adaptive response, Anti-
inflammatory. 
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 Table 5. MMP concentrations among women 1 (n = 48) vs 2+ (n = 37) HPV genotypes. 
  Unadjusted Adjusted 
Protein β-Coefficient 95% CI P-Value β-Coefficient 95% CI P-Value 
MMP-1 -0,247 (-0,653-0,159) 0,229 -0,225 (-0,634-0,184) 0,277 
MMP-2 0,306 (-0,190-0,802) 0,223 0,334 (-0,161-0,828) 0,183 
MMP-3 0,117 (-0,151-0,385) 0,388 0,129 (-0,140-0,398) 0,343 
MMP-7 0,230 (-0,119-0,578) 0,194 0,208 (-0,125-0,541) 0,217 
MMP-8 -0,390 (-1,570-0,790) 0,512 -0,392 (-1,597-0,812) 0,519 
MMP-9 -0,190 (-0,635-0,256) 0,400 -0,173 (-0,606-0,261) 0,430 
MMP-10 -0,197 (-0,576-0,182) 0,304 -0,188 (-0,572-0,196) 0,333 
MMP-12 -0,023 (-0,412-0,365) 0,905 -0,002 (-0,391-0,386) 0,990 
MMP-13 -0,081 (-0,468-0,305) 0,676 -0,057 (-0,436-0,321) 0,764 
 P-values were calculated using linear regression models. 
 
 Table 6. Cell frequencies among women 1 (n = 47) vs 2+ (n = 36) HPV genotypes. 
  Unadjusted Adjusted 
Cell Type β-Coefficient 95% CI P-Value β-Coefficient 95% CI P-Value 
LYMPHOCYTES 1,655 (-0,256-3,566) 0,089 1,603 (-0,333-3,538) 0,103 
CD3 0,462 (-5,967-6,892) 0,887 0,133 (-6,418-6,685) 0,968 
CD3CD38DR+CCR5+ -2,079 (-9,212-5,054) 0,563 -2,193 (-9,413-5,027) 0,547 
CD3CCR5+CD38+ -3,556 (-12,644-5,532) 0,439 -3,718 (-12,812-5,375) 0,418 
CD3CCR5+DR+ 0,064 (-10,385-10,514) 0,990 0,021 (-10,349-10,392) 0,997 
CD3CCR5+KI67+ 0,863 (-9,447-11,173) 0,868 0,652 (-9,677-10,981) 0,900 
CD3CD38+DR+ -3,691 (-12,021-4,639) 0,380 -3,784 (-12,086-4,518) 0,367 
CD3CCR5+ -2,020 (-14,101-10,061) 0,740 -2,062 (-14,021-9,897) 0,732 
CD3CD38+ -9,549 (-20,989-1,891) 0,101 -9,553 (-20,873-1,768) 0,097 
CD3HLA-DR 1,188 (-10,114-12,490) 0,835 1,031 (-10,133-12,194) 0,855 
CD3KI67 -2,980 (-14,762-8,802) 0,616 -3,169 (-14,909-8,570) 0,592 
CD3- 3,421 (-6,522-13,364) 0,495 3,141 (-7,076-13,358) 0,542 
NK Cells 2 -0,282 (-6,622-6,058) 0,929 -0,401 (-6,894-6,091) 0,542 
CD3 Activation 1 -5,386 (-17,224-6,451) 0,368 -5,395 (-16,878-6,088) 0,352 
CD4 -4,353 (-13,838-5,131) 0,364 -4,325 (-13,502-4,852) 0,351 
CD4CD38DR+CCR5+ 0,244 (-5,054-5,541) 0,927 0,160 (-5,172-5,491) 0,953 
CD4CCR5+CD38+ -2,263 (-11,675-7,150) 0,634 -2,170 (-11,229-6,888) 0,635 
CD4CCR5+DR+ 2,972 (-5,782-11,726) 0,501 2,735 (-6,149-11,619) 0,542 
CD4CCR5+KI67+ 4,021 (-5,903-13,944) 0,422 3,813 (-6,175-13,801) 0,449 
CD4CD38+DR+ -1,223 (-7,086-4,641) 0,679 -1,425 (-7,318-4,469) 0,632 
CD4CCR5 2,288 (-10,836-15,413) 0,730 2,280 (-10,618-15,178) 0,726 
CD4CD38 -8,401 (-19,589-2,787) 0,139 -8,244 (-19,198-2,711) 0,138 
CD4HLA-DR 2,652 (-7,039-12,342) 0,588 2,161 (-7,678-12,000) 0,663 
CD4KI67 0,772 (-11,092-12,635) 0,897 0,477 (-11,521-12,475) 0,937 
CD4 Activation 1 -2,781 (-15,615-10,054) 0,668 -2,860 (-15,598-9,877) 0,656 
CD8 1,695 (-6,000-9,390) 0,662 1,708 (-5,985-9,402) 0,660 
CD8CD38DR+CCR5+ -2,386 (-9,710-4,937) 0,519 -2,305 (-9,546-4,936) 0,528 
CD8CCR5+CD38+ -3,662 (-12,544-5,219) 0,414 -3,736 (-12,686-5,215) 0,409 
CD8CCR5+DR+ 3,981 (-6,049-14,011) 0,432 3,963 (-6,104-14,030) 0,409 
CD8CCR5+KI67+ 2,354 (-8,159-12,867) 0,657 2,307 (-8,346-12,960) 0,668 
CD8CD38+DR+ -3,237 (-13,534-7,059) 0,533 -2,995 (-12,814-6,824) 0,545 
CD8CCR5 1,811 (-9,939-13,562) 0,760 1,748 (-10,175-13,671) 0,771 
CD8CD38 -7,023 (-19,305-5,259) 0,259 -6,916 (-19,013-5,182) 0,259 
CD8HLA-DR 6,162 (-7,186-19,511) 0,361 6,168 (-6,954-19,289) 0,352 
CD8KI67 -0,479 (-14,383-13,424) 0,945 -0,351 (-14,416-13,713) 0,960 
CD8 Activation 1 1,396 (-12,025-14,816) 0,837 1,373 (-11,963-14,710) 0,838 
 P-values were calculated using linear regression models. Trending values indicated in bold. 1Activation refers to cells 
expressing CCR5, HLA-DR and/or CD38. 2NK cells refers to those expressing CD56+CD16+ markers. 
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APPENDIX D 
Association between oncogenic HPV infections and soluble protein biomarkers of 
inflammation  
Table 7. Cytokine concentrations among women with LR (n = 39) and HR (n = 43) HPV. 
  Unadjusted Adjusted 
Cytokine β-Coefficient 95% CI P-Value β-Coefficient 95% CI P-Value 
IL-1α 0,099 (-0,095-0,293) 0,312 0,087 (-0,095-0,268) 0,344 
IL-1β 0,280 (-0,039-0,599) 0,084 0,268 (-0,031-0,567) 0,078 
IL-6 0,088 (-0,123-0,300) 0,407 0,098 (-0,114-0,309) 0,359 
IL-12P40 0,082 (-0,145-0,308) 0,475 0,074 (-0,154-0,303) 0,518 
IL-12P70 0,154 (-0,003-0,311) 0,054* 0,150 (-0,009-0,309) 0,064 
IL-18 -0,035 (-0,260-0,191) 0,761 -0,044 (-0,270-0,183) 0,702 
MIF -0,027 (-0,273-0,219) 0,828 -0,028 (-0,278-0,222) 0,821 
TNF-α 0,124 (-0,035-0,282) 0,125 0,120 (-0,037-0,277) 0,132 
TNF-β 0,094 (-0,048-0,237) 0,192 0,086 (-0,055-0,227) 0,228 
TRAIL 0,207 (-0,029-0,443) 0,085 0,192 (-0,042-0,425) 0,107 
CTACK 0,113 (-0,068-0,293) 0,217 0,103 (-0,077-0,282) 0,259 
EOTAXIN 0,285 (-0,028-0,598) 0,074 0,284 (-0,027-0,595) 0,073 
GRO-α 0,142 (-0,245-0,528) 0,468 0,131 (-0,252-0,515) 0,497 
IL-8 0,228 (-0,026-0,481) 0,077 0,222 (-0,034-0,479) 0,088 
IL-16 0,171 (-0,049-0,390) 0,125 0,163 (-0,058-0,383) 0,146 
IP-10 0,355 (-0,022-0,731) 0,064 0,341 (-0,008-0,690) 0,055 
MCP-1 0,124 (-0,001-0,249) 0,052* 0,127 (0,002-0,252) 0,046* 
MCP-3 -0,012 (-0,238-0,215) 0,918 -0,024 (-0,249-0,201) 0,834 
MIG 0,287 (-0,010-0,585) 0,058 0,268 (-0,020-0,556) 0,067 
MIP-1α 0,107 (-0,116-0,329) 0,344 0,099 (-0,121-0,319) 0,372 
MIP-1β 0,034 (-0,225-0,292) 0,796 0,028 (-0,233-0,290) 0,829 
RANTES 0,198 (-0,115-0,512) 0,212 0,188 (-0,126-0,502) 0,237 
IFN-α2 0,081 (-0,013-0,175) 0,088 0,075 (-0,018-0,169) 0,111 
SDF-1α 0,037 (-0,111-0,184) 0,624 0,033 (-0,116-0,182) 0,663 
β-NGF 0,163 (-0,208-0,535) 0,384 0,149 (-0,225-0,522) 0,430 
FGF BASIC 0,027 (-0,023-0,076) 0,284 0,024 (-0,025-0,073) 0,332 
G-CSF 0,139 (-0,131-0,408) 0,309 0,146 (-0,126-0,418) 0,289 
GM-CSF 0,019 (-0,016-0,054) 0,278 0,021 (-0,013-0,056) 0,219 
HGF 0,139 (-0,083-0,361) 0,216 0,130 (-0,087-0,348) 0,237 
IL-3 0,027 (-0,082-0,136) 0,626 0,022 (-0,088-0,131) 0,695 
IL-7 0,110 (-0,022-0,241) 0,101 0,106 (-0,026-0,238) 0,113 
IL-9 0,070 (-0,041-0,181) 0,214 0,065 (-0,046-0,175) 0,248 
LIF 0,049 (-0,097-0,195) 0,503 0,043 (-0,102-0,188) 0,556 
M-CSF 0,123 (-0,036-0,281) 0,128 0,117 (-0,041-0,275) 0,145 
PDGF-BB 0,103 (-0,027-0,234) 0,120 0,101 (-0,030-0,233) 0,130 
SCF 0,179 (-0,050-0,408) 0,124 0,163 (-0,059-0,386) 0,149 
SCGF-β 0,059 (-0,194-0,313) 0,642 0,052 (-0,204-0,308) 0,689 
VEGF 0,182 (-0,018-0,382) 0,074 0,175 (-0,027-0,377) 0,088 
IFN-γ 0,106 (-0,019-0,232) 0,096 0,105 (-0,021-0,230) 0,102 
IL-2 0,277 (-0,063-0,617) 0,109 0,307 (-0,021-0,634) 0,066 
IL-4 0,073 (-0,022-0,167) 0,130 0,071 (-0,023-0,165) 0,137 
IL-5 0,070 (-0,248-0,388) 0,662 0,066 (-0,250-0,381) 0,679 
IL-13 0,119 (0,013-0,224) 0,028* 0,117 (0,011-0,224) 0,031* 
IL-15 0,188 (-0,211-0,587) 0,352 0,211 (-0,182-0,603) 0,288 
IL-17 0,104 (-0,015-0,223) 0,085 0,100 (-0,020-0,219) 0,101 
IL-2rα 0,103 (-0,032-0,238) 0,134 0,093 (-0,040-0,225) 0,167 
IL-10 0,064 (-0,022-0,150) 0,144 0,063 (-0,024-0,150) 0,152 
IL-1rα 0,021 (-0,093-0,134) 0,717 0,028 (-0,082-0,137) 0,618 
P-values were determined using linear regression models. P<0.05 indicated with (*) and trends in bold. 
Cytokine/Chemokine functions: Pro-inflammatory, Chemokines, Growth Factors, Adaptive response, Anti-
inflammatory. 
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 Table 9. Cellular frequencies among women with LR (n = 39) and HR (n = 44) HPV. 
  Unadjusted Adjusted 
Cell Type β-Coefficient 95% CI P-Value β-Coefficient 95% CI P-Value 
LYMPHOCYTES 1,910 (0,024-3,795) 0,047* 1,987 (0,077-3,898) 0,042* 
CD3 -1,913 (-8,284-4,458) 0,552 -2,214 (-8,725-4,296) 0,500 
CD3CD38DR+CCR5+ -0,567 (-7,645-6,512) 0,874 -1,055 (-8,252-6,142) 0,771 
CD3CCR5+CD38+ -0,154 (-9,212-8,904) 0,973 -0,886 (-9,986-8,214) 0,847 
CD3CCR5+DR+ -2,303 (-12,639-8,034) 0,659 -3,346 (-13,637-6,945) 0,519 
CD3CCR5+KI67+ 0,680 (-9,532-10,892) 0,895 0,741 (-9,536-11,018) 0,886 
CD3CD38+DR+ -1,533 (-9,816-6,750) 0,714 -2,409 (-10,695-5,877) 0,564 
CD3CCR5+ 0,982 (-11,021-12,984) 0,871 -0,198 (-12,126-11,731) 0,974 
CD3CD38+ -4,731 (-16,235-6,773) 0,416 -5,913 (-17,321-5,495) 0,305 
CD3HLA-DR -3,654 (-14,821-7,514) 0,517 -5,074 (-16,124-5,976) 0,363 
CD3KI67 0,384 (-11,333-12,101) 0,948 0,523 (-11,199-12,245) 0,929 
CD3- 1,964 (-7,914-11,842) 0,693 1,757 (-8,398-11,913) 0,731 
NK Cells 2 4,036 (-2,205-10,276) 0,201 4,096 (-2,336-10,527) 0,207 
CD3 Activation 1 -3,892 (-15,675-7,891) 0,513 -5,519 (-16,961-5,922) 0,340 
CD4 -0,306 (-9,772-9,160) 0,949 0,060 (-9,139-9,258) 0,990 
CD4CD38DR+CCR5+ 0,829 (-4,415-6,073) 0,754 0,535 (-4,769-5,839) 0,841 
CD4CCR5+CD38+ -0,005 (-9,365-9,355) 0,999 -1,057 (-10,096-7,982) 0,817 
CD4CCR5+DR+ 1,558 (-7,130-10,246) 0,722 1,239 (-7,618-10,095) 0,781 
CD4CCR5+KI67+ 5,725 (-4,061-15,511) 0,248 5,802 (-4,086-15,690) 0,246 
CD4CD38+DR+ 0,144 (-5,670-5,958) 0,961 -0,104 (-5,976-5,768) 0,972 
CD4CCR5 5,641 (-7,341-18,624) 0,390 4,508 (-8,318-17,333) 0,486 
CD4CD38 -3,517 (-14,752-7,718) 0,535 -4,684 (-15,708-6,340) 0,400 
CD4HLA-DR 0,537 (-9,078-10,152) 0,912 0,347 (-9,455-10,148) 0,944 
CD4KI67 7,105 (-4,572-18,781) 0,230 7,251 (-4,596-19,098) 0,227 
CD4 Activation 1 1,815 (-10,938-14,568) 0,778 0,638 (-12,073-13,348) 0,921 
CD8 3,336 (-4,279-10,950) 0,386 3,554 (-4,082-11,190) 0,357 
CD8CD38DR+CCR5+ 2,441 (-4,811-9,693) 0,505 1,524 (-5,691-8,740) 0,675 
CD8CCR5+CD38+ 2,821 (-6,013-11,655) 0,527 2,035 (-6,914-10,985) 0,652 
CD8CCR5+DR+ 3,662 (-6,277-13,601) 0,466 2,632 (-7,407-12,671) 0,603 
CD8CCR5+KI67+ 1,193 (-9,229-11,615) 0,820 1,373 (-9,235-11,981) 0,797 
CD8CD38+DR+ -1,936 (-12,150-8,278) 0,707 -3,665 (-13,422-6,093) 0,457 
CD8CCR5 6,483 (-5,104-18,070) 0,269 5,905 (-5,911-17,720) 0,323 
CD8CD38 -4,179 (-16,437-8,080) 0,500 -5,675 (-17,765-6,414) 0,353 
CD8HLA-DR 1,459 (-11,828-14,745) 0,828 -0,360 (-13,490-12,769) 0,957 
CD8KI67 2,094 (-11,704-15,892) 0,763 2,617 (-11,390-16,623) 0,711 
CD8 Activation 1 1,631 (-11,694-14,955) 0,808 0,356 (-12,940-13,652) 0,958 
 P-values were calculated using linear regression models. P<0.05 are indicated by (*). 1Activation refers to cells expressing 
CCR5, HLA-DR and/or CD38. 2NK cells refers to those expressing CD56+CD16+ markers. 
 Table 8. MMP concentrations among women with LR (n = 39) and HR (n = 43) HPV. 
  Unadjusted Adjusted 
Protein β-Coefficient 95% CI P-Value β-Coefficient 95% CI P-Value 
MMP-1 0,169 (-0,235-0,573) 0,408 0,163 (-0,245-0,571) 0,429 
MMP-2 0,371 (-0,118-0,860) 0,135 0,349 (-0,142-0,840) 0,161 
MMP-3 0,247 (-0,014-0,508) 0,063 0,239 (-0,025-0,503) 0,075 
MMP-7 -0,002 (-0,351-0,347) 0,991 -0,031 (-0,365-0,303) 0,854 
MMP-8 0,285 (-0,885-1,455) 0,630 0,236 (-0,962-1,434) 0,696 
MMP-9 0,378 (-0,057-0,814) 0,088 0,347 (-0,078-0,772) 0,108 
MMP-10 0,103 (-0,275-0,480) 0,590 0,090 (-0,294-0,473) 0,643 
MMP-12 0,289 (-0,090-0,669) 0,133 0,280 (-0,100-0,661) 0,147 
MMP-13 0,200 (-0,181-0,581) 0,299 0,177 (-0,197-0,552) 0,349 
 P-values were calculated using linear regression model. Trending values indicated in bold. 
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APPENDIX E 
Association between HPV, STI and soluble protein biomarkers of inflammation 
Table 10. Cytokine concentrations among HPV-STI-, HPV+STI-, HPV-STI+ and HPV+STI+ women. 
  HPV-STI- (N = 67) HPV ONLY (N = 66) STI ONLY (N = 14) HPV+STI+ (N = 15)   
Cytokine 
Median (IQR) log10 
pg/ml 
Median (IQR) log10 
pg/ml 
Median (IQR) log10 
pg/ml 
Median (IQR) log10 
pg/ml 
P-Value 
IL-1α 2,032 (1,614-2,473) 2,143 (1,834-2,444) # 2,683 (1,930-3,111)* 2,540 (2,247-2,797)* 0.006a 
IL-1β 1,563 (1,009-2,098) 1,557 (1,044-2,251) 2,395 (1,650-2,826)*  2,118 (1,719-2,335)* 0.005a 
IL-6 0,795 (0,522-1,256) 1,004 (0,787-1,351)* 1,207 (0,972-1,735)* # 0,892 (0,711-1,055) 0.004a 
IL-12P40 2,425 (2,296-2,507) 2,423 (2,320-2,520) 2,551 (2,370-2,731)* 2,512 (2,317-2,594) 0.065 
IL-12P70 1,709 (1,457-1,939) 1,774 (1,476-2,072) 1,892 (1,481-2,160) 1,943 (1,617-2,054) 0.230 
IL-18 2,351 (1,855-2,677) 2,293 (1,954-2,684) 2,541 (2,037-2,801) 2,219 (2,113-3,025) 0.352 
MIF 3,551 (3,244-3,904) 3,549 (3,249-3,834) 3,617 (3,197-3,902) 3,487 (3,085-3,948) 0.960 
TNF-α 0,983 (0,769-1,388) 1,074 (0,906-1,348) 1,369 (1,085-1,874)* 1,209 (1,031-1,483) 0.029a 
TNF-B 0,542 (0,387-0,633) 0,537 (0,405-0,661) # 0,560 (0,403-1,005) 0,734 (0,524-0,848)* 0.072 
TRAIL 1,420 (1,092-1,738)  1,472 (1,236-1,842) # 1,861 (1,448-2,354)* 1,866 (1,489-2,004)* 0.001a 
CTACK 1,222 (1,040-1,402)  1,216 (1,084-1,405) # 1,392 (1,284-1,759)* 1,481 (1,195-1,590)* 0.004a 
EOTAXIN 0,732 (0,418-0,996) 0,823 (0,475-1,063) 1,003 (0,460-1,299) 0,900 (0,732-1,064) 0.117 
GRO-A 2,693 (2,192-3,456) 2,956 (2,352-3,484) 3,075 (2,778-3,754) 3,206 (2,532-3,783) 0.311 
IL-8 2,601 (2,143-3,038) 2,692 (2,344-3,050) 3,028 (2,589-3,638)* 2,962 (2,669-3,221) 0.108 
IL-16 1,542 (1,349-1,816) 1,578 (1,437-1,890) 1,876 (1,673-2,332)* 1,828 (1,456-2,137)* 0.022a 
IP-10 2,306 (1,599-2,728) 2,322 (1,704-2,959) 2,636 (2,290-3,472)* 2,280 (1,901-3,523) 0.153 
MCP-1 1,458 (1,368-1,544) 1,469 (1,356-1,611) 1,540 (1,377-1,800) 1,458 (1,316-1,485) 0.465 
MCP-3 1,036 (0,751-1,156) 0,975 (0,774-1,185) # 1,047 (0,920-1,457) 1,184 (0,958-1,365)* 0.091 
MIG 2,422 (1,821-2,889) 2,466 (2,059-3,046) 3,200 (2,447-3,821)* 3,247 (2,299-3,516)* 0.004a 
MIP-1α 0,009 (-0,252-0,316) 0,008 (-0,204-0,313) 0,314 (0,028-0,698)* 0,193 (-0,004-0,483) 0.026 
MIP-1B 1,043 (0,728-1,663) 1,281 (0,846-1,752) 1,487 (1,135-1,877)* 1,224 (1,015-1,940) 0.070 
RANTES 0,754 (0,340-0,975) 0,793 (0,525-1,114) 1,161 (0,796-1,527)* 1,035 (0,732-1,251)* 0.005a 
IFN-α2 1,225 (1,143-1,345) 1,242 (1,119-1,369) # 1,379 (1,233-1,648)* 1,437 (1,160-1,518)* 0.011 
β-NGF -0,131 (-2,000-0,246) -0,117 (-0,498-0,302) 0,221 (-0,144-0,754)* 0,366 (-0,377-0,630)* 0.016a 
FGF BASIC 1,409 (1,358-1,493) 1,422 (1,371-1,482) 1,503 (1,426-1,587)* 1,481 (1,353-1,562) 0.043a 
G-CSF 2,199 (1,591-2,701) 2,395 (2,066-2,965)* 2,517 (2,202-3,307)* 2,239 (1,800-2,730) 0.053 
GM-CSF 1,840 (1,789-1,908) 1,855 (1,802-1,907) # 1,890 (1,775-1,932) 1,799 (1,751-1,861) 0.165 
HGF 2,167 (1,747-2,748) 2,323 (1,918-2,780) 2,788 (2,227-3,329)* 2,575 (2,299-2,915)* 0.005a 
IL-3 2,024 (1,891-2,114) 1,997 (1,951-2,154) 2,118 (1,996-2,479)* 2,258 (1,964-2,326)* 0.030 
IL-7 0,781 (0,547-1,049) 0,865 (0,683-1,031) 0,992 (0,741-1,073) 0,903 (0,780-1,086) 0.166 
IL-9 0,655 (0,515-0,844) 0,733 (0,590-0,848) 0,785 (0,617-1,021) 0,815 (0,717-0,930)* 0.068 
LIF 1,073 (0,899-1,262) 1,075 (0,936-1,239) # 1,164 (1,100-1,620)* 1,305 (1,216-1,375)* 0.006a 
M-CSF 1,778 (1,565-2,020) 1,926 (1,598-2,121) 1,995 (1,661-2,350) 2,056 (1,729-2,203)* 0.065 
PDGF-BB 1,078 (0,817-1,300) 1,127 (0,966-1,361) 1,270 (1,040-1,669)* 1,276 (0,971-1,392)* 0.040 
SCF 0,960 (0,694-1,232) 1,010 (0,765-1,337) 1,443 (0,894-1,810)* 1,477 (0,887-1,706)* 0.012a 
SCGF-β 2,548 (2,090-2,900) 2,734 (2,384-3,037) 3,137 (2,438-3,350)* 2,756 (2,367-3,094) 0.036a 
SDF-1A 2,303 (2,054-2,646) 2,426 (2,188-2,679) 2,511 (2,375-2,734)* 2,511 (2,216-2,736) 0.109 
VEGF 2,333 (1,943-2,571) 2,405 (2,092-2,710) 2,581 (2,108-3,058) 2,681 (2,275-2,833) 0.164 
IFN-G 1,312 (1,060-1,536) 1,371 (1,192-1,530) 1,562 (1,222-1,826)* 1,448 (1,335-1,615) 0.087 
IL-2 0,446 (0,236-0,659) 0,436 (0,187-0,680) 0,546 (0,389-0,886) 0,322 (-0,495-0,520) 0.264 
IL-4 -0,013 (-0,181-0,158) 0,025 (-0,107-0,133) 0,204 (-0,034-0,399)* 0,093 (-0,066-0,290) 0.046 
IL-5 -0,051 (-1,222-0,403) 0,243 (-0,253-0,500)* 0,496 (0,266-0,727)* 0,427 (0,255-0,593)* 0.001a 
IL-13 0,535 (0,332-0,728) 0,563 (0,329-0,733) 0,614 (0,392-0,813) 0,543 (0,403-0,780) 0.657 
IL-15 0,093 (-1,260-0,614) 0,350 (-1,260-0,700) 0,532 (-1,260-0,943) 0,188 (-1,260-0,496) 0.171 
IL-17 1,069 (0,937-1,266) 1,093 (0,975-1,279) 1,201 (1,034-1,698)* 1,129 (0,977-1,406) 0.054 
IL-2rα 1,272 (1,115-1,420) 1,241 (1,081-1,420) #  1,476 (1,319-1,957)* 1,562 (1,246-1,673)* 0.002a 
IL-10 1,606 (1,434-1,715) 1,626 (1,513-1,815) 1,694 (1,518-1,873)* 1,640 (1,608-1,773) 0.150 
IL-1RA 4,107 (3,911-4,211) 4,115 (3,985-4,248) # 4,108 (4,000-4,291) # 3,943 (3,749-4,095) 0.113 
Mann-Whitney U tests were used to compare medians between groups. P-values<0.05 were considered significant. * denote 
significant differences between HPV-STI-  and HPV only, or STI only or HPV+STI+; while # represents a statistical difference in 
medians between  HPV+STI+ and HPV only, or STI only. * or # in red print indicate p values significant after multiple comparisons 
adjustment by Dunn’s post-testing. Cytokines are ordered according to functionality: pro-inflammatory, chemokines, growth 
factors, adaptive response and anti-inflammatory cytokines. 
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Table 11. MMP concentrations among HPV-STI-, HPV+STI-, HPV-STI+ and HPV+STI+ women. 
  HPV-STI- (N = 67) HPV ONLY (N = 66) STI ONLY (N = 14) HPV+STI+ (N = 15)   
Protein 
Median (IQR) log10 
pg/ml 
Median (IQR) log10 
pg/ml 
Median (IQR) log10 
pg/ml 
Median (IQR) log10 
pg/ml 
P-Value 
MMP-1 2,690 (3,150-3,440) 2,435 (3,150-3,420) 3,163 (3,550-3,848)* 3,160 (3,350-3,480) 0.018 
MMP-2 2,700 (3,340-3,770) 2,838 (3,525-3,780) # 3,415 (4,050-4,355)* 3,400 (3,730-4,160)* 0.002
a 
MMP-3 2,630 (2,810-3,170) 2,510 (2,930-3,273) 2,813 (3,265-3,603)* 2,810 (3,170-3,240)* 0.027 
MMP-7 1,810 (2,420-3,110) 2,003 (2,515-3,150) 2,098 (2,760-3,330) 2,210 (2,460-3,610) 0.199 
MMP-8 4,190 (5,000-5,920) 4,108 (4,950-6,223) 4,905 (6,560-7,623)* 4,930 (5,240-6,050) 0.020
a 
MMP-9 3,890 (4,500-5,410) 3,680 (4,635-5,443) 4,340 (5,685-6,335)* 4,510 (5,000-5,440) 0.017
a 
MMP-10 2,290 (2,890-3,180) 2,270 (2,960-3,313) 2,793 (3,135-3,538) 2,700 (2,900-3,010) 0.310 
MMP-12 2,440 (2,830-3,230) 2,268 (2,855-3,408) # 2,895 (3,330-4,013)* 2,840 (3,240-3,700)* 0.013 
MMP-13 1,710 (2,140-2,630) 1,708 (2,185-2,605) # 2,278 (2,595-2,965)* 2,270 (2,490-2,690) 0.027 
Mann-Whitney U tests were used to compare medians between groups. P-values<0.05 were considered significant. * denote 
significant differences between HPV-STI-  and HPV only, or STI only or HPV+STI+; while # represents a statistical difference in 
medians between  HPV+STI+ and HPV only, or STI only. * or # in red print indicate p values significant after multiple comparisons 
adjustment by Dunn’s post-testing. 
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Table 12. Cellular frequencies among HPV-STI-, HPV+STI-, HPV-STI+ and HPV+STI+ women. 
 HPV-STI- (N = 66) HPV ONLY (N = 69) STI ONLY (N = 14) HPV+STI+ (N = 13) 
 
Cell Type Median % (IQR) Median % (IQR) Median % (IQR) Median % (IQR) P-Value 
LYMPHOCYTES 1,083 (2,170-5,350) 0,982 (2,290-5,715) 0,631 (3,520-7,860) 1,050 (2,940-4,365) 0.971 
CD3 1,178 (10,350-27,730) 2,755 (13,400-23,450) 3,678 (10,190-38,700) 1,290 (11,400-24,350) 0.773 
CD3CD38DR+CCR5+ 0,829 (4,770-13,530) 1,550 (5,090-13,730) 6,935 (10,300-26,850)* 3,625 (6,450-30,500) 0.060 
CD3CCR5+CD38+ 4,650 (16,400-25,600) 6,170 (17,900-27,800) 13,250 (28,800-42,600)* 15,600 (21,900-40,950) 0.056 
CD3CCR5+DR+ 3,403 (8,990-19,980) 3,883 (11,000-28,500) 8,050 (14,600-51,600) 6,885 (25,200-50,200)* 0.081 
CD3CCR5+KI67+ 0,000 (3,800-13,850) 0,000 (8,765-24,900) 0,074 (17,700-57,350) 0,000 (16,600-28,050) 0.353 
CD3CD38+DR+ 3,135 (10,200-20,450) 4,680 (11,050-24,550) 13,250 (18,900-28,850)* 6,150 (16,900-47,000) 0.037 
CD3CCR5+ 21,100 (38,700-59,950) 22,250 (44,600-57,850) 34,200 (57,450-73,050) 30,950 (46,700-84,000) 0.163 
CD3CD38+ 21,180 (37,600-52,380) 16,900 (42,400-53,650) 32,700 (54,700-73,550)* 26,350 (61,700-75,600) 0.045 
CD3HLA-DR 10,550 (23,900-40,900) 13,230 (24,950-49,530) # 21,150 (27,800-61,050) 24,000 (34,900-66,500)* 0.111 
CD3KI67 0,513 (13,500-31,180) 0,049 (21,400-40,750) 0,072 (21,600-63,280) 3,342 (29,000-38,250) 0.656 
CD3- 23,650 (41,500-59,780) 21,850 (35,500-58,850) 24,880 (29,750-67,780) 22,550 (33,200-59,800) 0.909 
NK Cells 2 1,580 (5,520-12,350) 1,830 (4,080-17,500) 0,403 (2,730-20,650) 1,283 (3,745-12,530) 0.972 
CD3 Activation 1 53,250 (68,200-91,030)  55,150 (74,600-86,850) # 75,250 (86,050-93,630)* 76,500 (90,100-98,850)* 0.007a 
CD4 49,030 (62,250-72,880) 48,350 (58,000-67,050) 53,780 (64,450-70,300) 29,050 (45,900-63,850) 0.135 
CD4CD38DR+CCR5+ 0,084 (3,715-10,980) 0,608 (4,125-12,180) 4,065 (7,610-18,900) 1,260 (5,910-15,200) 0.375 
CD4CCR5+CD38+ 3,370 (16,700-30,700)  4,725 (18,600-31,500) # 9,128 (26,950-38,280) 18,300 (27,300-56,000)* 0.098 
CD4CCR5+DR+ 2,270 (8,740-19,380) 2,090 (8,940-28,300) 5,310 (12,600-37,850) 1,260 (9,460-28,450) 0.843 
CD4CCR5+KI67+ 0,000 (3,770-19,250) 0,000 (3,400-27,780) 0,000 (0,275-37,950) 0,000 (18,200-26,550) 0.959 
CD4CD38+DR+ 1,230 (8,160-17,450) 1,890 (8,770-18,230) 7,685 (12,300-21,750) 2,180 (6,920-21,850) 0.409 
CD4CCR5 24,800 (44,700-69,200) 19,750 (43,300-62,800) 24,380 (56,550-75,830) 30,700 (54,500-95,450) 0.337 
CD4CD38 21,280 (39,650-58,100)  17,700 (42,900-54,600) # 26,080 (56,150-74,880) 30,800 (63,600-75,400) 0.074 
CD4HLA-DR 7,140 (16,800-32,750) 5,500 (19,100-41,550) 9,795 (20,300-43,950) 3,050 (10,800-35,950) 0.894 
CD4KI67 0,000 (12,050-33,430) 0,000 (8,860-36,850) 0,000 (0,240-44,880) 0,000 (25,000-36,050) 0.978 
CD4 Activation 1 50,850 (72,750-91,580)  53,000 (72,700-84,400) # 62,350 (83,050-91,980) 74,650 (84,300-98,950) 0.092 
CD8 24,080 (35,650-49,100) 24,400 (36,600-45,700) 29,600 (32,350-44,430) 20,700 (35,100-54,000) 0.995 
CD8CD38DR+CCR5+ 0,000 (3,615-9,955) 0,000 (6,280-13,700) 4,735 (11,600-17,100)* 3,165 (8,320-30,550) 0.067 
CD8CCR5+CD38+ 0,597 (9,300-18,550) 3,585 (12,900-22,850) 9,155 (18,250-46,430)* 6,360 (18,100-36,050) 0.084 
CD8CCR5+DR+ 0,137 (8,110-19,130) 1,958 (12,150-26,500) 8,830 (14,300-27,950) 4,765 (23,600-51,350) 0.157 
CD8CCR5+KI67+ 0,000 (2,380-13,900) 0,000 (5,265-26,180) 0,000 (0,171-47,150) 0,000 (9,520-24,900) 0.694 
CD8CD38+DR+ 0,163 (10,400-21,600)  1,830 (12,700-30,980) # 15,050 (18,800-34,800)* 5,865 (34,900-68,700)* 0.030 
CD8CCR5 14,250 (28,500-51,250) 17,450 (31,900-50,000) 24,830 (42,500-64,200) 17,150 (32,600-70,750) 0.470 
CD8CD38 8,730 (33,200-50,200)  13,150 (38,600-54,100) # 32,050 (50,100-75,680)* 23,700 (67,400-81,800)* 0.033 
CD8HLA-DR 6,210 (29,900-54,050) 10,550 (36,650-57,150) # 29,350 (40,000-68,150) 28,750 (54,300-85,850)* 0.072 
CD8KI67 0,000 (13,500-35,100) 0,000 (11,700-41,050) 0,000 (20,000-97,680) 0,000 (26,100-39,700) 0.902 
CD8 Activation 1 45,230 (67,950-90,580) 50,500 (70,800-88,150) # 73,580 (85,150-94,200)* 71,900 (88,400-99,750)* 0.014 
Mann-Whitney U tests were used to compare medians between groups. P-values<0.05 were considered significant. * denote significant differences between 
HPV-STI-  and HPV only, or STI only or HPV+STI+; while # represents a statistical difference in medians between  HPV+STI+ and HPV only, or STI 
only. * or # in red print indicate p values significant after multiple comparisons adjustment by Dunn’s post-testing.1Activation refers to cells expressing 
CCR5, HLA-DR and/or CD38. 2NK cells refers to those expressing CD56+CD16+ markers. 
